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Summary 
 
Neuroblastomas are the most common extracranial solid tumors in early childhood and 
account for 7% of all pediatric cancers. Amplification of the MYCN gene occurs in 20-30% of 
neuroblastoma cases and is associated with aggressive cancers and a poor outcome for the 
patients. Despite decades of research on MYCN and c-MYC and several known functions of 
these proteins, there are no therapeutic approaches targeting transcription factors of the MYC 
family.  
BET inhibitors inhibit growth and induce apoptosis in several MYC-overexpressing cancer 
types. Based on these findings, BET inhibitors were tested as part of this thesis for MYCN 
amplified neuroblastoma in vitro and in vivo. A panel of 23 neuroblastoma cell lines was 
screened for sensitivity upon treatment with the BET inhibitor JQ1 by using viability assays, 
soft agar assays and FACS live/dead and cell cycle staining. Based on the viability screening, 
55% of the MYCN amplified and 30% of the MYCN non-amplified cell lines were categorized 
as JQ1 sensitive. Reduced viability was mirrored by the absence of anchorage independent 
growth and an increase of G1 and sub-G1 fraction after JQ1 treatment. Protein expression 
data were estimated by western blot and Reverse Phase Protein Array, showing that MYCN 
protein levels were reduced in 70% of the MYCN amplified neuroblastoma cell lines and that 
further proteins related to the G1/S-transition of the cell cycle were lower expressed. A shRNA-
mediated BRD4 knockdown in MYCN amplified IMR5/75 cells did not affect MYCN protein 
levels but reduced the expression of Cyclin D1. Global mRNA expression of four JQ1-treated 
cell lines was analyzed by RNA-sequencing, showing differential expression of genes related 
to cell cycle, damage response and chromatin methylation. In vivo, treatment with the BET 
inhibitor BAY1238097 prolonged the survival of mice harboring xenograft tumors deriving from 
the neuroblastoma cell line LS. 
Common neuroblastoma mouse models either belong to the MYCN amplified or to the MYCN 
non-amplified group of neuroblastoma. No neuroblastoma mouse model is available harboring 
both a strong and a low MYCN gene expression, allowing the analysis of MYCN on and MYCN 
off conditions with the same genetic background. A MYCN high/low orthotopic neuroblastoma 
mouse model was established with a tumor growth rate of 80%. Tumor imaging was performed 
by Magnet-Resonance-Imaging and in vivo bioluminescence. The MYCN knockdown was 
analyzed and falcified by quantitative PCR and RNA-sequencing.   
In conclusion, BET inhibitors are probably an efficient therapeutic option for a genetically 
preselected number of neuroblastoma cases, although amplified MYCN alone is not 
predisposing neuroblastoma tumors for a therapy with BET inhibitors. The MYCN high/low 
mouse model needs further research for the establishment of a stable MYCN knockdown. 
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Zusammenfassung 
 
Das Neuroblastom ist mit 7 % aller pädiatrischen Krebserkrankungen der häufigste 
extrakraniale solide Tumor bei Neugeborenen und Kleinkindern. Eine Amplifikation des MYCN 
Gens liegt in 20-30 % der Fälle vor und ist mit aggressiven Verläufen assoziiert. Obwohl MYCN 
und c-MYC seit Jahrzehnten im Fokus der onkologischen Forschung stehen und eine Vielzahl 
an Funktionen bekannt sind, gibt es bislang noch keine auf MYC ausgerichtete Therapie.  
Inhibitoren für BET Proteine reduzieren die Proliferation und induzieren Apoptose in einer 
Vielzahl von MYC-überexprimierenden Tumorentitäten. Basierend hierauf wurden BET 
Inhibitoren im Rahmen einer präklinischen Studie für MYCN amplifizierte Neuroblastome in 
vitro und in vivo getestet. Eine Gruppe von 23 Neuroblastomzelllinien wurde mit dem BET 
Inhibitor JQ1 behandelt und hinsichtlich ihrer Sensitivität untersucht. Hiervon wurden 55 % der 
MYCN amplifizierten und 30 % der Zelllinien ohne MYCN Amplifikation als sensitiv gegenüber 
JQ1 eingeordnet. Bei FACS-Analysen wurde ein Anstieg der G1 und sub-G1 Fraktionen 
beobachtet. Die Proteinexpression wurde mittels Westernblot und Proteinarrays (RPPA) 
analysiert, hierbei zeigte sich durch die Behandlung mit JQ1 eine Reduktion der MYCN-
Proteinexpression in 70 % der MYCN amplifizierten Zelllinien. Des Weiteren konnten Effekte 
auf weitere zellzyklusrelevante Proteine, insbesondere für den G1/S-Übergang, nachgewiesen 
werden. Eine durch shRNA vermittelte Reduktion von BRD4 zeigte keine Auswirkungen auf 
die MYCN Proteinexpression von IMR5/75 Zellen, verringerte jedoch die Cyclin D1 
Expression. Umfangreiche Genexpressionsanalysen von vier mit JQ1 behandelten Zelllinien 
zeigten Veränderungen in der Expression von Genen, die mit dem Zellzyklus, Methylierung 
des Chromatins oder Schäden an der DNA in Verbindung stehen. In vivo verlängerte eine 
Therapie mit dem BET Inhibitor BAY1238097 das Überleben von Mäusen mit Tumoren, die 
von der Neuroblastomzelllinie LS abstammten. 
Standardmäßig genutzte Mausmodelle des Neuroblastoms gehören entweder zu den MYCN 
amplifizierten oder den nicht-amplifizierten Neuroblastomen. Es existieren keine 
Mausmodelle, die vor dem identischen genetischen Hintergrund alternativ eine starke oder 
schwache MYCN Expression zeigen. Im Rahmen der Arbeit wurde ein solches orthotopes 
Mausmodell etabliert. Als bildgebende Verfahren wurden Magnetresonanztomografie und in 
vivo Biolumineszenz eingesetzt. Eine Reduktion der MYCN Expression in den Tumoren konnte 
mittels quantitativer PCR und RNA-Sequenzierung nicht nachgewiesen werden.  
Zusammenfassend sind BET Inhibitoren eine Option für die Therapie einer vorselektierten 
Gruppe von Neuroblastomen. Eine Auswahl potentiell geeigneter Patienten muss neben einer 
MYCN-Amplifikation auf weiteren Faktoren beruhen. Um im Mausmodell stabil eine erniedrigte 
MYCN-Expression zu erreichen sind weitere Versuche erforderlich.  
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1 Introduction 
1.1 Neuroblastoma 
1.1.1 Clinical characteristics of neuroblastoma 
Neuroblastomas are the most common extracranial solid tumors in childhood. With about 130 
cases per year in Germany they account for 7% of all pediatric cancers and 15% of the deaths 
caused by pediatric malignancies. Neuroblastomas occur early in childhood, the median age 
at diagnosis is 1 year 2 months. For boys the incidence is 30% higher than for girls [1, 2]. 
Familiar cases are responsible for 1% of neuroblastomas and go along with multicentric tumors 
and early tumor onset [3].  
Origin of neuroblastoma tumors are neuronal precursor cells deriving from the neural crest cell 
lineage. The tumors show a wide field of clinical behavior: from neuroblastomas regressing 
without therapeutic intervention or tumors that mature to benign neuronal tissue or 
ganglioneuromas to progressive and aggressive metastatic disease with poor outcome [2].  
The localization of neuroblastomas is strictly correlating with the tissues deriving from neural 
crest precursor cells. The majority of the tumors occur in the adrenal gland, followed by 
parasympathic ganglia. About 70% of the tumors are located in the abdomen and 20% in 
thorax or neck. The main metastatic sites are bone marrow and bone [4]. 
Symptoms of neuroblastoma tumors are unspecific; the majority of the tumors are detected 
because of lesion expansion. Tiredness or pain in the bones are described, in a small 
proportion of cases neurological signs or paraneoplastic disorders occur [2, 3].  
Diagnosis is based on a histopathological analysis of tumor material, showing immature 
neuroblasts and a low content of swannian stroma cells [3]. The analysis is complemented by 
various imaging methods to determine the stage of the disease and by a genetic analysis of 
the tumor material for a small number of aberrations that are relevant for prognosis and choice 
of an adequate therapy.  
Neuroblastoma spreading is categorized according to the INSS staging system (Table 1). It 
includes three different localized stages (1-3) with 50% of all neuroblastoma cases, the 
metastatic stage 4 with 40% of the tumors and stage 4S which is occurring in 10% of the cases 
[3]. Stage 4S describes a metastatic disease of infants younger than 18 months at diagnosis 
harboring small primary tumors and metastases exclusively in skin, liver and bone marrow. 
Tumors belonging to this category undergo spontaneous regression in nearly all cases without 
therapeutic intervention [5]. Additional to the tumor stage, the prognosis for the patients is 
based on the age of the patients with a more favorable outcome for younger children and on 
genetic factors as described in section 1.1.2. 
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Table 1: INSS staging system of neuroblastomas (Adapted from Maris, 2007 [3]). 
INSS 
stage 
primary tumor lymph nodes metastases 
1 localized, complete resection neg. neg. 
2A localized, incomplete resection neg. neg. 
2B localized ipsilateral neg. 
3 unresectable, midline infiltrating pos. or neg. neg. 
localized, unilateral contralateral neg. 
unresectable, midline, bilateral extension pos. or neg. neg. 
4 any distant pos. 
4S (<18 
months) 
localized  limited to skin, liver, 
bone marrow 
 
Therapy of neuroblastomas includes surgery, chemotherapy and radiotherapy. Low risk 
tumors of INSS stage 1 or 2 are treated with surgery alone and chemotherapy is not necessary 
in most of these cases [6]. Patients with high risk neuroblastomas receive extensive high dose 
chemotherapy including myeloablative therapy with autologous stem cell transplantation, 
combined with surgery, radiotherapy and novel targeted drugs [7]. The overall survival of 
neuroblastoma patients ranges from more than 80-95% for intermediate and low risk cases to 
less than 40% for patients with high risk tumors [8, 9]. 
To date, no screening method is available for neuroblastomas. The attempt to examine the 
urine of infants for katecholamines increased the number of detected neuroblastoma tumors 
but could not reduce the mortality and was therefore abandoned [10, 11]. 
 
1.1.2 Biological characteristics of neuroblastoma 
Over the past decades, neuroblastoma research revealed a number of genetic alterations 
occurring frequently in neuroblastomas. Most of them are associated with good or bad 
prognosis and can contribute to the risk stratification for individual patients (Table 2). 
An amplification of the MYCN oncogene found in 20-30% of neuroblastoma cases is the 
genetic modification most important for risk stratification. It occurs mainly in INSS stage 4 
neuroblastomas and is associated with a bad prognosis [12] (Figure 1). In MYCN amplified 
cases, the neuroblastoma cells contain 10-500 copies of the MYCN oncogene which can be 
structured as double minutes or homogeneously stained region [2]. In additional 8% of 
neuroblastomas the MYCN oncogene is not amplified in large extent but overexpressed by 
single copy gain or unbalanced translocations [13].  
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Figure 1: MYCN amplification as risk factor for poor outcome. Kaplan-Meier-plot of neuroblastomas comparing 
the overall survival of MYCN amplified and non-amplified cases (from Brodeur, G.M., 2003 [14]). 
 
On chromosomal level, deletions of the chromosome arms 1p and 11q are associated with a 
poor outcome. These deletions occur frequently, a 1p deletion is found in 23% of 
neuroblastoma cases and deletions of 11q happen in 34% of neuroblastomas [15]. A number 
of genes have been identified in the deleted regions, for example loss of CAMTA1 in 1p36 is 
linked to a poor outcome [16]. Another common structural aberration is a copy gain of region 
17q which is found in about 60% of neuroblastomas and has no prognostic relevance [17]. 
Structural aberrations in other chromosomes are occurring less frequently, most of them go 
along with a bad prognosis [18]. Analysis of the ploidity of neuroblastomas revealed a good 
prognosis for triploid cases whereas diploid neuroblastomas have a poor prognosis [19].  
Frequent genetic aberrations in neuroblastomas are overexpression or activating mutations of 
the ALK gene (anaplastic lymphoma kinase), found in 20-25% of neuroblastoma cases and 
associated with a poor outcome for the patients [20, 21]. An increased kinase activity of ALK 
results in higher proliferation and reduced apoptosis. ALK induces the expression of MYCN, 
leading to higher MYCN protein levels and plays a role in stabilizing the MYCN protein [22, 
23]. A similar role is taken by AURKA (Aurora kinase A), this protein binds to MYCN and 
prevents it from proteasomal degradation and thus is a negative prognostic factor for 
neuroblastoma [24, 25]. LIN28B is another gene linked to MYCN expression in neuroblastoma. 
LIN28B upregulates the expression of MYCN, whereas MYCN induces LIN28B through micro-
RNA regulation [22]. 
The neurotrophin receptors Trk A and Trk B are deregulated in a number of neuroblastoma 
cases. Whereas Trk A and its ligand NGF are leading to differentiation and regression of the 
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tumor and therefore go along with a good prognosis, overexpression of Trk B and its ligand 
BDNF occurs in unfavorable neuroblastomas and correlates with amplified MYCN [2].  
In contrast to many adult cancer entities, well known oncogenes involved in tumorigenesis of 
these tumors such as TP53, RAS or CDKN2A are not mutated in new diagnosed 
neuroblastoma [3]. In the case of TP53, mutations occur solely in relapsed neuroblastomas at 
a low rate [26]. Additionally the TP53 pathway may be inactivated in neuroblastoma through 
mutations of other components of the pathway despite TP53 [27]. 
Mutations of PHOX2B are found in 2% of the neuroblastomas and show a coincidence with 
neurological diseases as hirschsprung disease [3, 28]. Together, PHOX2B and ALK mutations 
are responsible for most of the familiar neuroblastoma cases.  
Recent findings link prolonged telomeres and telomerase activity with high risk neuroblastoma 
cases. TERT, a subunit of telomerase was found to be activated by rearrangements to 
chromosomal regions controlled by strong enhancers [29]. In other high risk cases the 
telomeres are prolonged by the ALT pathway, describing an alternative way for lengthening of 
telomeres independent from telomerase activation but involving an ATRX deletion in a high 
proportion of cases [30]. Including the information regarding telomere status, three 
independent groups of high-risk neuroblastomas can be defined that are not overlapping and 
are all related with a poor outcome: amplified MYCN is found in 37% of stage 3 and stage 4 
neuroblastomas, TERT rearrangements in 23% and ATRX deletions in 11% of the stage 3 and 
4 tumors [31]. 
 
Table 2: Favorable and unfavorable biologic characteristics of neuroblastomas.  
 
unfavorable favorable 
no prognostic 
relevance 
MYCN amplification, overexpression   
Structural 
aberrations 
1p del., 11q del.  17q gain 
Ploidity near diploid triploid  
Neurotrophin 
receptors 
Trk B expression Trk A expression  
ALK activating mutation, amplification   
Telomeres TERT rearrangement+activation, 
ATRX deletion 
  
others Aurora kinase, PHOX2B, LIN28-B   
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1.2 MYCN and c-MYC 
1.2.1 MYC protein family 
The family of MYC transcription factors comprises c-MYC MYCN and MYCL. C-MYC is globally 
expressed, whereas MYCN and MYCL are limited to certain tissues and phases during 
embryogenesis [32]. The MYCN gene is located on chromosome 2p24 and characterized by 
a high expression in early embryogenesis, becoming lower during cell differentiation. It is found 
especially in neuronal precursor cells and during brain and lung development [33]. The 
expression pattern of MYCL is even more limited [34]. MYC transcription factors are crucial 
during embryonic development, embryos negative for MYCN or c-MYC die between day 9 and 
11 [35, 36]. As c-MYC, MYCN and MYCL resemble each other in structure and function, they 
are summarized as MYC in the sections 1.2.1 and 1.2.2. 
MYC proteins harbor a basic region, a helix-loop-helix and a leucine zipper structure at the C-
terminus, responsible for the formation of heterodimers and for recognition and binding of their 
DNA binding sites [32] (Figure 2). At the N-terminus four regions called mycboxes are located. 
Mycbox I includes phosphorylation sites and is responsible for turnover of the MYC protein 
through proteasomal degradation [37]. Mycbox III plays a role in MYC protein stability, 
transcriptional repression and apoptosis induction [38, 39]. The biologic functions of MYC, 
such as transcriptional activation and repression, as well as nuclear localization are involving 
protein binding to mycbox II [40]. 
For MYC mediated transcriptional activation, MYC forms heterodimers with MAX. The MYC-
MAX heterodimers bind to E-box elements in promoter regions (CACGTG) and recruit p-TEFb, 
a complex of CDK9 and Cyclin T. P-TEFb phosphorylates the carboxyl-terminal domain of 
RNA polymerase II, which leads to the release of the RNA polymerase from the transcription 
initiation complex and to transcriptional elongation [41-43]. MYC mediated transcriptional 
repression works by dimerization of MAX with MAD or MNT. These heterodimers bind to E-
box elements and impede MYC binding to the DNA [44, 45]. In a second, E-box independent 
way of transcriptional repression, MYC forms a complex with MIZ-1 and initiates DNA 
methylation resulting in transcriptional repression [46, 47].  
MYC proteins are characterized by a short half life of 20-30 min and a high turnover rate [48]. 
The presence of MYC in the cells is regulated by transcription of the MYC gene on one hand 
and the degradation of MYC on the other hand. The transcription of MYC is regulated through 
a number of different signaling pathways involving for example Wnt/ β-Catenin or PI3K/AKT 
[32]. MYC degradation works via ubiquitination and proteasomal degradation. Phosphorylation 
of the serine 62 residue stabilizes MYC, whereas a sole threonine 58 phosphorylation marks 
the protein for ubiquitination through the SCFFBW7 ubiquitin ligase and degradation [49, 50].  
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MYC is involved in the regulation of a high proportion of genes, more than 25000 binding sites 
are known in vivo, with only a small fraction of them with E-boxes in the promoter region [51, 
52]. It is supposed that MYC mediated transcription follows a general amplifier model with MYC 
activating the transcription on open promoters in the cell, resulting in individual gene 
expression patterns for different cell types [53]. Additional to the transcription of RNAs by RNA 
polymerase 2, MYC is also mediating transcription of tRNAs and rRNAs by the RNA 
polymerases 1 and 3 [54, 55]. 
 
 
Figure 2: MYC domains and binding sites. C-terminus with basic region (BR), helix-loop helix (HLH) and leucine 
zipper (LZ) domains for dimerization of MYC with MAX or MIZ-1. N-terminus containing myc-boxes I-III, interacting 
with proteins responsible for MYC functions, MYC turnover, stability and with phosphorylation sites for regulation of 
proteasomal degradation (From Adhikary, S. and Eilers, M., 2005 [56]). 
 
1.2.2 MYC and its cellular functions 
A variety of different and contrary cellular processes are influenced by proteins of the MYC 
family. On one hand MYC is activating tumor promoting effects such as cell proliferation, 
inhibition of differentiation, cell growth, vascularization, genomic instability, reduced adhesion 
and metastasis. On the other hand, tumor suppressing processes, for instance apoptosis, cell 
differentiation or cell adhesion are positively influenced by MYC. MYC is also playing a role in 
metabolism [56].  
Cell proliferation is mainly regulated at the transition from G1 to S phase of the cell cycle. MYC 
is involved in a number of control mechanisms at the G1/S transition whereof a deregulation 
of MYC proteins can lead to enhanced cell proliferation. One way of influencing cell cycle 
progression is through the MYC downstream targets CDK4 and D-type cyclins, with Cyclin D1 
as the most prominent member of the family. The CDK4/Cyclin D1 complex phosphorylates 
Retinoblastoma protein (pRB), which leads to a conformational change of pRB. Thereby, the 
transcription factor E2F-1, bound to hypophosphosphorylated pRB, is released and initiates 
the synthesis of genes required for G1-S transition [57]. 
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Whereas CDK4 protein expression is induced by MYC, it is not finally clarified how D-type 
cyclins, especially CCND1, are regulated by MYC proteins [58, 59]. In fibroblasts it was found 
that the CCND1 expression is repressed by c-MYC [60]. In contrast, research on targets of the 
sonic hedgehog pathway indicates that Cyclin D1 is activated by MYCN, probably by an 
indirect pathway [61]. Cyclin D2 is a direct target of c-MYC [62]. 
Another way how MYC is influencing the G1-S transition involves TP53. When DNA damage 
occurs, TP53 is stabilized and induces the synthesis of the CDK inhibitor p21, which binds to 
CDK-Cyclin complexes and prohibits the phosphorylation of target genes [63]. Thereby, the 
replication start is impeded, and the cell is arrested in the G1 phase of the cell cycle. MYC 
directly represses the expression of p21, which results in enhanced proliferation irrespective 
of potential DNA damage [64, 65]. TP53 is also directly activated by MYCN and c-MYC, leading 
to the induction of a second, proapoptotic pathway involving TP53 [59, 66]. The activation of 
the expression of p19ARF by MYC promotes the apoptotic pathway by stabilization of TP53 
through MDM2 inhibition [67]. 
MYC is also promoting apoptosis by repression of the antiapoptotic proteins BCL2 and BCL-
xL, as well as by the indirect induction of BIM, leading to the release of cytochrome c from the 
mitochondria [68, 69].  
The oncogenic transformation by MYC is involving Ras, which stabilizes MYC by influencing 
the phosphorylation directly and indirectly through GSK3β [50]. In a second pathway promoting 
oncogenic transformation, the Ras downstream effector AKT phosphorylates MIZ-1 and 
thereby abrogates the MYC dependent transcriptional repression [70]. Additionally, AKT 
phosphorylates FOXO, which is a co-factor of MYC and inhibits MYC-dependent transcription 
of MYC target genes in its hypophosphorylated state [71]. 
 
1.2.3 MYCN as a target gene in neuroblastoma 
A deregulated MYCN expression is found in a number of malignancies including 
neuroblastoma, medulloblastoma, rhabdomyosarcoma, Wilm’s tumor, lymphatic leukemias, 
lung cancer, prostate cancer and basal cell carcinoma [72]. Therapeutic targeting of MYCN 
would be of significance for treatment of these diseases.  
In vitro studies targeting MYCN by RNA interference in various neuroblastoma cell lines 
resulted in a growth arrest of the neuroblastoma cells in the G1 phase of the cell cycle, in cell 
death and differentiation of the tumor cells [73, 74]. Nevertheless achieving similar results in 
vivo is challenging. An attempt to target MYCN or other MYC transcription factors directly is 
not feasible as the structure of the MYC proteins does not provide structures on the surface 
where inhibitors could bind and prohibit MYC functions [75]. Therefore, indirect attempts were 
in the focus for targeting MYCN in neuroblastoma.  
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Inhibition of the MYCN-MAX dimerization through small molecule inhibitors resulted in cell 
death and differentiation of neuroblastoma cells under cell culture conditions [76].  
Pharmacokinetic analysis of these inhibitors revealed a short half-life in vivo, which 
consequently makes them not suitable for clinical usage [77].  
Stability and degradation of the MYCN protein are influenced by Aurora A kinase and the 
PI3K/AKT/mTOR signaling pathway. An Aurora A kinase inhibitor (alisertib) showed promising 
results in preclinical studies, however it was not effective for neuroblastoma patients in a phase 
I clinical trial, especially not for patients with MYCN amplified tumors [78, 79]. An activation of 
the PI3K/AKT/mTOR pathway decreases the expression of GSK3β, which results in a higher 
MYCN activity. Inhibition of this pathway using different small-molecule inhibitors, leads to 
growth arrest and cell death of neuroblastoma cells [80, 81].  
Downstream of MYCN, the inhibition of ALK with Crizotinib results in a lower proliferation rate 
of neuroblastoma cells with mutations in the ALK gene [23]. In vivo ALK inhibitors show 
promising results, though treatment in combination with other chemotherapeutic drugs is 
advisable due to increasing resistance of the tumors [82]. The TP53 axis in neuroblastoma is 
often affected by MDM2 overexpression. Targeting MDM2 with nutlin-3 reestablishes the 
function of p53 and is therefore a potential therapeutic option, especially effective for MYCN 
overexpressing neuroblastoma cells [83]. 
Influencing the gene transcription activity of MYCN would be a promising therapeutic option 
for malignancies with deregulated MYCN. Usage of bromodomain inhibitors as an attempt to 
block transcription of the MYCN gene is a central topic of this work and deeply introduced in 
part 1.3. 
 
1.3 BET proteins 
1.3.1 BET family of transcription factors 
The BET (bromodomain and extraterminal domain) protein family comprises of the 
transcription factors BRD2, BRD3, BRD4 and BRDT. At the N-terminus BET proteins have two 
bromodomains named BD1 and BD2. At the C-terminal they share an extra-terminal domain 
important for protein-protein interactions [84]. In general, BET proteins function as epigenetic 
readers.  
Bromodomains recognize and bind acetylated lysine residues on histones and other cellular 
proteins [85]. They are composed of four α-helices connected by two loops. Together with the 
α-helices, these ZA and BC loops form a hydrophobic cavity binding aminoacetyl groups [86]. 
The binding affinity is increased with multiple acetylated sites compared to single acetylated 
lysines [87]. 
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In the human genome, 61 bromodomains are encoded, belonging to 46 different bromodomain 
containing proteins. These proteins can be assigned to eight bromodomain containing protein 
families [87]. In general, the BD1 domains from different proteins are closer related than BD1 
and BD2 on the same protein [86]. 
Among the BET protein family, BRD4 is the protein studied best. One mechanism of action is 
the participation with P-TEFb for transcriptional regulation (Figure 3). P-TEFb, comprising of 
CDK9 and Cyclin T, is recruited to the acetylated DNA by BRD4. Belonging to the transcription 
initiation complex, P-TEFb recruits RNA polymerase II to the DNA and phosphorylates the C-
terminal domain (CTD) of RNA polymerase II to release the polymerase from the transcription 
initiation complex and to promote transcriptional elongation [88, 89].  
Additionally, BRD4 itself harbors a kinase and acetyltransferase activity and can phosphorylate 
the CTD of RNA polymerase II and acetylate histones H3 and H4 directly [90, 91]. A third 
function of BRD4 is as histone chaperone. Thereby, BRD4 is facilitating the passage of RNA 
polymerase II along acetylated nucleosomes during transcriptional elongation [92]. 
  
 
Figure 3: Transcriptional regulation by BRD4 and P-TEFb. BRD4 binds acetylates lysines on histones. P-TEFb 
phosphorylates the CTD of RNA polymerase II, leading to elongation of mRNA transcription. Purple=nucleosomes; 
green= aminoacetyl-groups;  orange= BRD4; blue= p-TEFb; yellow=RNA polymerase II; red stars= phosphorylated 
sites (adapted from Popovic et.al., 2012 [93]). 
  
BRD4 is part of the mediator complex incorporating RNA polymerase II with multiple 
transcription factors [94]. In this context, BRD4 stabilizes the binding of the transcription factors 
to the DNA, especially at enhancer and super enhancer regions [95, 96]. In contrast, a function 
as transcriptional repressor involving PPARγ was found for BRD2 [97]. 
BRD4
AcAc
P-TEFb
BRD4
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P-TEFb
RNA-pol II
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BET proteins are involved in different pathological processes. For example, they play a role in 
inflammation and cardiac insufficiency [98, 99]. Viral gene expression of latent viruses such as 
HIV or HPV is also involving BET proteins [100, 101]. 
 
1.3.2 Role and function of BET proteins in cancer 
BET proteins are involved in the biology of a variety of different haematologic and solid 
malignancies. An inhibition of BET proteins is leading to a lower phosphorylation of RNA 
polymerase II and to a severe reduction of global mRNA levels. This includes the suppression 
of proto-oncogenes, for example members of the MYC family or Bcl2 [84].  
BRD4 directly interacts with specific cancer promoting transcription factors, including p53, c-
JUN or the MYC/MAX heterodimer [102]. By occupying the MYC promoter, BRD4 prevents the 
induction of the MYC-dependent apoptotic pathway resulting from DNA damage [103]. Aurora 
B, whose expression is depending on BRD4, is necessary for the chromosomal segregation 
during mitosis; thereby BRD4 is involved in cell proliferation [104].  BRD4 also promotes 
metastasis by direct interaction with the acetylated transcription factor Twist, which leads to 
the induction of epithelial-to-mesenchymal-transition [105]. 
Besides BRD4, BRD2 and BRD3 are also involved in cancer promoting pathways. BRD2 
associates with the transcription factors E2F1 and E2F2 important for the synthesis of genes 
for the G1/S transition of the cell cycle [106]. BRD3 was found to downregulate the RB-E2F 
axis in nasopharyngeal cancer [107]. 
On the genome, BRD4 globally associates with active promoters and enhancers, the latter 
identified by acetylation of the histone H3K27 [95]. The enhancers bound by BRD4 are located 
near genes sensitive for BET inhibition [108, 109]. Especially high BRD4 occupancy and high 
levels of transcription factor and mediator binding were detected on large enhancers, called 
super-enhancers. In multiple myeloma these super-enhancers are associated with genes 
known to be involved in carcinogenesis such as c-MYC, CCND2 or Bcl-xL. These super-
enhancer regulated genes are highly dependent on BRD4 [95]. At the enhancers BRD4 is 
forming complexes with the Jmjd6 demethylase, facilitating the recruitment of P-TEFb to the 
location on the genome [110].  
Cell cycle progression is influenced by BRD4 in different cell cycle phases. The G2/M transition 
is promoted by recruitment of P-TEFb for the transcription of postmitotic genes and thereby 
preparation of the next cell cycle [111]. In this context, BRD2 and BRD4 have the ability to bind 
to mitotic condensed chromatin [112]. The role of BRD4 at the G1/S transition is ambivalent: 
On one hand, BRD4 inhibition using shRNA leads to a G1 arrest and reduced expression of 
G1 genes [113]. On the other hand, ectopic BRD4 overexpression has the same effect. The 
repression of replication factor C mediated by BRD4 arrests the cells at the G1/S transition 
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[114]. Both studies rely on fibroblast cells (NIH 3T3) and were using serum starvation for 
synchronization. 
 
1.3.3 BET protein inhibitors 
As BET proteins, especially BRD4, are heavily involved in cancer progression and beyond that 
offer a strategy to target MYC indirectly, they have become a focus in cancer research during 
the past years. 
First of all, BRD4 was used as a target gene for NUT-midline carcinoma. This cancer harbors 
a BRD4-NUT translocation leading to high BRD4 protein expression [115]. Treatment with the 
BET inhibitor JQ1 results in abandoning of BRD4-NUT from the chromatin, in cancer cell 
differentiation and growth arrest [116].  
JQ1, a thienotriazolodiazepine, targets the BD1 of BRD4 and other BET family proteins by 
competitive inhibition (Figure 4A). JQ1 has two enantiomeres, solely (+)-JQ1 has a high affinity 
for bromodomain binding [116, 117]. Similar characteristics concerning affinity and inhibition 
behavior account for the BET inhibitors I-BET762 and I-BET151 [98]. All three inhibitors are 
hydrophobic, which limits the bioavailability, shortens the half-life of the inhibitor in vivo and 
reduces the possibility for chemical modifications [118].  
 
 
Figure 4: BET inhibitors. A) Chemical structure of JQ1 (from Filippakopouls et. al. [116]). B) List of currently 
available BET inhibitors for preclinical use and in clinical phase I and II studies (adapted from Gelato et. al. [119]). 
 
A negative influence of BET inhibition on MYC gene expression was discovered in preclinical 
studies on multiple myeloma, acute myeloid leukemia, and lymphoma in 2011 [103, 108, 120]. 
Besides growth arrest and a reduction of tumorigenic characteristics, a direct downregulation 
of MYC mRNA and protein levels as well as MYC target genes was shown in all three cancer 
entities. For neuroblastoma, the first preclinical studies using BET inhibitors were published in 
2013 [121, 122]. Both studies show growth inhibition, a cell cycle arrest in G1 and increased 
Preclinical Clinical
JQ1 ABBV-075 GS-5829
I-BET762 BAY1238097 GSK 525762
I-BET151 BI 894999 INCB054329
BMS-986158 TEN-010
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fractions of cell death as well as reduced MYCN expression. A study with five different 
neuroblastoma cell lines using the BET inhibitor OTX015 suitable for clinical applications also 
reveals an influence on MYCN gene expression [123]. 
Up to date, 12 different BET inhibitors have been tested in clinical phase I and phase II trials 
(Figure 4B). These studies include NUT midline carcinoma, acute myeloid leukemia, 
myelodysplastic syndrome, lymphoma, multiple myeloma, breast-, prostate and colorectal 
cancer, pancreatic ductal adenocarcinoma and neuroblastoma [124]. Both single agent 
therapies and combination therapy with other drugs are tested. 
 
1.4 Neuroblastoma mouse models 
Modeling of neuroblastoma in animals is an important tool for neuroblastoma research, 
especially for analysis of tumorigenesis and for testing of promising therapeutic agents. Animal 
models deliver additional information concerning aspects of tumor diseases that cannot be 
modeled in cell culture. These include the formation of blood vessels with their contribution to 
tumor growth and therapeutic relevance, the role of the immune system in neuroblastoma 
tumorigenesis, invasive growth and metastasis of neuroblastomas, and the formation of 
complex tumors in the appropriate microenvironment.  
For neuroblastoma a variety of mouse models have been established over the past decades 
[125, 126]. They can be assigned to the two main categories of transgenic neuroblastoma 
mouse models and xenograft neuroblastoma mouse models.  
Transgenic neuroblastoma mouse models are generated by genetic modification and 
systematic breeding of mice. Once established, the tumors of these mice are developing on 
their own at early age and undergo a tumor evolution resembling the natural tumor evolution 
including early stages of disease. For neuroblastoma several different transgenic tumor 
models were established.  
- The TH-MYCN mouse model is the transgenic mouse model mostly used for research. 
In this neuroblastoma mouse model MYCN is overexpressed in cells deriving from the 
neural crest [127]. The expression of MYCN in these mice is controlled by the rat 
tyrosine hydroxylase promoter, which is active in migrating cells from the neural crest 
cell lineage. The mice develop neuroblastoma-like tumors in thorax and abdomen. 
Analysis of TH-MYCN tumors revealed additional genetic and chromosomal changes 
in the tumors that resemble the genetics of human neuroblastomas. 
- The LSL-MYCN;Dbh-iCre neuroblastoma mouse model is also based on MYCN 
overexpression [128]. In this double transgenic mouse model, MYCN is induced in 
neural crest cells expressing β-hydroxylase. The tumors of LSL-MYCN;Dbh-iCre mice 
resemble human neuroblastomas more than tumors of TH-MYCN mice with regard to 
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tumor location and genomic aberrations and show a higher incidence in a number of 
mouse strain backgrounds.  
- Additionally to the models using MYCN overexpression, several other transgenic 
neuroblastoma mouse models exist, without being commonly used [125]. Many of 
those are involving viral constructs as SV40 T-antigen as driver for tumorigenesis. 
Compared to the MYCN involving models it is unsure if virus-based transgenic models 
are suitable for research on neuroblastoma tumorigenesis.  
 
Neuroblastoma xenograft models are the second main category of neuroblastoma mouse 
models. In these models, human tumor material is introduced in immunocompromized mice; 
the human cancer cells settle and form tumors. Xenograft tumors allow the analysis of tumors 
close to the genetics and growth behavior of human neuroblastomas. Nevertheless the 
predictive value of these models concerning therapeutic attempts remains unclear. Among the 
xenograft tumor models, three different versions are in common use. 
- In heterotopic xenograft tumor models the human tumor cells are injected at a location 
in the bodies of the mice that is not related to the tumorsite of origin. In most cases, the 
tumor cells are injected subcutaneously into the flank, which facilitates documentation 
of tumor size through the skin. 
- Orthotopic xenografts are generated by implantation of human tumor cells at the 
original location of the tumor. This enables tumor growth in an adequate 
microenvironment with access to the blood vessels of the original tumor, which results 
in corresponding metastatic pathways. In orthotopic neuroblastoma mouse models the 
human tumor cells are injected into the adrenal gland or the surrounding fat pad of the 
mice [126].  
- Patient derived xenografts (PDX) are the animal model closest to the original tumor of 
the patient and are performed by implantation of a human tumor piece in 
immunocompromized mice. Neuroblastoma PDX models were generated by 
implantation of the human tumor next to the adrenal gland, subcutaneously or in 
teratoma tissue [129-132]. PDX animal models are performed in circles, the tumors 
grown in mice are explanted, divided and reimplanted or established in cell culture until 
enough material for extensive experiments is available. The use of tumor tissue instead 
of established cell lines protects the structure of the original human tumor and allows a 
closer modeling of the patient’s tumor as the stroma cells are of human origin- at least 
in the first generation of PDX.  
 
All transgenic and xenograft neuroblastoma mouse models harbor advantages and limitations. 
The tumors of the transgenic mouse models develop influenced by an intact immune system, 
which is an important factor in cancer and lacks all xenograft models. As well, the xenograft 
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models do not undergo different stages of tumor evolution but are displaying the tumor stage 
and characteristics the human tumor material derives from. The transgenic models are not 
capable of representing the variety of genetics of different neuroblastoma tumors, in contrast 
to the xenograft models that are using tumor material originating from a large number of 
neuroblastoma cases. Additionally, the orthotopic and heterotopic xenograft models enable 
genetic modifications of the tumor cells prior to implantation. Due to cell culture artifacts 
collected by established neuroblastoma cell lines over time used for the heterotopic and 
orthotopic xenograft models, the PDX tumor model is the mouse model closest to human 
tumors.  
Metastasis can occur in all neuroblastoma mouse models except the subcutaneously growing 
heterotopic xenograft model, though rate and location of metastasis are varying. The 
metastatic behavior closest to human neuroblastomas is observed in PDX models, whereas 
orthotopic neuroblastoma xenografts metastasize at a lower rate. Metastasis to the bone 
marrow is reduced in all neuroblastoma mouse models compared to human neuroblastomas 
[133].  
With regard to practical aspects the subcutaneous xenograft model has advantages compared 
to the other models. The implantation of the human tumor cells is easy and time-saving and 
tumor growth can be measured through the skin. In contrast, orthotopic neuroblastoma mouse 
models (cell lines or PDX) need imaging methods to follow up tumor growth and for 
implantation of the human tumor material anesthesia and invasive methods are unavoidable. 
In the genetic models, tumor onset is non-invasive as the tumors are growing on their own, 
whereas for monitoring of tumor growth, imaging methods are used. 
PDX neuroblastoma mouse models resemble the human tumors they are deriving from in 
many aspects. However, the material for first generation PDX mice is limited and tumor 
formation takes a long period of time. Differences between the first and following generations 
of one PDX lineage are a current focus of research [134].  
Additional to mouse models, neuroblastoma tumorigenesis can also be modeled in zebrafish, 
which is a useful model for questions regarding neuroblastoma pathogenesis and high-
throughput drug screenings [135]. Genetic manipulation of zebrafish is easier than for mice 
and the external evolution of the embryos facilitates insights into physiological and pathological 
behavior of neural crest cells. Available neuroblastoma tumor models in zebrafish are for 
example the MYCN-ALK model, the PHOX2B model or the NF-1 deficient/MYCN model [136-
138]. 
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2 Aim of the project 
 
Amplification of the proto-oncogene MYCN belongs to the most important risk factors within 
neuroblastoma disease. The resulting high MYCN expression levels are associated with poor 
response to therapy and a poor outcome for the patients. Despite MYCN was in the focus of 
neuroblastoma research since its importance was detected by Schwab et. al. in 1983, no 
therapeutic option is available yet targeting MYCN in neuroblastoma [12]. 
In 2011, Delmore et al., Mertz et al. and Zuber et al. have shown that inhibition of the BET 
protein BRD4 impairs the transcription of c-MYC and its target genes in MYC-dependent 
cancers [103, 108, 120]. Based on these findings, the effects of BRD4 inhibition in MYCN 
amplified and MYCN non-amplified neuroblastoma cell lines were analyzed in this thesis, 
focusing on the following tasks: 
- Classifying the response to BET inhibition in different neuroblastoma cell lines and 
integrating the results regarding the genetic background and biologic characteristics of 
the cell lines. 
- Characterization of the effects of BET inhibition on tumorigenic characteristics of the 
neuroblastoma cell lines, such as cell cycle or anchorage independent growth. 
- Analysis of genes and pathways affected by BET inhibition besides and related to 
MYCN by high throughput analysis of the transcriptome and proteome. 
- Performance of a treatment study with a BET inhibitor in a subcutaneous 
neuroblastoma mouse model. 
 
Both, for fundamental and preclinical research it is essential that suitable animal models are 
available. For neuroblastoma, genetic models are based on MYCN overexpression. 
Alternatively, xenograft models are using neuroblastoma cell lines or tumor pieces deriving 
from either MYCN amplified or MYCN non-amplified human neuroblastomas. Nevertheless, 
no neuroblastoma mouse model is available harboring both MYCN high and MYCN low 
conditions. Aiming to have a MYCN high/low neuroblastoma mouse model available in the 
neuroblastoma genomics group at the DKFZ, such a model was established by working on the 
following topics: 
- Generation of genetically modified neuroblastoma cells harboring both a luciferase 
gene and an inducible MYCN high/low system. 
- Technical establishment of the orthotopic neuroblastoma mouse model aiming a tumor 
growth rate of 80%. 
- Adaption of imaging methods and tumor sample handling for the orthotopic MYCN 
high/low mouse model. 
- Quantification of the MYCN knockdown in the xenograft tumors. 
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3 Materials 
3.1 Gadgets 
Gadget specification company 
bacteria centrifugation tubes  500 ml Beckmann  
bacteria shaker Innova 4300 New Brunswick Scientific  
bioanalyzer 2100 Bioanalyzer Agilent genomics 
bioluminescence imager 
  
IVIS Spectrum  Perkin Elmer 
built in-house DKFZ 
blotting chamber mini-PROTEAN Bio-Rad 
cell counter 
LUNA automated cell 
counter 
logos biosystems 
cell culture hood Cellgard Integra bioscience 
centrifuges 
  
  
Allegra X-12 Beckmann Coulter  
Thermo 17 Heraeus 
J2-21M/G Beckmann 
chemiluminescence detection Chemi-Capt 5000 Vilber  
colony counter gel doc Bio-Rad 
cryo container Mr. Frosty Nalgene  
FACS 
  
FACS Calibur BD Biosciences 
MacsQuant Milteny 
falcon roller Cat RM5 Neolab 
freezer -20°C   Liebherr 
freezer -80°C   Sanyo 
fridge 4°C   Liebherr 
gel holder/brace clip   Bio-Rad 
gelelectrophoresis chamber mini-PROTEAN Bio-Rad 
glass bottles 100, 500, 1000 ml Schott Duran 
glass plates/combs for mini gels   Bio-Rad 
graduated cylinder 100, 250 ml Vit Lab 
heater/shaker (reaction tubes) Thermomixer 5436 Eppendorf 
heating pad   AccuLux 
incubator cell culture Hepa Class 100 Thermoelectron Corporation  
isofluran vaporisator vapor 19.3 Dräger  
magnet resonance imager Symphonie 1.5 tesla Siemens 
magnetic stirrer MR 3001 Heidolph  
microscopes 
  
Axiovert 10 Zeiss 
CKX41 Olympus 
microwave   Bosch 
mouse magnetic coil built in-house DKFZ 
multichannel pipettes 0.5-10, 30-300 µl BioHIT 
multistepper pipet Multipipette M4 Eppendorf  
Nano- Drop   Peq-Lab 
narcotic box built in-house DKFZ 
PCR cycler Trio Thermoblock Biometra  
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pH-meter pH 540 GLP WTW  
photometer GeneQuant 1300 GE Healthcare 
pipetboy   Integra Bioscience 
pipettes 
0.5-10, 2-20, 10-100, 100-
1000 µl 
Eppendorf 
plate reader FLUOSTAR Optima BMG Labtech 
plate scanner Perfection 2450 Photo EPSON 
power supply PHERO-stab. 500 Biotec Fischer  
pumping apparatus built in-house DKFZ 
qPCR cycler ABI Prism 7000 Life Technologies 
Qubit 3.0 fluorometer   Life Technologies 
scales PE 3000, PM460 Mettler 
shaker (plates) KS250 basic IKA Labortechnik  
tissue homogenizer dounce tisue grinder Sigma-Aldrich  
vortexer Reax 2000 Heidolph 
water bath 37°C GFL 
 
3.2 Consumables 
material specification company 
cell culture dishes 60, 100, 150 mm TPP 
cell culture flasks 25, 75, 150 cm² TPP 
cell scraper   TPP 
cryo tubes   NUNC 
cuvettes (single use) half micro Greiner bio-one 
embedding molds 12 mm polysciences 
falcon tubes 15, 50 ml Greiner bio-one 
multistepper pipet tips Combitips advanced Eppendorf  
needles 30 G, 27 G, 24 G Braun 
nitrocellulose membrane Protran Whatman Schleicher & Schuell 
pasteur pipettes 150, 230 mm  WU Mainz  
pH paper 7 mm width Macherey-Nagel 
pipet tips 10, 200, 1000 µl Starlab 
pipet tips, filter 10, 20, 100, 200, 1000 µl Starlab 
pipet tips, narrow 200 µl  Bioscience inc. 
pipettes 5, 10, 25 ml Costar 
plates black 96 well Greiner bio-one 
plates transparent 
  
6, 96 well TPP 
12 well NUNC 
plates white 96 well NUNC 
qPCR plates 96 well Biozym Scientific 
qPCR top sheet Micro Amp Applied Biosystems  
qubit tubes   Thermo scientific 
reaction tubes, safe-lock 8x0.1, 0.5, 1.5, 2 ml Eppendorf 
reservoirs    Roth 
scalpel, single use   fine science tools 
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sheet protector    Leitz 
slides cell counter   logos biosystems 
sponges (western blot)   Bio-Rad 
staples   fine science tools 
suture, absorbable PGA, DSM 13 Resorba 
syringes 1 ml Dispomed  
tissue paper   Satino 
tube, flexible 
(mouse injections) 
Portex polythese tubing,  
OD=0.61 mm 
Smiths Medical  
International Ldt. 
whatman-paper 3 MM Chr. Whatman  
 
3.3 Chemicals 
chemical company  chemical company 
acrylamide/ bis 40% Serva  KH2PO4 Merck 
APS Roth  methanol Sigma-Aldrich 
bromophenol blue Serva  MgCl2 Roth 
BSA Sigma-Aldrich  milk powder Roth 
chloroform Baker  Na2HPO4 Sigma-Aldrich 
citrate monohydrate Riedel DeHaën  NaCl Sigma-Aldrich 
complete protease 
inhibitor  
Roche  NaHCO3 Merck 
crystal violett Serva  noble agar US-Biological 
DAPI AppliChem  
phosStop phosphastase 
inhibitor 
Roche 
DEPC Roth  propidium iodide Miltenyi 
DMSO Roth  RPMI 1640 powder PAN Biotech 
doxorubicin 
hydrochloride 
Sigma-Aldrich  SDS Gerbu 
DTT AppliChem  sodium acetate Roth 
EDTA Roth  sucrose Roth  
ethanol abs. Sigma-Aldrich  TEMED AppliChem 
formaldehyde 16% Sigma-Aldrich   tris base Sigma-Aldrich 
glycerol Roth  tris HCl AppliChem 
glycine Gerbu  Triton X-100 AppliChem 
goat normal serum Dianova  trypton DIFCO-biotest 
H2O dest from millipore  Tween 20 Gerbu 
HCl Sigma-Aldrich   urea Merck 
isopropanol Sigma-Aldrich  yeast extrakt Gerbu 
KCl Roth  β- mercaptoethanol Roth 
 
3.4 Mouse pharmaceuticals and applicants 
material specification company 
NaCl 0.9%, sterile 10 ml, ampulla Fresenius Kabi 
water, sterile 10 ml, ampulla Fresenius Kabi 
eye ointment bepanthen eye and nose Bayer 
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analgesic metamizole, 500 mg/ml WDT 
Isofluran  Baxter 
Matrigel Matrix, high concentration BD 
Doxycycline  Sigma-Aldrich 
D-luciferin  Synchem 
 
3.5 Cell culture materials 
3.5.1 Cell lines 
All neuroblastoma cell lines used for this thesis were purchased from the laboratory-internal 
stock from the Neuroblastoma Genomics group at the DKFZ. 
 
3.5.2 Media and supplemental 
material specification company 
RPMI-1640 L-Glutamin, 25 mM Hepes Lonza 
Opti-MEM  Gibco  
Neurobasal A Medium  Gibco  
PBS (sterile, for cell culture)  Gibco  
fetal bovine serum (FCS)  Biochrom AG 
Penicillin/Streptomycin 10000 U/m Serva 
B27 Supplement  Gibco  
FGF-b human  PromoKine 
EGF human  PromoKine 
L-Glutamin 200 mM Gibco 
Heparin  Sigma Aldrich 
Blasticidine 41,25 mg/ml MP Biomedicals 
Zeocin 100 mg/ml Invitrogen 
Hygromycin B 10 mg/ml Roche 
Tetracycline 10 mg/ml Sigma 
JQ1 (+)-enantiomere, item 11187 biomol 
BAY1238097  Bayer Healthcare 
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3.5.3 Cell culture media (cell line specific) 
basic cell culture medium, for all cell lines without stable transfections 
cell culture medium (500 ml) RPMI-1640 
FCS 10% 
Penicillin/Streptomycin 100 u/ml 
 
cell culture medium for suspension cells NB-S 124 
cell culture medium (500 ml) Neurobasal A 
B27 Supplement 2% 
FGF-b human 20 ng/ml 
EGF human 20 ng/ml 
L-Glutamin 0.5 mM 
Heparin 2 µg/ml 
Penicillin/Streptomycin 100 u/ml 
 
  IMR5/75 MYCN high/low IMR5/75 MYCN high/low / Luci 
cell culture medium (500 ml) RPMI-1640 RPMI-1640 
FCS 10% 10% 
Penicillin/Streptomycin 100 u/ml 100 u/ml 
Blasticidine 5 µg/ml 5 µg/ml 
Zeocin 50 µg/ml 50 µg/ml 
Hygromycin B -- 24 µg/ml 
 
   
  IMR32 MYCN high/low IMR32 MYCN high/low / Luci 
cell culture medium (500 ml) RPMI-1640 RPMI-1640 
FCS 10% 10% 
Penicillin/Streptomycin 100 u/ml 100 u/ml 
Blasticidine 5 µg/ml 5 µg/ml 
Zeocin 250 µg/ml 250 µg/ml 
Hygromycin B -- 27 µg/ml 
 
3.6 Surgical instruments/ mouse work 
instrument specification company 
sciccors straight, curved Fine science tools 
forceps  Fine science tools 
needle holder  Fine science tools 
spatle double, 6 mm Laborhaus Scheller 
ruler  Fine science tools 
feeding needles reuseable, 30 mm Fine science tools 
ear punch 3 mm Fine science tools 
clip applicator  Fine science tools 
sterilisation container   Fine science tools 
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3.7 Enzymes, standards and special reagents 
material specification company 
alamar blue   Serotec 
ampicillin   Sigma-Aldrich 
benzonase   Merck Bioscience  
bioanalyzer RNA kit 6000 Nano Assay Kit  Agilent genomics 
bradford reagent   Bio-Rad 
ECL detection reagent 
BM Chemiluminescence Blotting 
substr. 
Roche 
glo lysis buffer   Promega 
glycogen stock solution   Roche 
protein standard 10-170 kDa PageRuler Prestained Protein Ladder Fermentas 
Qiazol   Qiagen 
Qubit RNA quantification Qubit HS assay Invitrogen 
tissue tec   Sakura 
transfection reagent (stable) Effectene, EC buffer, enhancer Qiagen 
transfection reagent 
(transient) 
Lipofectamine 2000 Invitrogen 
Trizol   Ambion  
trypan blue   
Thermo fisher 
scietific 
 
3.8 Kits 
method specification company 
maxiprep Plasmid Maxi Kit Qiagen 
cDNA synthesis First Strand cDNA Synthesis Kit Fermentas 
qPCR 
Platinum SYBR Green qPCR SuperMix 
UDG 
Invitrogen 
luciferase expression Steady glo luciferase assay Promega 
DNA digestion DNase I set Qiagen 
RNA isolation/purification 
(tumor) 
Nucleo Spin 
Macherny-
Nagel 
RNA isolation/purification 
(cells) 
RNeasy Qiagen 
 
3.9 Antibodies 
3.9.1 Primary antibodies 
Protein Art company catalog no. 
Actin monoclonal Sigma A-5441 
BRD2 monoclonal Cell signaling technology CST 5848 
BRD3 polyclonal Abcam 83478 
BRD4 monoclonal Abcam ab128874 
CDK4 monoclonal Dianova 09583 
c-MYC monoclonal Santa Cruz sc-42 
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Cyclin D1 monoclonal Dianova 08330 
E2F-1 monoclonal 
Santa Cruz 
Cell signaling technology 
sc-251 
CST 3742 
GSK3-β monoclonal Cell signaling technology CST 9315 
phospho-GSK3-β monoclonal Cell signaling technology CST 9323 
MDM2 monoclonal Santa Cruz sc-965 
phospho-MDM2 polyclonal Cell signaling technology CST 3521 
MYCN monoclonal Santa Cruz sc-53993 
p53 monoclonal Santa Cruz sc-126 
Rad17 monoclonal Cell signaling technology CST 8561 
 
3.9.2 Secondary antibodies 
Protein Art company catalog no. 
goat anti mouse POD monoclonal  Dianova 115-035-003 
goat anti rabbit POD monoclonal  Dianova 111-035-003 
 
3.10 Primers 
gene sequence company 
HPRT1 
for TGACACTGGCAAAACAATGCA Sigma 
rev GGTCCTTTTCACCAGCAAGCT Sigma 
SDHA 
for TGGGAACAAGAGGGCATCTG Sigma 
rev CCACCACTGCATCAAATTCATG Sigma 
MYCN  
for GGCCCTCAGTACCTCCGG Sigma 
rev AACGCCGCTTCTCCACAG Sigma 
c-MYC 
for 
QuantiTect Primer Assay Qiagen 
rev 
CCND1 
for 
QuantiTect Primer Assay Qiagen 
rev 
BRD4 
for CCCCTCGTGGTGGTGAAG Sigma  
rev GCTCGCTGCGGATGATG Sigma  
BRD3 
for 
QuantiTect Primer Assay Qiagen 
rev 
BRD2 
for GTGGTCGGTACCATGGTGCAAAACGTGACTCCCCACA Sigma  
rev GGCTAGGAATTCAATCGTATTTTGTCCATG Sigma  
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3.11 siRNAs/shRNAs 
gene sequence company 
MYCN shRNA in pTer Plasmid CTGGACAGTCACTGCCACT   
BRD4 siRNA 1 
sense AGAUUGAAAUCGACUUUGAtt Ambion,  
silencer select antisense UCAAAGUCGAUUUCAAUCUcg 
BRD4 siRNA 2 
sense CCUGAUUACUAUAAGAUCAtt Ambion,  
silencer select antisense UGAUCUUAUAGUAAUCAGGga 
BRD3 siRNA 1 
sense AGAGGAAGUUGAAUUAUUAtt Ambion,  
silencer select antisense UAAUAAUUCAACUUCCUCUtg 
BRD3 siRNA 2 
sense AGAUAGAAAUUGACUUUGAtt Ambion,  
silencer select antisense UCAAAGUCAAUUUCUAUCUcg 
BRD2 siRNA 1 
sense CUGGGAGUCUUGAGCCUAAtt Ambion,  
silencer select antisense UUAGGCUCAAGACUCCCAGga 
BRD2 siRNA 2 
sense GGUCUACCGGAUUAUCACAtt Ambion,  
silencer select antisense UGUGAUAAUCCGGUAGACCca 
Control siRNA  negative control siRNA #1  Ambion 
 
3.12 buffers and prepared solutions 
 
PBS and TBS have been prepared as a 10x concentrated stock solution. The table describes 
the final concentration used for experiments. 
 
solution/buffer chemicals weight storage 
2x RPMI (500 ml) RPMI powder 15,87 g 4°C 
  NaHCO3 (7,5% solution) 26 ml   
  H2O dest. 474 ml   
  → steril filtrated   
  pen/strep 10 ml   
    
agar 1% (100 ml) noble agar 1 g 55°C 
  H2O dest. 100 ml   
  → boiled   
 
agar 1,6% (100 ml) noble agar 1,6 g 55°C 
  H2O dest. 100 ml   
  → boiled   
    
Amresco running buffer,  0,025 M Tris (Base) 3,03 g RT 
 SDS-PAGE (1 l) 0,192 M glycine 14,4 g   
  0,1% SDS (20% solution) 5 ml   
  H2O dest. 995 ml   
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BAY1238097 (15 ml) BAY1238097 30 mg   4°C 
 NaCl 0.9% sterile, ampulla 15 ml  
 → pH 4  
    
complex blocking solution  20% milk powder 200 g -20°C 
(1 l) 20% FCS 200 ml   
  3% BSA 30 g   
  1% goat normal serum 10 ml   
  0,2% Tween 20 2 ml   
  PBS 788 ml   
    
crystal violet solution (50 ml) 0,1% crystal violet in ethanol 2,5 ml RT 
 PBS 47,5 ml  
    
DEPC- water (500 ml) 0,1% DEPC spatula tip RT 
  H2O dest. 500 ml   
  → autoclaved   
    
glycine 1.25 M (200 ml) glycine 18,77 g 4°C 
 H2O dest. 200 ml  
 
Lämmli-buffer (50 ml) 0,5 M Tris HCl 4 g RT 
  
4% SDS 10ml 
(20% solution) 
  
  20% glycerol 10 ml   
  β- Mercaptoethanol 5 ml   
  H2O dest. 25 ml   
 bromophenole blue spatula tip  
    
LB- Medium (1 l) yeast extrakt 5 g 4°C 
 trypton 10 g  
 NaCl 10 g  
 H2O dest. 1000 ml  
 → autoclaved  
 
luciferin solution (10 ml) D-luciferin potassium salt 1 g -80°C 
 NaCl 0.9% sterile, ampulla 10 ml  
    
M-per buffer (10 ml) phosphatase Inhibitor 1 tablet 4°C 
 complete protease inhibitor 1 tablet  
 EDTA 2mM 40 µl  
 H2O dest. 10 ml  
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PBS (1 l) 137 mM NaCl 8 g RT 
  2,68 mM KCl 0,2 g   
  10 mM Na2HPO4 1,42 g   
  1,76 mM KH2PO4 0,24 g   
  H2O dest. 1000 ml   
  → pH 7,4   
PBS-T (1 l) + Tween 20 1000 µl  RT 
PBS-PI (50 ml) + complete protease inhibitor  1 tablet 4°C 
    
PEG 80% (20 ml) polyethyleneglycol 16 ml 4°C 
 H2O sterile, ampulla 4 ml  
 
phospho- DAPI (100 ml) NaHPO4 7,1 g RT, dark 
  
DAPI- stock solution  
(1,26 mM) 
500 µl 
 
  H2O dest. 100 ml   
    
protein lysis buffer (50 ml) Tris (Base) 1 ml (1M) -20°C 
  Triton X-100 500 µl   
  Urea 21 g   
  DTT 5 ml (1M)   
  MgCl2 2 ml (1M)   
  complete protease inhibitor 2 tablets   
 H2O dest. 42 ml  
    
running gel buffer,  1,5 M Tris (Base) 90,9 g RT 
SDS-PAGE (500 ml) 0,4% SDS (20% solution) 10 ml   
 H2O dest. 500 ml  
  → pH 8,8   
    
stacking gel buffer,  1 M Tris (Base) 12,1 g RT 
SDS-PAGE (100 ml) 0,4% SDS (20% solution) 2 ml   
  bromophenol blue spatula tip   
 H2O dest. 100 ml  
  → pH 6,8   
 
TBS (1 l) 50 mM Tris 6 g RT 
  150 mM NaCl 8,8 g   
  H2O dest. 1000 ml   
  → pH 7,6   
 TBS-T + Tween 20 1000 µl   
    
Transfer buffer, western blot  25 mN Tris (Base) 3 g 4°C 
 (1 l) 192 mM glycine 14,4 g   
  20% methanol 200 ml   
  H2O dest. 800 ml   
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Versene (100 ml) PBS  100 ml 4°C 
  10 mM EDTA 0,3 g   
  → pH 7,0   
 
3.13 EDV 
Hardware PC (LG) 
Software Word, Excel, Powerpoint, Paint (Microsoft) 
 Acrobat Reader, Photoshop (Adobe) 
 EndNote X8 (Thomson Reuters) 
 ABI Prism 7000 (Applied Biosystems) 
 Chemi-Capt 5000 (Vilber) 
 CW4000 FISH (Leica) 
 FlowJo_V10 (Flexera Software) 
 
Imagescope (Aperio) 
Cell B Image (Olympus) 
 ImageJ (Wayne Rasband) 
 MITK (DKFZ) 
Web-Tools Venny 2.1.0 [139] 
 Reactome [140] 
 Uni-Prot [141] 
 Molbiotools [142] 
  
4 Methods 
4.1 Mouse experiments 
4.1.1 General animal keeping 
For mouse experiments, seven week old male CD-1 nude and NMRI mice were purchased 
from Charles River Sulzfeld. NSG mice were breeded at the DKFZ animal core facility. The 
mice were kept in isolated ventilated Cages (IVC) in a room with 12h day and night illumination 
and at constant room temperature. Food and water were provided ad libitum. The animal basic 
service like feeding and cleaning of the cages was done by in-house animal keepers. 
 
4.1.2 Anaesthesia and analgesia 
Mice were anaesthetized using inhalation anesthesia. Oxygen flow rate was 0.5 l/min with 1.5-
2 Vol% isofluran. Anaesthesia was initiated having the mice in a narcotic box. When the mice 
were narcotized, the eyes were protected using eye ointment and the mice were relocated to 
a heated ground to avoid cooling of the body. 
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Working with the orthotopic neuroblastoma mouse model, 200 mg/kg metamizol were applied 
subcutaneously before surgery. The analgetic therapy was continued for 48h, if necessary. 
 
4.1.3 Subcutaneous neuroblastoma model 
For the subcutaneous neuroblastoma mouse model, human neuroblastoma cells were injected 
in the right flank of immunocompromized mice. For this experiment, the cell lines IMR5/75, LS, 
NBL-S, SH-SY5Y and KELLY were used.  
First of all, the cells were prepared for implantation. The cells were harvested, counted, washed 
twice and resuspended in PBS and matrigel, mixed in a 1:1 ratio. The concentration was 
adjusted so that for every mouse, 5x105 cells in 100 µl PBS/matrigel were prepared in syringes. 
From cell line SH-SY5Y 1x106 cells were diluted in 150 µl PBS/matrigel. 
The mice were anaesthetized with isofluran. Then a 27 G needle was linked to the syringe with 
the cells prepared earlier and the cells were injected subcutaneous into the right flank of the 
mice.  
After implantation the mice were monitored daily for weight and general health condition. The 
tumor size was measured with a caliper twice a week or daily, depending on the experimental 
conditions. 
 
4.1.4 Orthotopic neuroblastoma model 
Establishment of orthotopic neuroblastoma tumors was achieved by injecting tumor cells in the 
left adrenal gland of immunocompromized mice. The mice were anaesthetized and bedded on 
the right side. An incision of 1-1.5 cm was made through skin and peritoneum. The left adrenal 
gland was exposed by carefully dislocating the left kidney using a scoop.   
For implantation of the tumor cells a special constructed pumping apparatus was used. A 
flexible tube was connected to a 30 G needle. Enough cells for 2 injections were gathered in 
the tube, then the needle was fixed with a needle holder and carefully inserted into the adrenal 
gland, taking care that the cutting of the needle was completely inside of the adrenal gland. 
Then 5x105 cells were injected in a volume of 10 µl cell culture medium. Successful 
implantation could be visually determined by swelling of the adrenal gland or of the surrounding 
fat pad. After injection, the needle was kept in the adrenal gland for a few seconds and then 
was taken out slowly to prevent leakage of the tumor cell solution. The incision on the 
peritoneum was closed by surgical stitching, whereas for the skin staples were used.  
During the first days after surgery wound healing was monitored daily. The staples were taken 
out 7-10 days after tumor cell implantation under short anesthesia using isofluran. 
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4.1.5 MYCN- repression 
To induce repression of MYCN levels in orthotopic neuroblastomas, doxycycline was added to 
the drinking water of the mice. For each 250 ml bottle of drinking water, 0.5 mg doxycycline 
and 3.125 g sucrose were prepared, correlating with a final concentration of 2 g/l doxycycline 
and 12.5 g/l sucrose. Treatment with doxycycline-containing water started 14 days after tumor 
cell implantation and was continued until the end of the experiment. 
 
4.1.6 Drug treatment 
Drug treatment with BAY1238097 started when the tumor reached a size of 3 mm in diameter. 
BAY1238097 was administered by oral gavage to the mice. The drug was solved in 0.9% NaCl, 
pH adjusted to 4. All mice were treated once a day with 10 mg per kg bodyweight for maximum 
30 days. The dose was adapted daily at the current weight of each animal. An appropriate 
volume was taken up with a syringe, a feeding needle was placed on the syringe and the 
remaining air was ejected. Then the mouse was fixed with one hand, the feeding needle was 
inserted down the throat until it reached the stomach and the drug was ejected.  
Treatment with JQ1 was performed at the group of Johannes H. Schulte, Charité Berlin. JQ1 
or the vehicle, 12.5% DMSO in PBS, were administered intraperitoneally. The mice were 
treated with 50 mg/kg body weight at the time points 0h, 12h, 24h and 36h.  
 
4.1.7 Euthanasia and tumor tissue samples 
The mice were euthanized at the end of the maximal duration of the experiment, when the 
maximal tolerable tumor size was reached, weight loss exceeded 20% or when they showed 
severe health problems. The mice were first anaesthetized with isofluran, and then euthanized 
by CO2 intoxication. 
The body of the dead mouse was opened on the ventral side (orthotopic tumors) or the flank 
(subcutaneous model) and pictures of the tumor in situ were taken. The tumor was taken out, 
weighed and photographed. The size was measured with a ruler, then the tumor was sliced 
into two parts. One piece was subsequently shock frozen in liquid nitrogen for RNA and protein 
analysis. The other part was embedded in tissue tec or formaline for histological analysis. From 
mice with huge orthotopic tumors, lung and liver were embedded in tissue tec to search for 
metastases. At the treatment study with BAY1238097, lung, colon, kidneys, liver, spleen and 
heart were conserved in formaline for toxicity evaluation. 
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4.2 In vivo imaging 
4.2.1 Magnet resonance imaging 
Magnet resonance imaging was done in cooperation with the DKFZ group “Molecular Imaging” 
headed by Dr. Dorde Komljenovic. A magnet resonance tomograph (MRT) for humans was 
modified with a mouse adapter with a small magnet coil for mice, which was installed 90° 
turned on the original MRT examination couch.  
The mice were anaesthetized with isofluran, eye ointment was applied, and they were placed 
in the mouse coil. For every mouse, a positioner program was run first to calibrate the machine, 
then T2 measurements in coronar and sagital directions were performed. Width of slices was 
1.0 mm, which was the smallest setting available. For analysis of the pictures and tumor 
volume calculation the software MITK was used.  
 
4.2.2 In vivo bioluminescence imaging 
For in vivo bioluminescence measurement two different imaging systems were tested. The first 
one was an imaging system built by the DKFZ group “Functional and Molecular Emission 
Computed Tomography” headed by Dr. Jörg Peter. The mice were anaesthetized with 
isofluran, eye ointment was applied and 150 µl luciferin solution were injected intraperitoneally. 
After two minutes, to ensure the luciferin reached the tumor cells, luminescence was 
subsequently measured. The measuring time varied between one and five minutes, images 
were taken from mice positioned on the back, on the side and on the venter. Additionally, 
incident light photographs were taken for positioning. 
The second bioluminescence measurement was performed with an IVIS Spectrum. The 
procedure was similar to the first measurement. With this imager up to three mice could be 
scanned in parallel. 
 
4.3 Basic cell culture methods 
4.3.1 Culturing cells 
Human derived neuroblastoma cell lines were cultured in RPMI 1640 medium containing 10% 
fetal bovine serum and 1% antibiotics (penicillin/streptomycin), hence called full medium. 
Adherent cells were cultured in cell culture flasks or cell culture dishes. Depending on the cell 
line, cell culture medium was changed up to three times per week.  
NB-S 124 suspension cells were cultured in Neurobasal A medium with supplements, called 
suspension medium here. To change the medium of the suspension cells, cell culture flasks 
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were positioned on a side for a few minutes, until the cells had sedimented. Then the upper 
fraction of the cell culture medium was replaced. 
The cells were kept in a cell culture incubator with 37°C temperature, 85% humidity and 5% 
CO2. 
 
4.3.2 Detaching cells 
Adherent cells were detached from the cell culture plates using Versene. Versene is an EDTA-
containing solution that detracts Ca2+-ions from adherent junctions from the cells.  
First, the medium was completely removed from the cell culture dish. Versene was added to 
the plate until the bottom was completely covered. The cells were incubated with Versene for 
3-5 minutes at room temperature. When the cells rounded up, which was monitored under the 
microscope, they were rinsed by pipetting. Addition of cell culture medium stopped the reaction 
and the cells were capable to attach again to the surface of a cell culture dish. 
Detaching of adherent cells was necessary for splitting of cultured cell lines, for counting and 
seeding for experiments and for harvesting of cells. 
 
4.3.3 Pelleting cells 
For some experiments, it was necessary to condense the cells to a pellet. This was achieved 
by centrifugation at 800 rpm for 5 minutes and room temperature. 
 
4.3.4 Freezing cells 
A freezing medium was prepared containing 45% RPMI 1640, 45% FCS and 10% DMSO. 
Cells were pelleted, and the supernatant was removed. Cells were resuspended in cold 
freezing medium; 1.5 ml cell suspension was transferred to each cryotube and the cells were 
put on ice quickly. Slow freezing of the cells was achieved by using a cryo container with 
isopropanol. This allows a continuous decrease of temperature by -1°C per minute. Cells were 
left at -70°C for about a week; afterwards they were brought to liquid nitrogen for long term 
storage. 
 
4.3.5 Thawing cells 
For thawing, a 15 ml falcon tube was prepared with 10 ml preheated full medium. 600 µl of the 
prepared medium were pipetted to the cryotube and transferred back to the falcon tube after a 
few seconds. This was repeated several times until the cells were completely thawed. The full 
medium with the cells was transferred to an appropriate cell culture flask. Medium was 
changed when the cells were attached, usually the next day. 
  Dissertation Maike Christine Nortmeyer 
42 
 
 
4.3.6 Counting cells 
For counting, 10 µl of cell suspension were mixed with 10 µl of 0.1% trypanblue and pipetted 
to a luna counting chamber. Cell number per mL and cell viability was calculated automatically 
using a luna automated cell counter. 
 
4.3.7 Harvesting cells 
At the end of an experiment, cells were harvested for further analysis. First, the cell culture 
medium was collected in an appropriate falcon tube. Then, the cells were detached using 
versene, added to the medium collected previously and pelleted by centrifugation. The 
supernatant was discarded. Further processing of the cell pellets was dependent on the 
experiments they were used for. 
a) For RNA-Isolation followed by qPCR, 1 ml Trizol was used for resuspending.  
b) Samples for RNA-sequencing were resuspended in 700 µl Qiazol. Samples were stored 
at -80°C. 
c) Cells analyzed by FACS were resuspended in PBS for cell death or citric acid for cell 
cycle analysis and processed further directly for measurement. 
 
4.4 Assays Cell Biology 
4.4.1 Viability assay 
For viability analysis of JQ1-treated cells, alamar blue viability assay was used. 
The cells were harvested, counted and seeded in a 96 well plate, cell number ranging from 
1.000 to 5.000 cells per well, depending on the doubling time of the tested cell line. To 
guarantee equal cell distribution of the cells to the wells, a multichannel pipette was used for 
seeding. 
On the next day, cells were treated with different concentrations of JQ1. 100 µl medium 
containing different concentrations of JQ1 were added to each well. The final concentrations 
of JQ1 ranged from 0.05-5 µM JQ1. DMSO in the DMSO only control was equal to DMSO in 
the highest JQ1 concentration (Figure 5). 
The treated cells were kept in the incubator for 72 hours. Then, 20 µl of alamar blue reagent 
were pipetted to the cells and the cells were put back to the incubator for another four hours. 
From each well, 100 µl were transferred to a black 96 well plate and the fluorescence was 
measured with the plate reader (extinction 540 nm, emission 580 nm).   
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Viability analysis with the BAY1238097 inhibitor was performed according to the same 
protocol. 
 
  
Figure 5: Layout of viability experiment. Blank= medium only, Cells=cells only control, DMSO=DMSO-treated 
control. For blank and cells three technical replicates were analysed. For each JQ1 concentration and DMSO 
control, six values were measured for each experiment. 
 
4.4.2 Soft agar assay 
Soft agar assays were performed in 6 well plates. A pipetting schedule, giving the amounts for 
a 6 well plate, is shown in table 3.   
First, the base agar was prepared: 2x RPMI, FCS and JQ1 or DMSO were pipetted into a 15 
ml falcon tube and prewarmed to 37°C in the waterbath. The 1.6% agar solution was added, 
the mixture was inverted and 1.5 ml were pipetted to each well. To get an even surface, the 
plate was slewed gently, then kept under the hood for hardening for 30 min and stored in the 
cell culture incubator overnight.  
On the next day, the top agar, including the cells, was prepared. First, 2xRPMI, FCS and JQ1 
or DMSO were mixed in a 15 ml falcon tube and prewarmed in the waterbath. The cells were 
harvested and counted, 5x104 cells were pelleted and resuspended in 1 ml serum free RPMI 
medium. To the prewarmed solution, 1% agar was added and the solution was carefully mixed 
by inverting. The cells were added and the top agar was pipetted up and down a few times. To 
each well with base agar, 1 ml of top agar was added, the plate was slewed and kept under 
the hood for 30 min until the top agar was solid. In the meantime, full medium with 0.5 µM JQ1 
or DMSO was prepared and after the 30 min hardening time, 3 mL were pipetted carefully to 
each well and the plates were placed in the cell culture incubator. 
The soft agar assay was monitored for 2-4 weeks, every week 2 ml of medium were replaced 
by fresh medium containing JQ1 or DMSO. When colonies were visible, the plates were 
1 2 3 4 5 6 7 8 9 10 11 12
A
B Blank DMSO
0.05 µM 
JQ1
0.1 µM 
JQ1
0.25 µM 
JQ1
0.5 µM 
JQ1
1 µM 
JQ1
2.5 µM 
JQ1
5 µM 
JQ1
C Blank DMSO
0.05 µM 
JQ1
0.1 µM 
JQ1
0.25 µM 
JQ1
0.5 µM 
JQ1
1 µM 
JQ1
2.5 µM 
JQ1
5 µM 
JQ1
D Blank DMSO
0.05 µM 
JQ1
0.1 µM 
JQ1
0.25 µM 
JQ1
0.5 µM 
JQ1
1 µM 
JQ1
2.5 µM 
JQ1
5 µM 
JQ1
E Cells DMSO
0.05 µM 
JQ1
0.1 µM 
JQ1
0.25 µM 
JQ1
0.5 µM 
JQ1
1 µM 
JQ1
2.5 µM 
JQ1
5 µM 
JQ1
F Cells DMSO
0.05 µM 
JQ1
0.1 µM 
JQ1
0.25 µM 
JQ1
0.5 µM 
JQ1
1 µM 
JQ1
2.5 µM 
JQ1
5 µM 
JQ1
G Cells DMSO
0.05 µM 
JQ1
0.1 µM 
JQ1
0.25 µM 
JQ1
0.5 µM 
JQ1
1 µM 
JQ1
2.5 µM 
JQ1
5 µM 
JQ1
H
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stained using crystal violet. Therefore, medium was removed completely, 500 µl crystal violet 
solution were applied to each well and the plates were incubated at 37°C for 1h. After 
incubation, crystal violet was removed and the plates were scanned. Counting was performed 
automatically with the gel doc program. 
 
Table 3: Reagents for soft agar assays. Amount is named for one plate with 6 wells each. 
 base agar top agar medium 
RPMI full medium   20 ml 
2x RPMI 6 ml 4 ml  
FCS 1.5 ml 1 ml  
JQ1/DMSO 0.68 µl 0.5 µl 1.00 µl 
cells/ RPMI   5x104 in 1 ml  
Agar 1.6% 6 ml   
Agar 1.0%  4 ml  
    
per well 1.5 ml 1 ml 3 ml 
 
 
4.4.3 Sensitivity testing 
To determine the amount of selection markers needed for selection of stably-transfected cells, 
a sensitivity testing was performed separately for each cell line used for stable transfections. 
The cells were harvested, counted and 1x105 cells were seeded with 2 ml medium in each well 
of a 12 well plate. On the next day, different concentrations of hygromycin were added in the 
range 0-100 µg/ml, always three wells containing the same concentration. The metabolic 
activity of the remaining living cells was tested after seven days. Therefore, 1.000 µl of medium 
per well were discarded and 100 µl alamar blue were added to each well. After 3 hours 
incubation in the cell culture incubator 2x 100µl from each well were transferred to a black 96 
well plate and the fluorescence was measured with a plate reader (extinction 540 nm, emission 
580 nm).  
 
4.4.4 Stable transfection/establishment of monoclonal cell lines 
For stable transfection with the luciferase containing plasmid pGL4.50, the transfection reagent 
effectene was used. First, 3x105 cells were seeded in a 25 cm² flask. On the next day, 150 µl 
EC buffer, 8 µl enhancer and 1 µg plasmide DNA were mixed in a reaction tube. After 5 min of 
incubation, 25 µl effectene were added, the solution was mixed carefully and kept under the 
hood for 10 min to form lipid complexes. Meanwhile the medium of the cells was replaced by 
5 ml fresh cell culture medium. After incubation, the transfection complexes were transferred 
to the cells dropwise and the cells were kept in the incubator overnight.  
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One day after transfection, the medium was changed to selection medium containing 
hygromycin, the concentration was depending on the transfected cell line. The medium was 
changed every 2-3 days, until the surviving cells started growing again despite presence of the 
selection marker. Then the cells were expanded and polyclonal cells were frozen as backup. 
To generate monoclonal cell lines, cells were seeded in 96 well plates with the goal to have 
only one single cell per well. This was achieved by a special pipetting schedule, which diluted 
the cells down to single cells per well (Figure 6). After 3-4 weeks single cell clones were picked 
and expanded. The luciferase expression of the different clones was checked by luciferase 
assay. 
 
 
Figure 6: Pipetting schedule to generate monoclonal cell lines. Per well 100 µl, in column 1 200 µl medium 
were pipette to each well. In well A1 100 µl medium containing 1x105 cells were added, mixed and 100 µl were 
transferred to well B1. This was continued along the whole column. Next, the cells were horizontally diluted the 
same way, resulting in continuous thinning out of the cells from the upper left to the lower right corner of the plate.  
(Adapted from Ryan, J.A., 2008 [143]) 
 
4.4.5 Luciferase assay 
From each clone, 1x106 cells were seeded in a 100 mm cell culture dish. The cells were 
harvested at 80% confluence, which took approximately three days. The cell pellet was lysed 
with 100 µl glo lysis buffer. To estimate the protein concentration of the sample, a Bradford 
assay was performed as described in section 4.6.4.  
For luciferase measurement, 300 µg protein lysate from each sample were transferred to a 
white 96 well plate and the volume was complemented with glo lysis buffer to a total volume 
of 80 µl. As substrate, 80 µl of steady glo luciferase assay were added per well. The 96 well 
plate was mixed on the shaker for 3 min, then the luminescence signal was measured at the 
1 2 3 4 5 6 7 8 9 10 11 12
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plate reader. The luminescence signal was recorded for 30 seconds per well and the average 
was used for further calculation.  
For each clone, technical duplicates were analyzed. The luciferase expression was compared 
to a positive and a negative control. As a positive control, stable luciferase expressing Hela 
cells were used. As negative control, untransfected cells from the same cell line were taken. 
 
4.4.6 siRNA transfection 
SiRNA transfection was performed with lipofectamine 2000. For RNA, 3.75x105 cells were 
seeded in 60 mm dishes, for protein analysis 100 mm plates were prepared with 1x106 cells 
per dish (Table 4). For each condition, two dishes for RNA and two dishes for protein were 
seeded. Cells were transfected on the next day, at a confluency of about 30%. For each 
transfection, two falcons were prepared with 2 ml Opti-MEM medium. To one of the falcons, 
40 µl lipofectamine 2000 were added, to the other one 16 µl of siRNA (50 µM). The two falcons 
were pooled and lipofectamine and siRNA were incubated for 20 min. In the meantime, 
medium of the prepared cells was changed. To 60 mm dishes, 5 ml of cell culture medium 
were added, protein plates received 15 ml medium. After incubation, the Opti-MEM medium 
containing the transfection complexes was divided between RNA and protein dishes: To the 
RNA dish, 1 ml of the transfection medium was added dropwise, 3 ml were pipetted to the 100 
mm dish. 
All transfections were stored at the incubator for 48 h, and then harvested according to the 
harvesting protocol for RNA and protein. 
 
Table 4: siRNA transfection. Amount is named per cell culture dish. 
 RNA protein 
cells 3.75x105 in 60 mm dish 1x106 in 100 mm dish 
siRNA 200 pmol in 500 μl Opti-MEM  600 pmol in 1500 μl Opti-MEM  
Lipofectamine 2000 10 μl in 500 μl Opti-MEM  30 μl in 1500 μl Opti-MEM  
cell culture medium 5 ml 15 ml 
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4.5 Molecular biology methods 
4.5.1 Plasmid preparation 
For plasmid preparation, first 500 ml lysogeny broth (LB) medium were inoculated with  E. coli 
carrying the plasmid of interest and kept at the shaker overnight at 37°C. On the next day, the 
LB medium with the bacteria was transferred to centrifugation tubes and the bacteria were 
pelleted by centrifugation with 6.000 g for 15 min at 4°C. The supernatant was discarded.  
For isolation of plasmid DNA, the Qiagen maxi kit was used. The bacteria pellet was 
resuspended in 10 ml buffer P1, 10 mL of buffer P2 were added and the suspension was mixed 
by inverting 5-6 times. After incubation for 5 min at room temperature, 10 ml of ice-cold buffer 
P3 were added. Again, the suspension was mixed by inverting and incubated on ice for 20 min 
followed by centrifugation with 20.000 g at 4°C for 30 min. The supernatant, containing the 
soluble cell components, was transferred to a new tube. To eliminate the cell debris completely, 
a second centrifugation step was performed with 20.000 g at 4°C for 15 min.  
Meanwhile, a DNA binding column was equilibrated with 10 ml QBT buffer. The supernatant 
was applied on the column and let run through. The column was washed two times by applying 
30 ml QC buffer per washing step on the column and let it flow through. For elution the column 
was placed over a new 50 ml falcon and 15 ml of buffer QF were applied on the column and 
collected together with the plasmid DNA in the falcon. DNA was precipitated by adding          
10.5 ml isopropanol to the DNA and pelleted by centrifugation with 15.000 g at 4°C for 30 min. 
The supernatant was discarded and the DNA pellet was washed with 5 ml 70% ethanol. After 
centrifugation with 15.000 g for 10 min, the supernatant was discarded and the pellet was air-
dried by turning the falcon upside down for 5-10 min. The plasmid DNA was resolved with    
500 µL H2O and transferred to a 1.5 ml reaction tube. DNA concentration was measured using 
a nanodrop and the DNA was stored at -20°C. 
 
4.5.2 RNA isolation and purification for qPCR (cell culture) 
Cells were harvested as described and the cell pellet was resuspended in 1 ml Trizol reagent. 
The samples were frozen at -80°C.  
For isolation and purification of total RNA, samples were thawed at room temperature and    
200 µl chloroform were added to every sample. The samples were shaken vigorously for 
approximately 15 seconds and then incubated 3 min at room temperature. By centrifugation 
with 11.500 rpm at 4°C for 15 min, the RNA accumulated in the upper aqueous phase and was 
separated from DNA and proteins. The upper phase was transferred to a new reaction tube. 
For RNA visualization and precipitation 1 µl Glycogen and 500 µl isopropanol were added and 
the samples were incubated for 10 min at room temperature. After centrifugation with 11.500 
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rpm at 4°C for 10 min, the RNA was pelleted at the bottom of the reaction tube. The supernatant 
was discarded and the pellet was washed with 1 ml 75% ethanol, followed by centrifugation 
with 7.500 rpm at 4°C for 5 min. The supernatant was completely discarded and the pellet was 
air-dried for 5 min. The RNA was resolved by adding 70 µl H2O and 10 min incubation at 56°C. 
Total RNA concentration was measured using a nanodrop. The RNA was stored at -80°C. 
 
4.5.3 RNA isolation for RNA-sequencing (cell culture) 
The samples resuspended in qiazol were thawed at room temperature. To each sample,       
140 µl chloroform were added, the samples were shaked vigorously for 15 sec and incubated 
at room temperature for 2-3 minutes. Centrifugation for 15 min with 12.000 g at 4°C separated 
the samples into two phases. The aqueous phase was transferred to a new reaction tube,    
700 µl of 70% ethanol were added and the samples were mixed by vortexing. The samples 
were applied on RNeasy Mini spin columns and centrifuged with 10.000 rpm for 15 sec at room 
temperature. The flow-through was transferred to a new reaction tube and stored at -80°C for 
potential isolation of miRNAs later on. On the column binding the mRNAs, 350 µl RWT buffer 
were applied, the columns were centrifuged with 10.000 rpm for 15 sec at room temperature 
and the flow-through was discarded. For DNA digestion, a master mix was prepared. Per 
sample, 10 µl DNase I stock solution and 70 µl buffer RDD were mixed. On each column,        
80 µl of the DNase master mix were pipetted and the columns were incubated for 15 min at 
room temperature. After the incubation, 350 µl buffer RWT were added, the columns were 
centrifuged with 10.000 rpm for 15 sec at room temperature and the flow-through was 
discarded. Next, the samples were washed two times with 500 µl buffer RPE each, the flow-
through was discarded both times. The columns were placed on new collection tubes and the 
mRNA was eluted from the column with 40 µl RNase free water. For this step, the water was 
applied on the column; the columns were incubated for 2 min at room temperature and then 
centrifuged for 1 min with 10.000 rpm at room temperature. 
RNA concentration was measured using a Nanodrop. RNA quality was checked by running 
the samples on a bioanalyzer. For RNA-seq, 2.200 ng of RNA were diluted with H2O dest. to 
a total volume of 50 µl and submitted to the DKFZ core facility for further sample preparation 
and sequencing. Remaining RNA was stored at -80°C. 
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4.5.4 RNA isolation (tumor tissue) 
For RNA-Isolation from mouse tumor tissue the NucleoSpin kit from Macherey-Nagel was 
used. Between 10 and 100 mg tumor tissue were weighted and disrupted into small pieces 
using a scalpel. For lysis, 350 µl buffer RA1 were added and mixed with the sample by pipetting 
up and down for several times. The lysate was transferred to a reaction tube. With an additional 
350 µl RA1 the remaining tissue fragments were collected, lysed and transferred to the same 
reaction tube. Disruption and lysis were performed on dry ice to avoid thawing of the tumor 
tissue. To the lysate, 7 µl of β-Mercaptoethanol were added, and the lysate was incubated on 
a shaker at room temperature for 10 min.  
The lysate was pipetted on a NucleoSpin filter column and the column was centrifuged for         
1 min with 11.000 g at room temperature. After centrifugation, the column was discarded and 
the flow-through was transferred to a new reaction tube. 700 µl ethanol 70% were added to 
the lysate and mixed by vortexing. Half of the lysate was loaded on a NucleoSpin RNA column 
and centrifuged for 1 min with 11.000 g at room temperature. The flow-through was discarded 
and loading was repeated with the rest of the lysate using the same column. Next, 350 µl MDB 
buffer were applied on the column, followed by centrifugation for 1 min with 11.000 g. For DNA 
digestion, a mastermix was prepared with 90 µl reaction buffer and 10 µl rDNase per sample. 
From the DNase mastermix 95 µl were pipetted on each column and incubated for 15 min at 
room temperature. The reaction was stopped by adding 200 µl buffer RAW2, then the column 
was centrifuged for 30 sec with 11.000 g at room temperature and flow-through and collection 
tube were both discarded. The column was washed two times with buffer RA3, first time with 
600 µl followed by 30 sec centrifugation, second time with 250 µl RA3 followed by 2 min 
centrifugation with 11.000 g at room temperature. After the second washing step, the collection 
tube was discarded and the column was placed in a new reaction tube. To elute the RNA,       
60 µl RNase free water were pipetted on the column and incubated for 5 min at room 
temperature. Then the column was centrifuged for 1 min with 11.000 g.  
The RNA concentration was measured using a Nanodrop, quality was checked by running a 
bioanalyzer chip. For RNA-seq, 2.200 ng of RNA were diluted with H2O dest. to a total volume 
of 50 µl and submitted to the DKFZ core facility for further sample preparation and sequencing. 
For RNA analysis in qPCRs, the cDNA and qPCR protocols were followed. Remaining RNA 
was stored at -80°C. 
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4.5.5 cDNA synthesis 
For the synthesis of cDNA the First strand cDNA synthesis kit was used, all enzymes and other 
reagents were provided with the kit. From each sample, 1 µg of RNA was transferred to a      
0.5 ml reaction tube and H2O was added up to a total volume of 10 µl. To each sample, 1 µl 
random hexamer primer was added and RNA and primer were incubated for 5 min at 70°C. In 
the meantime, a mastermix containing the remaining reagents was prepared: 
 4 µl/ sample 5x reaction buffer 
 2 µl/ sample dNTP mix 
 2 µl/ sample MuLV reverse transcriptase 
 1 µl/ sample ribolock 
The heated samples were spinned down for a few seconds and then 9 µl of mastermix were 
added to each sample. Using a cycler, the samples were incubated according to the following 
protocol: 
  25°C for 10 min 
37°C for 60 min 
70°C for 10 min  
When synthesis was finished, the samples were spinned down and the cDNA was stored at    
-20°C. 
 
4.5.6 Quantitative real time PCR 
The quantification of mRNA was based on an internal standard curve and the comparison with 
two different housekeeping genes. To prepare the different mRNA standards, a small amount 
of each cDNA sample was separated, pooled and diluted with H2O dest. to a total volume of 
80 µl (160 µl for more than 10 samples) (Table 5). This first standard was diluted four times in 
a ratio of 1:4 to have a standard curve with five dilutions. The remaining cDNA samples were 
diluted with H2O dest. to a total volume of 60 µl. Genomic DNA and H2O dest. were included 
as controls. All samples, standards and controls were measured in triplicates. 
Primer dilutions were prepared for each plate directly before pipetting according to table 6. 
SDHA and HPRT1 were included as housekeeping genes and used to calculate the relative 
changes in gene expression for the genes of interest. Samples, standards and controls were 
measured for every primer pair, which allows a direct comparison calculation of mRNA 
expression based on the standard curve for every single gene. 
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Table 5: Pipetting schedule for qPCR standard curve. Volumes depending on the number of samples.  
No. of samples   8 9 10 11 12 
For standard curve per sample 4 µl 3 µl 3 µl 5 µl 5 µl 
  samples sum 32 µl 27 µl 30 µl 55 µl 60 µl 
  add H2O 48 µl 53 µl 50 µl 105 µl 100 µl 
 total volume 80 µl 80 µl 80 µl 160 µl 160 µl 
Remaining sample   16 µl 17 µl 17 µl 15 µl 15 µl 
  add H2O 44 µl 43 µl 43 µl 45 µl 45 µl 
 total volume 60 µl 60 µl 60 µl 60 µl 60 µl 
 
 
 
Table 6: Primer dilutions for qPCR. 
mRNA Primer for (100 pmol/µL) Primer rev (100 pmol/µL) H2O dest 
MYCN 4 µl 4 µl 192 µl 
c-MYC primer assay used, no dilution necessary 
CCND1 primer assay used, no dilution necessary 
BRD4 6 µl 6 µl 188 µl 
BRD3 primer assay used, no dilution necessary  
BRD2 6 µl 6 µl 188 µl 
HPRT1 6 µl 6 µl 188 µl 
SDHA 6 µl 6 µl 188 µl 
 
 
A master mix was prepared with 13 µl SYBR-mix, 2.5 µl primer dilution and 7 µl H2O dest. per 
sample. From the master mix, 22.5 µl were pipetted into each well, 2.5 µl of sample, standard 
or control were added and the plate was sealed with a transparent foil. After a short 
centrifugation step to spin down the samples completely, the plates were put in the qPCR 
machine to start and measure amplification of the cDNA using the following protocol. 
50°C 2:00 min  
95°C 2:00 min  
95°C 0:15 min 
40 cycles 
60°C 0:30 min 
60°C→ 95°C (melting curve) 
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4.6 Biochemical methods 
4.6.1 Cell lysis for SDS-PAGE (cell culture) 
Cells were harvested as described. The cells were disrupted by resuspending the cell pellet in 
30-100 µl protein lysis buffer, depending on the size of the cell pellet. After this step, lysates 
could be stored at -80°C.  
To digest DNA and RNA, 1 µl of benzonase was added to each sample and the samples were 
incubated at 37°C for 15 min. The cell debris was pelleted by centrifugation at 10.000 rpm for 
3 min and the supernatant containing the proteins was transferred to a clean reaction tube and 
stored at -80°C. 
 
4.6.2 Cell lysis for SDS-PAGE (tumor tissue) 
For protein lysates, a piece of 50-100 mg was cut from every tumor sample. The tumor piece 
was placed on a cell culture plate on dry ice and was shredded into small pieces using a 
scalpel. In the next step, 150-200 µl protein lysis buffer were added to the tissue pieces and 
the tumor tissue was minced together with the buffer. The sample was transferred to a  1.5 ml 
reaction tube and the cell culture plate was washed out with additional 100 µl of protein lysis 
buffer to have no tissue left on the plate. The lysate was grinded by pipetting up and down until 
all visible pieces of tumor tissue had disappeared. In a last step, the lysate was transferred to 
a tissue homogenizer to finalize lysis.  
To the completely homogenized tissue lysates, 1 µl of benzonase was added to digest DNA 
and RNA. The lysates were incubated at 37°C for 15 min and the debris was pelleted by 
centrifugation at 10.000 rpm for 3 min. The supernatant was transferred to a clean reaction 
tube and stored at -80°C. 
 
4.6.3 Cell lysis for RPPA (cell culture) 
Cells were harvested as usual. Cells pelleted by centrifugation were resuspended and lysed 
in 25 µl M-PER buffer. Lysates were stored at -80°C. After determining the protein 
concentration using Bradford-assay, the samples were handed over to the core facility for 
further analysis. 
 
4.6.4 Bradford assay 
Protein concentration was determined using the Bradford assay. A cuvette with 200 µl Bradford 
reagent and 800 µl water was prepared for every protein sample. 1 µl protein lysate was added 
and the sample was mixed by vortexing.  
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The photometer was calibrated at 595 nm wavelength using a blank sample without protein. 
The absorbance of all samples was measured with the photometer. Additionally, eight different 
protein standards with defined protein concentrations in the range 0-20 µg/µl were measured 
to generate a standard curve for calculation of the protein concentrations of the samples. 
 
4.6.5 Polyacrylamide gels 
For preparation of polyacrylamide gels the BioRad system for mini gels was used. The glass 
plates were cleaned with water and 70% ethanol, braced with a plate clip and fixed in the gel 
holder. The running gel was prepared as described in table 7. APS and TEMED were added 
directly before use. The running gel solution was filled in the gap between the glass plates up 
to 1 cm below the upper border and was overlayed with 500 µl isopropanol to get an even 
surface on the running gel. Polymerization of the running gel took approximately 30 min. After 
polymerization the isopropanol layer was removed completely. The stacking gel was prepared, 
filled in the remaining space between the glass plates up to the upper border and a comb was 
inserted immediately to create pockets for the samples. The polymerization of the stacking gel 
took about 15 min. Then the gels were taken out of the gel holder and used directly or wrapped 
in wet paper and stored for up to two weeks at 4°C. 
 
Table 7: Preparation of polyacrylamide gels. Each column gives the reagents for two gels. 
 running gel 15% running gel 12,5% stacking gel 
running gel buffer 3,75 ml 3,75 ml -- 
stacking gel buffer -- -- 1,2 ml 
H2O dest. 5,4 ml 6,4 ml 2,75 ml 
20% SDS 75 µl 75 µl 25 µl 
Acrylamid/bis-
acrylamide 40% 
5,7 ml 4,7 ml 0,375 ml 
10% APS 150 µl 150 µl 150 µl 
TEMED 6 µl 6 µl 6 µl 
 
 
4.6.6 SDS-PAGE 
From each sample for SDS-PAGE 50 µg of protein were taken and lämmli buffer was added 
to a total volume of 15 µl. The samples were heated to 95°C for 5 min and spinned down for a 
few seconds in a centrifuge. Two of the gels were braced in a running chamber and amresco 
electrophoresis buffer was filled in the chamber and between the gels. After taking out the 
combs, the pockets were cleared by rinsing amrecso buffer. The samples were loaded on the 
gel. To estimate molecular weight of the bands, 6 µl PAGE ruler were loaded in an additional 
pocket. The voltage was set to 80 V until the samples had passed the stacking gel and were 
collected to the same level. When entering the running gel, the voltage was raised to 120 V. 
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Gel electrophoresis was stopped when the lowest PAGE ruler band had passed the gel 
completely. The gels were taken out of the electrophoresis chamber and were either wrapped 
in wet paper and kept at 4°C overnight or were directly used for western blot. 
 
4.6.7 Western blot 
The proteins were transferred from the polyacrylamide gel to a nitrocellulose membrane by 
wet blot technique. The glass plates enclosing the gel were opened, the stacking gel was 
discarded and the running gel was taken out and equilibrated in transfer buffer. Then the blot 
was stacked, starting from the anodic side: Sponge, 3x whatman paper, nitrocellulose 
membrane, polyacrylamide gel, 3x whatman, sponge. All components were soaked with 
transfer buffer before use. Air bubbles were eliminated by rolling the blot. The blot was put in 
a transfer chamber and covered completely with transfer buffer. To keep the temperature low, 
ice falcons were placed inside the chamber and the blotting chamber was kept on ice. The 
transfer was running for 2h at 440 mA.  
The blot was disassembled, the membrane was taken out, shortly washed with PBS-T and the 
positions of the bands of the protein standard were marked on the membrane. To reduce 
unspecific binding of antibodies, the membrane was incubated with blocking solution for 1h at 
room temperature. Afterwards, the membrane was washed 3x for 5 min at room temperature. 
The first antibody against the protein of interest was diluted in 5% milk or BSA (see table 8 
below) and incubated on the membrane overnight at 4°C. On the next day, the first antibody 
was taken off and the membrane was washed again 3x for 5 min. The second antibody, 
conjugated with a peroxidase, was incubated on the membrane for 2h at 4°C. Then, the 
membrane was washed again 3x for 5 min.  
 
Table 8: Dilution of antibodies for western blot.  
protein origin buffer and dilution molecular weight 
β- Actin mouse 5% milk in PBST, 1:5.000 42 kDa 
BRD2 rabbit 5% milk in PBST, 1:1.000 110 kDa 
BRD3 rabbit 5% milk in PBST, 1:1.000 85 kDa 
BRD4 rabbit 5% milk in PBST, 1:1.000 132 kDa 
CDK4 mouse 5% milk in PBST, 1:1.000 34 kDa 
c-myc mouse 5% milk in PBST, 1:1.000 67 kDa 
Cyclin D1 mouse 5% milk in PBST, 1:1.000 36 kDa 
E2F-1 mouse 5% milk in PBST, 1:1.000 60 kDa 
MYCN mouse 5% milk in PBST, 1:1.000 65 kDa 
p53 mouse 5% milk in PBST, 1:1.000 53 kDa 
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For detection, 3 ml solution A and 30 µl solution B from the ECL-kit from Roche were pipetted 
on the membrane and incubated for about 1 min on room temperature. The membrane was 
placed in the chemicapt and a photograph was taken from the chemiluminescent bands. After 
detection, the membrane was washed again 3x for 5 min and either another first antibody was 
incubated over night or the membrane was dried and stored at -20°C. 
 
4.7 Flow Cytometry 
4.7.1 Live/dead measurement 
For live/dead analysis by FACS the cells were harvested and resuspended in 500 µl PBS as 
described in 4.3.7. For each time point and condition triplicates were analysed. The 
measurement of cell death was done with a MACSQuant FACS machine. The complete        
500 µl samples were transferred to FACS tubes. Immediately before measurement, 5 µl 
propidium iodide were added and the sample was mixed by flipping the tube. From each 
sample, 200 µl were analysed using FACS. The software Flow-Jo was used for data 
evaluation. 
 
4.7.2 Cell cycle measurement 
As described in 4.3.7, cells harvested for cell cycle analysis were resuspended in 500 µl citric 
acid, which destroyed the cell membrane and only left the nuclei for FACS analysis. Technical 
triplicates were harvested and analyzed per condition and time point. The samples were kept 
at 4°C for up to one week, then stained with phospho-DAPI solution and measured by Dr. 
Volker Ehemann, a collaboration partner from the pathological institute at the University 
Hospital Heidelberg. 
 
4.8 Histological analyses 
 
Histological analyses were performed by the pathological institute. The cryo-conserved 
material was sectioned and stained with haematoxylin eosin staining. Material conserved by 
formaline was embedded in paraffin, sectioned and stained with haematoxylin eosin. A 
professional evaluation of the tumor material was done by Dr. med. vet. Tanja Poth. The tumor 
samples were characterized in regard to tumor entity, and necrosis and stroma parts were 
described. 
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5 Results 
5.1 Characterization of a MYCN high/low cell culture model 
An amplification of the MYCN gene is an important risk factor for bad outcome of 
neuroblastoma disease. Different MYCN amplified and MYCN non-amplified neuroblastoma 
cell lines have limited value for analyzing the role of MYCN in neuroblastoma because of 
manifold genetic aberrations differing between the cell lines. Therefore a MYCN knockdown 
model inducible by tetracycline was established for MYCN amplified neuroblastoma cell lines 
in the DKFZ group of Neuroblastoma Genomics. This MYCN high/low model has the 
advantage that high and low levels of MYCN gene expression can be compared in the same 
genetic background. The effects observed can be assigned directly to low or high MYCN and 
are not distorted by other genetic factors of the cell lines.  
So far, for the two neuroblastoma cell lines IMR5/75 and IMR32 the MYCN high/low model 
was already established. As these cell lines were used for several experiments of this thesis, 
the working principle and a short characterization of the IMR5/75 MYCN high/low cell line are 
described at the beginning of the results part. 
 
5.1.1 Concept of the MYCN knockdown in MYCN amplified neuroblastoma cells 
The MYCN knockdown is based on two plasmids: The first plasmid is coding for the tetracycline 
repressor (TetR), a protein that binds tetracycline molecules and thereby changes its 
conformation. The second plasmid contains a MYCN shRNA. In the promoter region of the 
shRNA binding sites for the tetracycline repressor (TetO2-element) are included, regulating the 
expression of the MYCN shRNA (Figure 7).  
Without the presence of tetracycline the TetR binds to the TetO2-elements and blocks the 
transcription of the MYCN shRNA. In absence of MYCN shRNA the MYCN expression is not 
affected and the cells are in the MYCN high condition. 
When tetracycline is present, it binds to the TetR. The TetR changes its conformation towards 
its inactive form and dissociates from the TetO2-elements of the DNA. The MYCN shRNA is 
transcribed and the MYCN mRNA is degraded, leading to decreasing levels of MYCN in the 
MYCN low condition.  
The MYCN high/low cell models deriving from IMR5/75 and IMR32 were established as 
monoclonal cell lines. The tetracycline derived knockdown model is also sensitive to treatment 
with doxycycline instead of tetracycline.  
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Figure 7: Schematic presentation of the MYCN knockdown. Upper line: genetic construct in absence of 
tetracycline. The TetR is bound to the TetO2-elements and blocks the transcription of the MYCN shRNA. Lower 
line: situation in presence of tetracycline. Tetracycline inactivates the tetracycline repressor and the MYCN shRNA 
is transcribed. TetO2= tetracycline operator sequence, TetR= tetracycline repressor, purple triangle= 
tetracycline/doxycycline molecule (adapted from Invitrogen, T-REx System User Manual [144]). 
 
5.1.2 Quantification of the MYCN knockdown in IMR5/75 neuroblastoma cells 
To estimate the magnitude of the MYCN knockdown, IMR5/75 MYCN high/low cells were 
treated with tetracycline for 48h and the MYCN protein expression was analyzed by western 
blot (Figure 8). Both western blots showed a decrease of the MYCN protein expression under 
the tetracycline treated MYCN low condition (Figure 8A and 8B). Quantification and 
normalization against the loading control β-actin revealed a marginal significant decrease in 
MYCN protein expression (Figure 8C). The mean of the remaining MYCN protein expression 
was 25.6%, which was low enough to clearly observe MYCN dependent effects.  
Experiments from colleagues using the MYCN high/low cells revealed, that the extent of the 
MYCN knockdown varies during the first few hours after induction of the expression of the 
MYCN shRNA in a periodic manner (data not shown). To analyze cells with a stable 
knockdown, tetracycline pretreatment for 48h was performed for all experiments with the 
MYCN high/low cell lines.  
 
Promoter TetO2 TetO2 MYCN shRNA
Promoter TetO2 TetO2 MYCN shRNA
TetR
TetR
TetRTetR
+Tet/Doxy
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Figure 8: MYCN protein expression in IMR5/75. IMR5/75 MYCN high/low cells were treated with 1 µM tetracycline 
or appropriate amount 70% ethanol for 48h. The MYCN protein knockdown was quantified by western blot with β-
actin as loading control. A)+B) Western blot analysis of two biological replicates. C) Quantification of MYCN protein 
expression, normalized to the β-actin bands of the western blots (WB= western blot). P-value was <0.05 (student t-
test). 
 
5.1.3 MYCN knockdown prolongs the cell cycle of IMR5/75 neuroblastoma cells 
After proving the effectiveness of the MYCN knockdown achieved in the IMR5/75 MYCN 
high/low cells, the cells were characterized regarding their MYCN high and MYCN low 
conditions. As cell division is essential for tumorigenesis and MYCN target genes are involved 
in cell cycle regulation [56], the cell cycle distribution was analyzed by flow cytometry. 
Upon MYCN knockdown, an increase of the G1 fraction from 48% to 61% of total cells was 
observed (Figure 9A). The S-phase fraction decreased from 34% to 26%, the G2- fraction was 
slightly smaller in MYCN low IMR5/75 cells. The results suppose that IMR5/75 with low MYCN 
expression remain longer in the G1 phase, resulting in a slow down of the cell cycle.  
A more precise analysis of the cell cycle effects on IMR5/75 MYCN high and MYCN low cells 
has been achieved by synchronization of the cells (Figure 9B). This experiment was concepted 
and performed by Dr. Emma Bell [145]. The IMR5/75 cells were synchronized by a thymidine 
block. In both MYCN high and MYCN low conditions the G1-fraction increased during the first 
10 hours after release from the thymidine block. After 15h the MYCN high cells showed an 
increase of the S-phase fraction and a decrease of the G1 arrested fraction. In contrast, the 
MYCN low cells stayed arrested in the G1 phase for more than 24h.   
These results show that the MYCN amplified IMR5/75 cells are highly dependent on the 
expression of MYCN for passaging through the cell cycle and cell division.  
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Figure 9: Cell cycle analysis of IMR5/75 MYCN high/low cells. A) Cell cycle distribution of IMR5/75 MYCN 
high/low cells. The cells were treated with 1 µM tetracycline or appropriate amount of 70% ethanol for 48h and 
analyzed by flow cytometry. One biological replicate with three technical replicates was analyzed. Due to the low 
number of replicates, no significance test was performed. B) Cell cycle analysis of IMR5/75 MYCN high/low cells 
synchronized by thymidine block. The cells were analyzed by flow cytometry. Red= G1-phase, blue= S-phase, 
green=G2-phase (Figure 9B gently provided by Dr. Emma Bell, [145]).  
 
5.1.4 MYCN knockdown increases cell death in IMR5/75 neuroblastoma cells 
As MYCN target genes are also involved in cell death signaling [56], cell death was measured 
in the MYCN high/low IMR5/75 cell line using flow cytometry to estimate if the induction of 
spontaneous cell death is dependent on MYCN expression in MYCN amplified neuroblastoma 
cells.  
Cell death increased upon MYCN knockdown in IMR5/75 cells from 20% in MYCN high cells 
to 33% in MYCN low cells (Figure 10). The total levels of cell death in both the MYCN high as 
well as in the MYCN low samples were relatively high, probably due to rupture of cells during 
sample preparation.  
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Figure 10: Cell death in IMR5/75 MYCN high/low cells. A) Cell death analysis of IMR5/75 MYCN high/low cells. 
The cells were treated with 1 µM tetracycline or equal amount of 70% ethanol for 48h and analyzed by flow 
cytometry. One biological replicate with three technical replicates was analyzed. Due to the low number of 
replicates, no significance test was performed. B) Flow cytometry analysis of IMR5/75 MYCN high/low cells. M1= 
sub-G1 fraction of dead cells. M2=fraction of viable cells.  
 
Taken together, the MYCN high/low system effectively reduces the MYCN expression of 
IMR5/75 cells after 48h of tetracycline treatment. Thereby, the system is a valuable tool for the 
analysis of the role of MYCN in MYCN amplified neuroblastoma cells. Nevertheless, when 
working with this system it is important to keep in mind that biological characteristics of the 
neuroblastoma cells are influenced by the knockdown. The increase of cell death and the 
influence on the cell cycle resulting in a decrease of the doubling time have to be considered 
when interpreting the data collected with this system. 
The experiments presented here were focusing on the IMR5/75 neuroblastoma cell line. The 
same MYCN high/low system is available for the MYCN amplified neuroblastoma cell line 
IMR32.  
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5.2 Treatment of neuroblastoma cell lines with BRD4 inhibitors 
 
It has been shown that the BRD4-mediated transcriptional regulation is essential for many 
cancer entities with overexpressed or amplified genes of the MYC protein family, which 
includes neuroblastoma having a deregulated MYCN gene in a high proportion of high-risk 
cases [103, 108, 120]. The effectiveness of BRD4 inhibitors, such as JQ1, on neuroblastoma 
has been tested in a number of studies [121-123]. Yet, most of them include only few cell lines 
in their analysis.  
The present BRD4 treatment study included a large panel of 23 neuroblastoma cell lines with 
different genetic backgrounds. The treatment of neuroblastoma cell lines with varying genetics 
aimed to identify factors that help to estimate if a patient’s tumor with similar biological 
characteristics would be sensitive for treatment with BRD4 inhibitors.  
For the experiments with BRD4 inhibition this work was supported by Dr. Emma Bell. 
Bioinformatic data were analyzed by Dr. Chunxuan Shao, Umut Toprak and Dr. Carl Herrmann. 
 
5.2.1 JQ1 treatment reduces viability of selected neuroblastoma cell lines 
First of all, the effectivity of BRD4 inhibition on neuroblastoma cells was estimated by a viability 
screen on a panel of 23 different neuroblastoma cell lines with different genetic backgrounds. 
The cells were treated with different concentrations of JQ1 or DMSO only control and the 
viability was measured using the alamar blue assay. The algorithm for calculation of the IC50 
and EC50 values was gently provided by Xiaoqi Jiang (DKFZ department Biostatistics). 
The panel of cell lines used for the viability screening is composed of 12 MYCN amplified cell 
lines and 11 MYCN non-amplified cell lines, including also one MYCN non-amplified cell line 
which expresses moderate levels of MYCN because of a translocation. Additional genetic 
changes are for example a p53 mutation in 7 out of the 23 cell lines, ALK mutations in five of 
the cell lines, a TERT activation in four of the tested cell lines or MDM2/CDK4/CCND1 
amplifications in three cell lines (Table 9). 
The IC50 values were not used for evaluation of the sensitivity. The varying dose response 
curves or low effects of JQ1 treatment on several of the neuroblastoma cell lines did not allow 
a calculation of IC50 values for 11 of the tested 23 cell lines. 
To rate the results of the viability screen, three different categories were defined, based on the 
EC50 values. Cell lines with an EC50 lower than 0.1 µM were categorized as JQ1 sensitive, 
cell lines with an EC50 value over 0.5 µM were defined as JQ1 resistant. All cell lines with an 
EC50 between these two borders were classified as JQ1 intermediate responders. 
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Table 9: Genetic aberrations of neuroblastoma cell lines. Cell lines listed in alphabetical order. Amp= amplified; 
non amp= non-amplified; tl= translocated; act= activated; mut= mutated; wt= wild type; dp= duplicated; del= deleted; 
bal= balanced; meth= methylated; het= heterozygous. 
 
 
In the group of the 12 MYCN amplified cell lines (Figure 11A), there are six cell lines counting 
to the group of JQ1-sensitive cell lines (IMR32, TR14, IMR5/75, NMB, SK-N-BE(2)c, LS) and 
four cell lines defined as JQ1-resistant (KELLY, LAN-5, SMS-KCNR, NGP). Only one cell line 
shows an intermediate response to JQ1 treatment (SK-N-BE(2)).  
For LAN-1 the used algorithm failed to calculate EC50 and IC50 values, probably due to high 
variability of the replicates.  
Among the MYCN non-amplified cell lines (Figure 11B), three cell lines were categorized as 
JQ1 sensitive (SH-EP, SK-N-AS, HD-N-33) and three cell lines as JQ1 resistant (GIMEN, 
SJNB1, SK-N-FI). Four cell lines belonged to the JQ1 intermediate response group (CHLA-90, 
NB69, SH-SY5Y), including the MYCN expressing NBL-S cell line. For LAN-6 the used 
algorithm failed to calculate the values due to variation in the data. SJNB1 and SK-N-FI were 
categorized as very resistant cell lines with no effect on viability measured at all. Due to the 
absence of viability reduction no EC50 values could be calculated for these cell lines.   
Neither for MYCN amplified nor for MYCN non-amplified cell lines the genetic background 
could help to identify additional criteria how the neuroblastoma cell lines would react on JQ1 
treatment. A separate analysis for TP53 mutant and TP53 wild type did not reveal differences 
in viability of both groups (data not shown). Additionally, JQ1 sensitivity was compared to the 
doubling time of the cell lines to exclude a low doubling time as a rescue factor for the resistant 
Cell line MYCN c-MYC TERT ALT TP53 MDM2 CDK4 CCND1 p16/p14 ALK 1p doubling time
CHLA-90 non amp mut mut wt tl 59h
GIMEN non amp act wt meth wt del 24h
HD-N-33 non amp del
IMR32 amp wt wt wt amp/wt del 20h
IMR5/75 amp wt wt tl, bal 20h
KELLY amp act mut wt mut 30-40h
LAN-1 amp mut wt mut tl, bal 100h
LAN-5 amp wt wt wt mut del 100h
LAN-6 non amp mut wt dp del del 150-170h
LS amp wt amp amp amp 45h
NB69 non amp tl wt wt del
NBL-S tl wt wt 36h
NGP amp act wt amp amp wt wt wt tl, bal 50-70h
NMB amp mut wt del, bal 40-50h
SH-EP non amp tl wt wt del mut
SH-SY5Y non amp tl wt wt wt mut 48h
SJNB1 non amp wt
SK-N-AS non amp tl act mut del, het wt del 39h
SK-N-BE(2) amp mut del 30h
SK-N-BE(2)c amp mut wt wt wt 18h
SK-N-FI non amp mut mut wt
SMSKCNR amp wt mut del 72h
TR14 amp wt amp amp wt wt del, bal 72h
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cell lines. Although the cell lines with very fast doubling times of 24h and less showed high 
sensitivity in the viability screen, the doubling time does not strictly correlate with JQ1 
sensitivity. 
Comparing the results for MYCN amplified and MYCN non-amplified cell lines, it was 
noticeable that the MYCN amplified cell lines belonged either to the JQ1 resistant or the JQ1 
sensitive group, nearly no MYCN amplified cell lines were categorized as intermediate 
responding. The MYCN non-amplified cell lines on the contrary were quite equally distributed 
over all three categories of JQ1 sensitivity.  
Based on the results of the viability screen, it was decided to work with 0.5 µM JQ1 as standard 
working concentration for further experiments.  
  
Figure 11: EC50 values of JQ1-treated neuroblastoma cell lines. The cells were treated with seven different 
JQ1 concentrations from 0.05-5 µM plus DMSO only control for 72h. Viability was measured using alamar blue 
reagent. Cells are categorized based on the EC50 values as JQ1 sensitive (EC50<0.1 µM), JQ1 intermediate 
response (EC50=0.1-0.5 µM) or JQ1 resistant (EC50>0.5 µM).  A) EC50 values of MYCN amplified cell lines. B) 
EC50 values of MYCN non-amplified cell lines. NBL-S is non-amplified but expressing MYCN because of a 
translocation. Res= cells resistant, no effects detectable. #NV= algorithm not able to calculate EC50 values. 
As a comparison, a second viability screen was performed with a second BRD4 inhibitor 
named BAY1238097. For this experiment, 10 neuroblastoma cell lines were chosen from the 
cell line panel tested with JQ1. Among the chosen neuroblastoma cell lines were MYCN 
amplified and non-amplified as well as JQ1 sensitive and JQ1 resistant cell lines.  
The BRD4 inhibitor BAY1238097 had similar effects on the neuroblastoma cell lines as JQ1. 
Cell lines categorized as JQ1 sensitive also showed high sensitivity when treated with 
BAY1238097 and JQ1 resistant cell lines were also resistant to BAY1238097 (Figure 12A). 
For all tested cell lines, the EC50 values for BAY1238097 were higher than the EC50 values 
A BCell line EC50 [µM] MYCN  status
IMR32 0,03 amp
TR14 0,05 amp
IMR5/75 0,06 amp
NMB 0,06 amp
LS 0,07 amp
SK-N-BE(2)c 0,08 amp
SK-N-BE(2) 0,38 amp
KELLY 0,54 amp
LAN-5 0,66 amp
SMSKCNR 0,80 amp
NGP 1,18 amp
LAN-1 #NV amp
Cell line EC50 [µM] MYCN  status
SH-EP 0,07 non amp.
SK-N-AS 0,07 non amp.
HD-N-33 0,09 non amp.
CHLA-90 0,11 non amp.
NB69 0,13 non amp.
SH-SY5Y 0,20 non amp.
NBL-S 0,29 translocated
GIMEN 0,57 non amp.
SJNB1 res. non amp.
SK-N-FI res. non amp.
LAN-6 #NV non amp.
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achieved with JQ1. The dose response curves of JQ1 and BAY1238097 clearly show this 
difference in an exemplarily chosen cell line sensitive to BRD4 inhibition (Figure 12B). In the 
resistant SK-N-FI cell line, no reduction in viability was detectable, neither with JQ1 nor with 
BAY1238097 (Figure 12C). Altogether, neuroblastoma cell lines are more sensitive to JQ1 
than to BAY1238097 treatment. 
 
Figure 12: Comparison of BAY1238097 and JQ1-treated neuroblastoma cell lines. The cells were treated with 
7 different concentrations of JQ1 or BAY1238097 ranging from 0.05-5 µM plus DMSO only control for 72h.  A) 
Overview of EC50 values of all cell lines tested with both components. B) Dose response curves of IMR5/75 cells 
sensitive to BRD4 inhibition. JQ1 treatment shown in blue, BAY1238097 treatment shown in green. C) Dose 
response curves of SK-N-FI cells resistant to BRD4 inhibition. 
 
Neuroblastoma cells treated with the working concentration of 0.5 µM JQ1 were also examined 
morphologically. First changes in morphology could be detected after 24h of JQ1 treatment 
with effects being most clearly at time point 48h.  
The different neuroblastoma cell lines showed a broad panel of morphological changes when 
treated with JQ1. Four examples are shown in Figure 13. The JQ1 sensitive IMR5/75 cells 
rounded up and completely detached from the cell culture plate. In contrast, JQ1-sensitive LS 
A
B C
Cell line EC50 JQ1 [µM] EC50 BAY [µM] MYCN  status
IMR32 0,03 0,22 amp
IMR5/75 0,06 0,22 amp
SH-EP 0,07 0,20 non amp.
LS 0,07 0,47 amp
SH-SY5Y 0,20 0,46 non amp.
NBL-S 0,29 1,18 translocated
KELLY 0,54 2,41 amp
GIMEN 0,57 1,02 non amp.
NGP 1,18 3,83 amp
SK-N-FI res. res. non amp.
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cells showed only marginal morphological changes and a slight increase of floating cells. The 
JQ1 resistant NGP cells detached and formed large, floating clusters. MYCN non-amplified 
and JQ1 sensitive SH-EP cells stayed adherent but changed their morphology becoming 
longer and thinner. The morphologic effects on neuroblastoma cells treated with BAY1238097 
were similar to effects on JQ1-treated cells from the same cell line. 
In summary, the morphological changes upon JQ1 treatment occured within 24h and were 
most prominent after 48h. No correlation was found between pattern of morphological changes 
and sensitivity to JQ1. 
 
Figure 13: Morphology of JQ1-treated cells. Pictures were taken after 48h treatment with JQ1 or DMSO using 
an objective lens with 20x magnification.  
 
5.2.2 JQ1 treatment induces changes in cell cycle distribution 
The cell cycle distribution of different neuroblastoma cells was analyzed by flow cytometry for 
up to 72h of JQ1 treatment to identify and characterize a potential growth arrest.  
The panel of cell lines used for cell cycle analysis consisted of ten different neuroblastoma cell 
lines. It contained JQ1 sensitive, intermediate responding and resistant cell lines as well as 
both MYCN amplified and MYCN non-amplified neuroblastoma cell lines. The effects on cell 
cycle distribution were most prominent at the 24h time point and are shown exemplarily in 
Figure 14A. 
Upon JQ1 treatment, a prominent G1 arrest with a statistically significant increase of the G1 
fraction was observed for all seven sensitive and intermediate responding cell lines, both in 
the MYCN amplified and MYCN non-amplified ones (p<0.001). The S-phase fraction was 
decreased in all JQ1 sensitive and intermediate responding cell lines. For example, the G1 
fraction in JQ1 sensitive IMR5/75 cells increased from 35.98% in DMSO control-treated to 
63.27% in JQ1-treated cells, whereas the S-phase fraction decreased from 46.35% to 28.26%. 
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For the G2 fraction, there was no consistent pattern detectable in JQ1 sensitive and 
intermediate responding cell lines. A decrease was detected in 3 out of 7 JQ1 sensitive and 
intermediate responding cell lines upon JQ1 treatment. In three cell lines there was no 
difference of G2 between JQ1-treated and DMSO control cells and in one JQ1 sensitive cell 
line the G2 fraction increased significantly.  
In the three tested JQ1 resistant neuroblastoma cell lines, only marginal changes in cell cycle 
distribution were measureable, irrespective of their MYCN status. 
For 12h and 48h JQ1 treatment, the cell cycle distribution measured for the individual cell lines 
was similar to the effects detected for 24h upon JQ1 (Figure 14B, IMR5/75 cell line exemplarily 
shown). At the 12h time point, the effects in cell cycle distribution were not yet established to 
full extent. The differences between JQ1 and DMSO control-treated cells were only statistically 
significant for the JQ1 most sensitive cell lines IMR5/75, IMR32 and SH-EP, although the 
tendency was seen in all tested cell lines as for 24h treatment. After 48h JQ1 treatment the 
results also resembled the cell cycle distribution measured after 24h JQ1, but with a 
significantly higher sub-G1 fraction of dead cells (sub-G1 data not shown). After 72h treatment 
with JQ1, the fraction of sub-G1 cells further increased and the differences between JQ1 and 
DMSO control-treated cells were less clearly, especially in the G1-fraction. Possibly, the cells 
arrested in the G1-phase after 24h JQ1 treatment partially underwent cell death after 48 or 
72h. 
In summary, analysis of cell cycle distribution revealed a significant increase of the G1 fraction 
and a decreased S-phase fraction in JQ1 sensitive and intermediate responding cell lines. In 
JQ1 resistant cell lines, no difference in cell cycle distribution was detected. This is true both 
for MYCN amplified and MYCN non-amplified neuroblastoma cell lines. 
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Figure 14: Cell cycle analysis of JQ1-treated cells. Neuroblastoma cells were treated with 0.5 µM JQ1 for 12, 
24, 48 or 72h. Harvested cells were fixed with citric acid, stained with phospho-DAPI and analyzed by flow 
cytometry. Biological and technical triplicates were analyzed. Significance was tested with student t-test. A) Cell 
cycle analysis after 24h JQ1 treatment. Green=JQ1 sensitive cell lines. Yellow= JQ1 intermediate responding cell 
lines. Red= JQ1 resistant cell lines. Left panel= MYCN amplified NB cell lines. Right panel= MYCN non-amplified 
NB cell lines. B) Cell cycle analysis of IMR5/75 cells over a period of 72h. 
 
 
5.2.3 Cell death is increased in selected JQ1-treated neuroblastoma cell lines 
To determine if the neuroblastoma cells treated with JQ1 are growth arrested or undergo cell 
death, cell death was analyzed by flow cytometry. For cell death analysis ten different 
neuroblastoma cell lines were tested, seven of them were MYCN amplified and three belonged 
to the MYCN non-amplified group. The cell line panel consisted of JQ1 sensitive, intermediate 
responding and resistant cell lines.  
A
B
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At the time points 12h and 24h nearly no differences in cell death rates were detectable 
comparing JQ1 and DMSO control-treated samples (Figure 15A). After 48h treatment, an 
increase of cell death was measureable in both JQ1 sensitive and MYCN amplified 
neuroblastoma cell lines IMR5/75, IMR32 and SK-N-BE(2)c. Cell death further increased upon 
72h JQ1 treatment in IMR5/75 from factor 2.43 after 48h to factor 3.84 after 72h and in IMR32 
from factor 1.75 (48h) to 2.43 (72h). The elevated levels of cell death were statistically 
significant for these two cell lines (p<0.001). In contrast, the sub-G1 fraction decreased in SK-
N-BE(2)c after 72h. The MYCN amplified, intermediate responding cell line SK-N-BE showed 
a slight increase in cell death. Among the JQ1 resistant MYCN amplified cell lines, marginally 
elevated levels of cell death were observed in NGP cells, whereas no induction of cell death 
was seen in LAN-5 cells over 72h JQ1 treatment.  
In contrast to the MYCN amplified JQ1 sensitive cell lines IMR5/75 and IMR32, the MYCN non-
amplified and JQ1 sensitive SH-EP cells did not show an increase in cell death over a period 
of 72h JQ1 treatment (Figure 15A). In the other two MYCN non-amplified cell lines, belonging 
to the JQ1 intermediate responding and resistant groups, no increase of cell death was 
detected as well.  
In Figure 15B, cell death measured in the JQ1 sensitive cell lines IMR5/75 and LS, as well as 
in the JQ1 resistant cell line NGP is shown for JQ1 and DMSO control treatment. The Figure 
reveals that the total levels of cell death in the DMSO-treated controls were varying between 
the cell lines. In LS, the total levels of cell death were low both in the DMSO and in the JQ1-
treated samples, with a sub-G1 fraction of less than 10%. In contrast, cell death in control-
treated IMR5/75 cells was ranging from 11% to 20%. In JQ1 resistant NGP cells no effect of 
JQ1 treatment on the sub-G1 fraction was detectable before 48h.  
Altogether, in MYCN amplified cell lines an increase of cell death can be detected in 4 out of 7 
neuroblastoma cell lines. The JQ1 sensitivity of the cell lines does not correlate with the 
proportion of cell death. The elevated levels of cell death upcoming at later time points are 
consistent with the results from cell cycle analysis, where larger sub-G1 fractions were 
detected after 48h and 72h JQ1 treatment. In MYCN non-amplified neuroblastoma cell lines, 
elevated levels of cell death were not observed. 
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Figure 15: Cell death analysis of JQ1-treated cells. Neuroblastoma cells were treated with 0.5 µM JQ1 or DMSO 
only control for 12, 24, 48 or 72h. The cells were resuspended in PBS, stained with propidium-iodide and analyzed 
by flow cytometry. Biological and technical triplicates were analyzed. Significance was tested with student t-test. A) 
Relative fraction of dead cells, calculated JQ1/DMSO-treated. Green dots = JQ1 sensitive cell lines. Yellow dots = 
JQ1 intermediate responding cell lines. Red dots = JQ1 resistant cell lines. Interrupted lines = MYCN non-amplified 
cell lines. B) Cell death analysis of 3 MYCN amplified cell lines. 
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5.2.4 Neuroblastoma cells show regrowth after JQ1 washout 
Taken together the results from viability, cell cycle analysis and cell death measurement, it 
remained unclear which proportion of neuroblastoma cells undergoes permanent damage 
resulting in cell death and if JQ1-treated cells are able to regrow after removing the inhibitor. 
As IMR5/75 cells belonged to the most sensitive cell lines in the viability screen and showed 
the highest proportion of cell death upon JQ1 treatment, this cell line was analyzed in the 
regrowth experiment. Additionally, to examine the influence of MYCN expression on the ability 
of JQ1-treated cells to regrow after treatment, the MYCN high/low system of this cell line was 
included as an additional parameter (described in section 5.1). MYCN low cells were treated 
with tetracycline throughout the whole experiment to achieve a knockdown of MYCN. The 
experimental outline of the experiment is shown in Figure 16. 
 
 
 
Figure 16: Experimental outline of regrowth experiment. Cells were seeded at day -4 and treated with 0.5 µM 
JQ1 or DMSO and tetracycline or 70% ethanol at day -3. At day 0, cells were counted and 5x104 cells were 
reseeded. Daily measurement of live and dead cell fraction using PI staining followed for five days. Per time point 
and condition technical triplicates were performed. 
 
Up to 48h after washout of JQ1 or DMSO, nearly no difference in growth was observed 
comparing JQ1- or DMSO-treated and MYCN high and MYCN low conditions (Figure 17). The 
MYCN high cells treated with DMSO started to regrow at day three after washout, nearly 
achieving 100% confluence after five days. In the MYCN high, JQ1-treated cells regrowth 
started approximately 24h later than in the DMSO-treated control cells. Additionally to the 
belayed regrowth, the cell proliferation rate was lower in the JQ1-treated MYCN high cells 
compared to DMSO control. 
In contrast, the MYCN low cells pretreated with JQ1 or DMSO were both regrowing very slowly. 
A small increase in the number of viable cells was not seen before day four after washout in 
both JQ1 and DMSO-treated cells.  
The results of the JQ1 regrowth experiment resemble observations with doxorubicin-treated 
neuroblastoma cells. Ryl et al. found that MYCN low cells undergo permanent senescence 
after treatment, whereas MYCN high cells treated shortly after cell division are capable of 
clonal regrowth [145]. Supposedly, like the doxorubicin-treated cells, JQ1-treated MYCN high 
cells do not undergo a permanent cell cycle arrest or differentiation and JQ1 is not capable to 
inhibit neuroblastoma tumor cell growth far beyond the treatment time. As the effects of JQ1 
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JQ1/tet
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day 0
Counting
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day +1
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day +2 day +4day +3 day +5
FACS FACS FACS FACS 
  Dissertation Maike Christine Nortmeyer 
71 
 
treatment are not permanent in MYCN high cells, MYCN promotes cell proliferation shorly after 
removing the inhibitor.   
 
Figure 17: Regrowth of JQ1 pretreated cells. Total number of cells measured one to five days after JQ1 washout. 
IMR5/75 cells were used. MYCN-knockdown was achieved by induction of an MYCN-shRNA by adding tetracycline. 
Cells were stained with propidium-iodide and analyzed by flow cytometry. P-value was <0.01 at day 4 in MYCN 
high cells (student t-test). 
 
5.2.5 Anchorage independent growth is absent in JQ1-treated cells 
Anchorage independent growth is a malignant characteristic of many neuroblastoma tumor 
cells. To test if treatment with JQ1 can prevent neuroblastoma cells from forming anchorage 
independent colonies, neuroblastoma cells from eight different cell lines were seeded in soft 
agar accompanied by JQ1 treatment. 
Colony formation was effectively inhibited by JQ1 treatment in all eight tested neuroblastoma 
cell lines (Figure 18A). In IMR32, IMR5/75, SK-N-BE(2)C, NGP and NBL-S, no colonies could 
be detected upon JQ1 treament compared to extensive colony growth in the DMSO control. In 
Figure 18B, soft agar assays with the JQ1 sensitive IMR5/75 and JQ1 resistant NGP cells are 
shown exemplarily. In the panel of cell lines used for soft agar assay, there is no difference 
detectable according to JQ1 sensitivity or MYCN amplification status. In LS, SK-N-BE(2) and 
NB69 sporadic colonies were assessed upon JQ1 treatment. Compared to the untreated 
control, the reduction of anchorage independent growth was highly significant (p<0.001).   
Taken together, anchorage independent growth is highly significantly inhibited in all tested 
neuroblastoma cell lines, independent from JQ1 sensitivity or MYCN status.  
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Figure 18: Anchorage independent growth of JQ1-treated cells. Cells were seeded in soft agar and treated with 
0.5 µM JQ1 or DMSO in base agar, soft agar and cell culture medium. Cell culture medium was replaced weekly. 
Cells were cultured for 3-4 weeks. Colonies grown in soft agar were stained with crystal violet and counted 
automatically. Per cell line and condition, 6 wells were analyzed. Significance was tested with student t-test. A) 
Number of colonies counted for different NB cell lines treated with JQ1 or DMSO only control. Green dots = JQ1 
sensitive cell lines. Yellow dots = JQ1 intermediate responding cell lines. Red dots = JQ1 resistant cell lines. Spotted 
dots = MYCN non-amplified cell lines. B) Exemplary pictures of soft agar from IMR5/75, JQ1 sensitive and NGP, 
JQ1 resistant cells.  
 
5.2.6 Changes in MYCN expression are induced by JQ1 treatment in MYCN amplified 
neuroblastoma cell lines 
In the previous sections it has been shown that different MYCN amplified and MYCN non-
amplified neuroblastoma cell lines respond individually and irrespective of a comparable 
genetic background to JQ1 treatment. Aiming to illuminate the molecular reactions of the cells 
on JQ1 treatment and to verify that the MYCN expression is influenced by JQ1 treatment [121-
123], MYCN protein levels were analyzed by western blot and RPPA in MYCN expressing 
neuroblastoma cell lines.  
Protein quantification by western blot included the MYCN amplified cell lines IMR32, IMR5/75, 
LS, SK-N-BE(2)c, SK-N-BE(2) and NGP as well as the MYCN translocated cell line NBL-S 
(Figure 19). A strong MYCN downregulation was detected in the JQ1 sensitive neuroblastoma 
cell lines IMR32 and SK-N-BE(2)c (p<0.05 for SK-N-BE(2)c and p<0.005 for IMR32). In the 
JQ1 sensitive IMR5/75 cells the MYCN protein levels were slightly reduced as well as in LS 
and SK-N-BE(2) cells at the 24h time point. For LS, the quantification of the MYCN protein 
expression at the 48h time point showed a strong upregulation. Though, the MYCN detection 
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of the western blot from LS was weak and the bands were blurred, which in total hampered 
MYCN quantification for this cell line. In the JQ1 resistant cell line NGP the MYCN protein 
levels were upregulated at both time points. In the MYCN translocated cell line NBL-S the 
MYCN protein expression was not affected.  
 
 
Figure 19: MYCN protein concentration analyzed by western blot. Neuroblastoma cells from six MYCN 
amplified and one MYCN translocated (*) cell lines were treated with 0.5 µM JQ1 or DMSO control for 24h or 48h. 
Three biological replicates were analyzed. The MYCN protein expression was detected by western blot. β-actin was 
used as loading control. The protein levels were quantified using ImageJ. Protein expression change was calculated 
JQ1-treated/DMSO-treated condition. The JQ1 sensitivity estimated by viability assays is noted. Significance was 
tested with student t-test. 
 
By Reverse Phase Protein Array (RPPA) the protein expression of nine MYCN amplified and 
six MYCN non-amplified neuroblastoma cell lines were analyzed in a high throughput manner 
including the quantification of 50 different proteins.  
Figure 20A shows the MYCN protein expression for the time points 12-48h, normalized to         
β-Actin protein levels. A reduction of MYCN protein levels was detected in 7 out of 9 MYCN 
amplified neuroblastoma cell lines. The most effective MYCN downregulation was measured 
in the JQ1 sensitive cell lines IMR32 and SK-N-BE(2)c as well as in the JQ1 resistant cell line 
LAN-5. For IMR5/75 no effect on the MYCN protein expression was detected by RPPA. LS 
cells showed a slight decrease of MYCN protein levels, which is contrary to the observations 
of the western blot. In KELLY, belonging to the JQ1 resistant cell lines, the MYCN protein 
expression was reduced at all three time points, whereas solely in the resistant NGP cells the 
MYCN protein levels were elevated.  
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Figure 20: MYCN and c-MYC protein concentration analyzed by RPPA. Neuroblastoma cells were treated with 
0.5 µM JQ1 or DMSO for 12h, 24h or 48h. The protein expression was analyzed by RPPA and normalized against 
β-actin. Changes in protein expression were calculated JQ1-treated/DMSO-treated condition. Per time point, 3 
biological replicates were analyzed. The categories observed in the viability assays are given. The MYCN 
translocated cell line NBL-S is marked (*). P-value was >0.05 for the majority of cell lines and time points (student 
t-test). A) Mean MYCN protein concentration of 9 MYCN amplified neuroblastoma cell lines and MYCN 
overexpressing NBL-S cell line. B) Mean c-MYC protein concentration of 6 MYCN non-amplified neuroblastoma 
cell lines. 
 
Altogether, western blot and RPPA delivered comparable results regarding MYCN protein 
expression after JQ1 treatment. With both methods, the strongest MYCN downregulation was 
observed in the JQ1 sensitive IMR32 and SK-N-BE(2)c cell lines, whereas in resistant NGP 
both methods revealed a strong upregulation of MYCN protein expression. Differences were 
mainly detected for IMR5/75, where no effects on MYCN protein expression have been 
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detected in RPPA in contrast to a slight reduction of MYCN protein levels observed with 
western blot. These relatively small differences can be explained by cell culture effects. 
The analysis of MYCN protein levels revealed that the reduction of MYCN is not correlating 
with the sensitivity of the cell lines towards JQ1 treatment. Among the group of JQ1 sensitive 
cell lines, IMR5/75 and TR14 showed no or slight differences in MYCN protein expression. In 
contrast, the JQ1 resistant neuroblastoma cell lines KELLY and LAN-5 responded with a strong 
MYCN downregulation on protein level upon JQ1 treatment. Hence, the third JQ1 resistant 
MYCN amplified cell line NGP showed a strong MYCN upregulation. 
In the MYCN non-amplified neuroblastoma cells included in the panel of cell lines for RPPA 
analysis, c-MYC protein expression was analyzed instead of MYCN (Figure 20B). A reduction 
of c-MYC protein levels was observed in NB69 and at the 48h time point of HD-N-33. In          
SH-EP cells highly sensitive towards JQ1 treatment the c-MYC protein expression was not 
affected. As expected, the effects on c-MYC protein expression were marginal compared to 
the effects on MYCN protein levels in the MYCN amplified cell lines. Summarizing the results 
from western blot and RPPA, about 70% of the MYCN amplified neuroblastoma cell lines 
showed a reduction of MYCN protein expression upon JQ1 treatment. This does not correlate 
with the sensitivity of the individual cell lines determined by viability assays. The c-MYC protein 
expression was marginally affected by JQ1 treatment. 
 
5.2.7 Cell cycle related proteins are affected by JQ1 treatment 
The analysis of MYCN protein expression in neuroblastoma cells revealed that MYCN protein 
levels are repressed in most, but not all MYCN amplified cell lines and that downregulation of 
MYCN does not strictly correlate with JQ1 sensitivity. To identify other possible targets of BET 
proteins affected by JQ1 treatment, further proteins were analyzed by RPPA and western blot.  
Out of 54 proteins analyzed by RPPA, using more than 70 different antibodies, 21 proteins 
(39%) were up- or downregulated in the MYCN amplified cell lines and 16 proteins (30%) 
showed changes in protein expression in MYCN non-amplified neuroblastoma cell lines. The 
analysis of the RPPA results focused on the late time points (12-48h) as the strongest effects 
were detected after at least 12h JQ1 treatment, whereas 3-6h treatment with JQ1 did not result 
in deviant protein expression. The proteins that were found to have the most interesting 
expression patterns upon JQ1 treatment will be described in the following section.  
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a) Cyclin D1 and CDK4 
The analysis of cell cycle distribution of JQ1-treated neuroblastoma cells showed an assembly 
in the G1 phase of the cell cycle, at least regarding the cell lines belonging to the sensitive and 
intermediate responding groups. This suggests that the G1/S transition of the cell cycle is 
influenced by JQ1. CDK4 and its corresponding binding partner Cyclin D1 are important for 
cell cycle progression into the S-phase. Especially Cyclin D1 is likely to be regulated by BRD4 
because its expression is regulated by a large Super-Enhancer region known to involve BRD4 
binding [146]. 
Antibodies for both CDK4 and Cyclin D1 were included in the RPPA antibody panel. The data 
for the MYCN amplified cell lines are presented in Figure 21. The CDK4 and Cyclin D1 levels 
of the MYCN non-amplified cell lines are not shown. 
In the RPPA analysis the Cyclin D1 protein expression was downregulated in all MYCN 
amplified samples at the 12h time point (Figure 21A). After 24h and 48h of JQ1 treatment, a 
decrease in Cyclin D1 protein levels was observed in most of the cell lines, at least for one of 
the two time points. In the JQ1 sensitive cell lines, Cyclin D1 downregulation was more 
prominent. The strongest decrease was detected in SK-N-BE(2)c cells. Among the MYCN non-
amplified cell lines analyzed by RPPA, Cyclin D1 upregulation was detected in one of the JQ1 
sensitive cell lines, whereas the other five MYCN non-amplified cell lines were not affected 
(data not shown). 
Downregulation of Cyclin D1 protein levels was validated by western blot, showing lower Cyclin 
D1 protein expression in 5 out of 6 MYCN amplified neuroblastoma cell lines and at the 24h 
time point of the MYCN translocated cell line NBL-S (Figure 22). In contrast to the results from 
the RPPA analysis, JQ1-treated LS cells analyzed by western blot did not show a 
downregulation, but instead presented with a slight increase of Cyclin D1 protein levels. 
Though, this increase is not significant and not consistent in all three biological replicates of 
the western blot. 
CDK4 is less dependent on periodic expression than Cyclin D1 [147]. A lower CDK4 protein 
expression was observed by RPPA in most JQ1 sensitive MYCN amplified and MYCN non-
amplified neuroblastoma cell lines (Figure 21B). The JQ1 resistant cell lines either showed 
equal levels of CDK4 or an upregulation. These results were comparable with the findings in 
western blots.  
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Figure 21: Protein concentration of Cyclin D1 and CDK4 analyzed by RPPA. MYCN amplified neuroblastoma 
cells were treated with 0.5 µM JQ1 or DMSO for 12h, 24h or 48h. The protein expression was analyzed by RPPA 
and normalized with β-actin protein levels. Changes in protein expression were calculated JQ1-treated/DMSO-
treated condition. The categories observed in the viability assays are given. A) Cyclin D1 protein concentration of 
nine MYCN amplified neuroblastoma cell lines. P-value was >0.05 for the majority of cell lines and time points 
(student t-test). B) CDK4 protein concentration of nine MYCN amplified neuroblastoma cell lines. P-value was >0.05 
(student t-test). 
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Figure 22: Cyclin D1 protein concentration analyzed by western blot. Neuroblastoma cells from six MYCN 
amplified and one MYCN translocated (*) cell lines were treated with 0.5 µM JQ1 or DMSO control for 24 or 48h. 
MYCN protein expression was detected by western blot. β-actin was used as loading control. The protein levels 
were quantified using ImageJ. The change in protein expression was calculated JQ1-treated/DMSO-treated 
condition. P-value was <0.05 for IMR32 (student t-test). The categories observed in the viability assay are noted. 
For NBL-S 48h no quantification is available. 
 
b) E2F-1 
E2F-1 belongs to the main cell cycle promoting genes inducing the transcription of a number 
of genes required for the S-phase of the cell cycle. Therefore E2F-1 was in the focus of the 
protein analysis of JQ1-treated neuroblastoma cells. Due to an insufficient E2F-1 antibody 
quality in the RPPA application, results for the E2F-1 protein expression are only available 
from western blot for six MYCN amplified neuroblastoma cell lines (data not shown). Lower 
E2F-1 protein levels were detected for the JQ1 sensitive cell lines IMR32, LS and SK-N-BE(2)c 
as well as for the JQ1 resistant cell line NGP. No differences were detected for IMR5/75 and 
SK-N-BE. The downregulation of the E2F-1 protein expression fits with the cell cycle arrest in 
JQ1 sensitive cell lines and a lower Cyclin D1/CDK4 activity estimated by RPPA. 
 
c) p53 and MDM2 
Another central protein at the G1/S transition is p53, responsible for cell cycle arrest or the 
induction of proapoptotic pathways. The RPPA analysis showed a downregulation of p53 
protein levels in all JQ1 sensitive MYCN amplified cell lines (Figure 23). The cell lines from the 
intermediate responding and resistant categories showed varying responses of p53 protein 
expression. Among the panel of MYCN amplified cell lines analyzed by RPPA, three cell lines 
harbored known inactivating mutations in the TP53 gene. These are SK-N-BE(2)c, SK-N-BE(2) 
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and KELLY. The informative value of the p53 protein expression is limited for these cell lines. 
The decrease of p53 protein expression in JQ1 sensitive cell lines was confirmed by western 
blot analysis, although interpretation of the results was impeded by technical difficulty, 
especially for IMR5/75 and LS (data not shown).  
The protein levels of the ubiquitin ligase and p53 regulator MDM2 were estimated by RPPA 
using antibodies both for MDM2 in its phosphorylated and unphosphorylated form. MDM2 
regulates the activity of p53 in a negative feedback loop [148], limiting growth arrest and 
impeding cell death in undamaged cells. In RPPA, MDM2 reflected the behavior of the p53 
protein upon JQ1 treatment. The MDM2 protein expression was not validated by western blot.  
 
Figure 23: p53 protein concentration analyzed by RPPA. Cells from nine MYCN amplified neuroblastoma cell 
lines were treated with 0.5 µM JQ1 or DMSO for 12h, 24h or 48h. The p53 protein expression was analyzed by 
RPPA and normalized with β-actin protein levels. Changes in protein expression were calculated JQ1-treated/ 
DMSO-treated condition. P-value was >0.05 for the majority of cell lines and time points (student t-test). The 
categories observed in the viability assays are given. 
 
d) GSK3-β 
The glycogen synthase kinase 3 β (GSK3-β) regulates the synthesis of glycogen by 
phosphorylation of the glycogensynthase and is part of a number of signaling pathways, for 
example Wnt, Shh or PI3K/AKT [149, 150]. Besides, GSK3-β plays an important role in the 
turnover of Myc proteins [151]. GSK3-β and phospho-GSK3-β have been included in the 
antibody panel for RPPA. 
Among the MYCN amplified neuroblastoma cell lines, elevated protein levels of GSK3-β were 
detected in 7 out of 9 cell lines after 24h and in 8 out of 9 cell lines after 48h JQ1 treatment 
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(Figure 24). Upregulation of GSK3-β was not correlated with sensitivity to JQ1. In the group of 
MYCN non-amplified cell lines, 4 out of 5 neuroblastoma cell lines showed increased GSK3-β 
protein levels. For the MYCN translocated cell line NBL-S similar GSK3-β protein expression 
levels were detected in JQ1-treated and control cells.  
Phosphorylation of GSK3-β at Serine 9 leads to inactivation of GSK3-β [152]. Phospho-   
GSK3-β was not affected by JQ1 treatment of MYCN expressing cells. Among the MYCN non-
amplified cell lines, lower levels of phospho-GSK3-β were detected after 48h treatment with 
JQ1. The effects on GSK3-β protein expression may be related to its role in MYC protein 
turnover [50], further discussed in section 6.2. 
 
Taken together, the analysis of more than 50 different proteins by RPPA revealed an influence 
of JQ1 treatment on 39% of the tested proteins in MYCN amplified and on 30% in MYCN non-
amplified cell lines. The proteins affected by JQ1 treatment included regulatory proteins of the 
cell cycle, such as Cyclin D1, p53 and E2F-1 or GSK3-β, the last being involved in MYC 
turnover. The results from RPPA were confimed by western blot. 
 
Figure 24: GSK3-β protein concentration analyzed by RPPA. Cells from nine MYCN amplified neuroblastoma 
cell lines were treated with 0.5 µM JQ1 or DMSO for 12h, 24h or 48h. The GSK3-β protein expression was analyzed 
by RPPA and normalized with β-actin protein levels. Changes in protein expression were calculated JQ1-treated/ 
DMSO-treated condition. P-value was <0.05 in NGP cells at 12h and 48h time points (student t-test). The categories 
observed in the viability assays are given. 
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5.2.8 MYCN is not a target of BRD4 in neuroblastoma 
The analysis of the MYCN protein concentration revealed that MYCN is downregulated in most 
but not all MYCN amplified neuroblastoma cell lines treated with JQ1. Especially in the JQ1 
sensitive cell lines IMR5/75 and TR14 as well as in the JQ1 resistant cell line NGP the effects 
of JQ1 treatment on the MYCN protein expression were marginal. To investigate if MYCN is 
directly regulated by BRD4 in neuroblastoma, IMR5/75 cells were transfected with siRNA 
against the BET proteins BRD2, BRD3 or BRD4 in separate experiments (Table 10).  
 
Table 10: Overview of experiments with BET siRNA in IMR5/75 cells.  
 
The knockdown of BRD4 was effective, with both siRNAs reducing the BRD4 protein 
expression to 21% of the BRD4 protein concentration in untreated IMR5/75 cells (Figure 25A, 
p<0.05). Despite the strong BRD4 knockdown, the MYCN protein expression was not 
decreased in the samples transfected with BRD4 siRNA. Knockdown of MYCN induced by 
treatment with tetracycline reduced the MYCN protein expression significantly to 51%, 
whereas the JQ1-treated cells had MYCN protein levels of 69% compared to control (both 
p<0.05). The Cyclin D1 protein expression was significantly lower in all treated samples, 
especially in the JQ1-treated cells (15% remaining, p<0.005) and in those transfected with 
siRNA BRD4/1 (16% remaining, p<0.005). Transfection with siRNA BRD4/2 reduced the Cyclin 
D1 protein level to 48% whereas the MYCN shRNA cells expressed 63% of Cyclin D1 
compared to control (p<0.05). The results from the western blot regarding BRD4, MYCN and 
Cyclin D1 were verified by qPCR (data not shown).  
Transfection with siRNAs targeting the other two globally expressed BET-family members 
BRD2 and BRD3 led to an effective knockdown of the target proteins (20-35% remaining) 
compared to control. A change in MYCN or Cyclin D1 protein expression was observed neither 
with siRNAs targeting BRD3 nor with BRD2 siRNAs (data not shown).  
As a comparison, transfection with BRD4 siRNAs was repeated in SK-N-BE(2)c cells, a cell 
line with a strong response regarding MYCN downregulation upon JQ1 treatment (Figure 25B). 
Nevertheless, neither the MYCN nor the Cyclin D1 protein expression were affected by 
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transfection with BRD4 siRNAs in this cell line, although the knockdown of BRD4 was highly 
effective. 
 
Figure 25: Comparison of BRD4- and MYCN knockdown and JQ1 treatment. Cells were transfected with two 
BRD4 siRNAs, treated with 0.5 µM JQ1 or treated with 1 µM tetracycline to induce a MYCN shRNA (Figure 25A 
only, introduced in results part 5.1). Untreated cells and cells transfected with a negative control siRNA were used 
as control. Three biological replicates, each with two technical replicates were analyzed. Cells were harvested after 
48h. Protein expression was analyzed by western blot and quantified with ImageJ. β-Actin was used for 
normalization. Untransfected cells were set to 100%. Significance was tested with student t-test. A) Protein 
expression of IMR5/75 cells. Data partly published in Nortmeyer, M., diploma thesis [153]. B) Protein expression of 
SK-N-BE(2)c cells. 
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For further comparison of the impact of BRD4 knockdown and JQ1 treatment on MYCN and 
Cyclin D1 protein levels, those were analyzed in a time dependent manner, using IMR5/75 
MYCN high/low cells.   
A reduction of the MYCN protein expression upon shRNA-mediated MYCN knockdown was 
observed for all time points (Figure 26). Upon JQ1 treatment the strongest downregulation of 
MYCN was observed at the 12h time point. After 6h of JQ1 treatment slightly lower MYCN 
protein levels were detected. Cyclin D1 protein expression was affected after 12h JQ1 
treatment and a strong decrease was detected at the 48h time point. At the 48h time point the 
total protein of all samples was lower observed in the detection of MYCN and Cyclin D1 as 
well as for the β-actin loading control.  
Altogether the comparison of the genetic knockdown of BRD4 by siRNA and the 
pharmacological inhibition by JQ1 treatment reveals distinct deviance between both methods 
to abrogate BRD4 functions. This leads to the conclusion that MYCN is not a direct target of 
BRD4-mediated gene transcription. 
 
 
Figure 26: Time dependent comparison of MYCN knockdown and JQ1 treatment. IMR5/75 cells were 
pretreated with 1 µM Tetracycline for induction of a MYCN shRNA (introduced in results part 5.1) or treated with 
0.5 µM JQ1 for 6h, 12h, 24h or 48h. MYCN and Cyclin D1 protein levels were estimated by western blot. β-Actin 
was used as loading control. Data partly published in Nortmeyer, M., diploma thesis [153]. 
 
5.2.9 High troughput analysis of JQ1-treated neuroblastoma cells and tumor models 
reveals large changes in gene expression 
So far, the analysis of the effect of JQ1 treatment on neuroblastoma cells was focusing on the 
protein expression. Aiming to get further insight into the genes and cellular functions affected 
by JQ1 on the transcriptional level, RNA-sequencing was performed. An overview of the 
experimental plan is shown in Figure 27.  
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Figure 27: Overview on RNA-sequencing. A time course was performed with the neuroblastoma cell lines 
IMR5/75, LS, NBL-S and NGP treated with 0.5 µM JQ1 or DMSO only control. Samples were collected after 6h, 
12h, 24h and 48h and analyzed by RNA-sequencing. With cell line IMR5/75, orthotopic xenografts were generated 
and treated peritoneally four times in three days with 50 mg/kg JQ1 (xenograft experiment performed by the group 
of Johannes H. Schulte, Charité Berlin).  
 
For the in vitro part, four different neuroblastoma cell lines were analyzed, including the two 
JQ1 sensitive cell lines IMR5/75 and LS, the intermediate responding cell line NBL-S and the 
resistant cell line NGP (Figure 28). Both, the sensitive and resistant cell lines included in this 
analysis are MYCN amplified, the intermediate responding cell line NBL-S harbors a MYCN 
translocation and is expressing MYCN, albeit in lower extent. 
 
 
Figure 28: Timeline for RNA-sequencing in cell culture. 2x105 cells for early time points and 1.5x105 cells for 
late time points were seeded 20h before treatment start. The cells were treated with 0.5 µM JQ1 or DMSO only 
control. For the 12h time point the treatment was time-shifted. Isolated RNA was sent to the DKFZ core facility for 
sample preparation and sequencing. 
 
In a second part, the RNA sequencing profile from JQ1-treated IMR5/75 cell cultures was 
compared with xenograft tumors deriving from the same cell line. Mice harboring the xenograft 
tumors were treated with 50 mg/kg JQ1 for 4 times in 36h, then the mice were sacrificed and 
the tumor material was prepared for RNA sequencing (Figure 29). 
  
RNA-seq
IMR5/75
(sensitive)
NBL-S
(intermediate)
Xenografts
(3d high dose treatment)
Cell culture
(time course, 0-48h)
LS
(sensitive)
NGP
(resistant)
Cell
seeding
-20h 0h
JQ1/DMSO 
treatment
6h, 24h, 48h
+6h
Harvesting
6h
+24h
Harvesting
24h
+48h
Harvesting
48h
+22h
Harvesting
12h
+10h
JQ1/DMSO 
treatment
12h
  Dissertation Maike Christine Nortmeyer 
85 
 
 
 
Figure 29: Timeline for RNA-sequencing in xenografts. IMR5/75 cells were implanted in the adrenal gland of 
immunodeficient mice. When tumors were established, the mice were treated with 50 mg/kg JQ1 for four times in 
36h. Mice were euthanized 72h after the first treatment and the tumor material was collected for RNA-sequencing. 
 
a) RNA-sequencing: IMR5/75 in cell culture 
The RNA-sequencing analysis of IMR5/75 was performed as described in Figure 28.  
First, a principal component analysis was performed with the data, showing that the mRNA 
expression profile at time point 48h differed from the time points 0-24h and that both biological 
replicates harvested after 48h JQ1 treatment diverged. Knowing from cell cycle and cell death 
analyses (section 5.2.2 and 5.2.3) that the fraction of dead cells significantly increased in 
IMR5/75 after 48h treatment with JQ1, a difference between the early and the late time points 
is allegeable. Due to the different gene expression patterns, the analysis of the IMR5/75 gene 
expression profile was focused on the time points 0-24h. 
The global gene expression patterns of the most significantly differentially expressed genes 
sorted by hierarchical clusters are presented in a heatmap (Figure 30A). A small group of 
strong upregulated genes are indicated in dark orange. The majority of those genes plays an 
important role in inducing cell cycle arrest at the G1/S cell cycle checkpoint or is involved in 
the recognition of DNA damage and pathways activated upon oxidative stress. Among the 
group of strong upregulated genes were CDKN1C and CDKN2D, coding for two inhibitors 
specific for the CDK-Cyclin complexes CDK4/6-Cyclin D and CDK2- Cyclin A/E that are active 
in G1 and at the G1/S transition. A larger group of genes downregulated upon JQ1 treatment 
is indicated in blue in the heatmap. Genes related to DNA damage response and repair or to 
the cytoskeleton and thereby involved in mitosis and cytokinesis were overrepresented among 
the downregulated genes. There were also several genes required for the G1/S transition or 
controlling cell cycle progression. One example for the JQ1 downregulated genes was CDK6, 
a CDK binding D-type cyclin in its active form and functionally involved in the cell cycle 
progression from G1 to S-phase. Other downregulated genes were URGCP, regulating 
CCND1 expression and E2F2, a transcriptional activator for genes required for the early S-
phase. Taken together, the upregulation of cell cycle inhibiting genes and downregulation of 
genes required for cell cycle progression at the G1-S transition should result in cell cycle arrest, 
as observed for JQ1-treated IMR5/75 cells. 
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Figures 30B and 30C present the gene expression profile of MYCN and CCND1 as exemplary 
genes throughout the time course for both biological replicates. The MYCN mRNA levels of 
the first replicate were reduced upon JQ1 treatment compared to the MYCN expression in 
DMSO-treated IMR5/75 cells (Figure 30B). In the second replicate the JQ1-treated cells 
showed a constant high MYCN gene expression. These ambiguous results concerning the 
MYCN expression upon JQ1 treatment in IMR5/75 cells are comparable with the results from 
the analysis of MYCN protein levels by western blot and RPPA. The CCND1 mRNA expression 
was considerably reduced in JQ1-treated IMR5/75 cells in both biological replicates (Figure 
30C). 
 
 
Figure 30: RNA-sequencing of JQ1-treated IMR5/75 cells. IMR5/75 cells treated with 0.5 µM JQ1 or DMSO as 
control were analyzed by RNA-sequencing. A) Clustering heatmap visualizing genes induced or repressed by JQ1 
treatment. Red = high expression, blue = low expression. B) MYCN mRNA expression throughout the time course. 
C) CCND1 mRNA expression throughout the time course.  
 
A Reactome analysis [140] of the cellular signaling pathways affected by JQ1 treatment in 
IMR5/75 neuroblastoma cells showed a focus of the differentially expressed genes on several 
cell cycle related pathways. Genes related to all cell cycle phases were found both among the 
upregulated and the downregulated genes (Table 11). Nevertheless, the downregulated genes 
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were best represented by G1/S transition related pathways, whereas the upregulated genes 
were found in G2/M gene expression profiles. Functional signatures for mitosis and cell cycle 
checkpoints were equally overrepresented in both JQ1 up- and downregulated gene 
expression data. Pathways belonging to DNA damage repair were overrepresented in the JQ1 
upregulated gene expression profile only, whereas the JQ1 downregulated genes were 
associated with p53 related DNA damage response and checkpoints. General transcriptional 
regulation induced by TP53 was associated with both JQ1 up- and downregulated gene 
expression profiles. 
 
Table 11: Pathway analysis of IMR5/75 RNA-sequencing data. 
Category JQ1 up- and 
downregulated 
JQ1 downregulated JQ1 upregulated 
DNA damage 
response and 
repair 
 
- p53-dependent G1/S 
DNA damage checkpoint 
- p53-dependent G1 DNA 
damage response 
- G1/S DNA damage 
checkpoints 
- HDR through Homologous 
Recombination (hrr) or Single 
Strand annealing (SSA) 
- DNA double-strand break 
repair 
- Homology directed repair 
p53 related 
pathways 
Transcriptional 
regulation by TP53 
 
TP53 regulates transcription of 
cell cycle genes    
Cell cycle, 
unspecific 
- Cell cycle 
- Regulation of mitotic 
cell cycle 
- Cell cycle, mitotic 
  
DNA-replication/ 
S-Phase 
- S-phase 
- DNA replication 
- DNA replication pre-
initiation 
- Assembly of the pre-
replicative complex  
- Synthesis of DNA 
 
Cell cycle 
checkpoints 
- Cell cycle checkpoints 
- G1/S transition 
- M/G1 transition phase 
- Mitotic G1-G1/S-phase 
- Cyclin E associated 
events during G1/S 
transition 
- Cyclin A:Cdk2-
associated events at S 
phase entry 
- G2/M transition 
- G2/M checkpoints 
Mitosis 
- Mitotic anaphase 
- Mitotic metaphase and 
anaphase 
- M-phase 
- Separation of sister 
chromatids 
Switching of origins to a 
postreplicative state 
- Mitotic G2-G2/M phases 
- Mitotic prometaphase 
 
b) RNA-seq: IMR5/75 in vivo 
In vivo RNA-sequencing profiles were performed in Nude mice with xenograft tumors deriving 
from human IMR5/75 neuroblastoma cells. The xenografts were injected with JQ1 or control 
intraperitoneally as described (Figure 29).  
  Dissertation Maike Christine Nortmeyer 
88 
 
The IMR5/75 RNA-sequencing profiles generated in vivo were compared with the in vitro 
IMR5/75 RNA-sequencing data. The gene expression data of both models were plotted in a 
diagram for the genes with the highest differential expression in JQ1-treated normalized to 
DMSO-treated conditions (Figure 31). Both IMR5/75 RNA-sequencing profiles are highly 
correlating with most genes either upregulated or downregulated both in vivo and in vitro. 
 
Figure 31: Correlation of RNA expression profiles in vivo and in vitro. Xenografts and cells were treated with 
JQ1 or vehicle as control. The gene expression changes of the xenograft tumors and the in vitro cell cultures were 
plotted for correlation analysis. The cutoff for DEG was set to a FDR of 0.01. 
 
The similarity of the in vivo and in vitro RNA-sequencing signatures was confirmed by 
analyzing the differentially expressed genes in Venn diagrams. The genes upregulated upon 
JQ1 treatment are shown in Figure 32A. From the upregulated genes, 111 genes (88%) were 
upregulated upon JQ1 treatment both in vitro and in vivo. Among the most differentially 
expressed genes, four genes were upregulated in vitro but not in vivo and 11 genes were 
upregulated in vivo only. The top hits among the upregulated genes identified by comparison 
of the 20 genes with the highest fold change in both the in vivo and in vitro RNA-sequencing 
profiles included several histone genes and members of growth promoting pathways, such as 
Jun or EGR1.  
The genes downregulated upon JQ1 treatment were analyzed by similar procedures (Figure 
32B). In both in vivo and in vitro, 126 genes (89%) were downregulated upon JQ1 treatment. 
A total number of 11 genes were identified as downregulated in vitro only, whereas four genes 
were downregulated in vivo but not in vitro. The list of the top hits comprised genes belonging 
to different functional and molecular terms, for example the gene TAL1 related to the NFκB- 
4
2
0
-2
-4
-2 -1 20 1
JQ1/Control in Xenograft [log2]
JQ
1
/C
o
n
tr
o
li
n
 C
e
ll
cu
lt
u
re
[l
o
g2
]
  Dissertation Maike Christine Nortmeyer 
89 
 
pathway, genes with metabolic functions, such as HS3ST4 or ARSJ, and genes involved in 
alternative splicing (SYT2, CALN1). 
 
 
Figure 32: Combined signatures of JQ1-treated IMR5/75 cell cultures and xenograft tumors. Comparison of 
the gene expression profiles generated in vivo and in vitro. A venn plot of the up- and downregulated genes is given, 
as well as the top candidates for both categories. Venn plots were generated by Venny 2.1.0 [139]. The cutoff for 
DEG was set to a FDR of 0.01. A) Genes upregulated upon JQ1 treatment. B) Genes downregulated upon JQ1 
treatment.  
 
c) RNA-seq: LS, NBL-S and NGP cell cultures 
With the aim to generate a broad insight into the gene expression patterns of JQ1-treated 
neuroblastoma cell lines, RNA-sequencing profiles from three additional neuroblastoma cell 
lines were generated. For the analysis, one cell line from each viability category was chosen: 
JQ1 sensitive LS and JQ1 resistant NGP, both MYCN amplified, and NBL-S cells, intermediate 
responding to JQ1 and MYCN translocated. The experiments were performed as described for 
IMR5/75 RNA-sequencing and as shown in Figure 28. 
The first analysis performed with the RNA-sequencing data from LS, NBL-S and NGP was a 
Principal Component Analysis (PCA), with the purpose to control the variance of the data 
especially regarding the similarity of the two biological replicates (Figure 33). For NGP and 
A
B
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NBL-S all samples from the same cell line closely clustered together and could clearly be 
separated from the samples of the other cell lines. The samples from cell line LS in general 
showed a similar clear clustering. However, two of the LS samples from the control group 
clustered together with the group of NBL-S samples instead of LS. It is assumed that a sample 
swap occurred in this case. To avoid a bias in the results, these two samples were excluded 
from further analysis. 
 
Figure 33: PCA Analysis of JQ1-treated cells. Principal component analysis of the RNA-sequencing profiles of 
LS, NBL-S and NGP. Red= LS samples, green=NBL-S samples, blue=NGP samples.  
 
The cell line LS was categorized as JQ1 sensitive in the viability screening. With an EC50 of 
0.07 µM LS ranked slightly behind IMR5/75. Genetically, LS cells harbor amplification statuses 
of MYCN, CCND1, CDK4 and MDM2. 
Differentially expressed genes, defined by a FDR of 0.01 or lower, were not identified for all 
time points of JQ1-treated LS cells. Upregulated genes were identified for the time points 24h 
and 48h, but not for 6h and 12h JQ1. The total number of upregulated genes was about 2.5 
times higher at the 24h time point compared to 48h JQ1 treatment (Figure 34A). A Venn 
diagram illustrates the overlap of 360 genes between both time points, which equates to 22.5% 
of the total upregulated differentially expressed genes. The top hits of the upregulated genes 
were identified by comparing the 50 genes with the lowest FDR of 24h and 48h JQ1-treated 
LS cells. The list includes EGR1, a transcription factor and tumor suppressor as well as NAB2, 
a transcriptional repressor for EGR1 and EGR2. Another top upregulated gene was DHRS2, 
which is known to stabilize p53 via the MDM2 axis and thereby induces a cell cycle arrest. In 
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contrast, SERTAD1 codes for a protein involved in cell proliferation by activation of the 
CDK4/Cyclin D1 complex. Further top upregulated genes are involved in metabolism or 
synaptic signal transmission and synaptic plasticity. Like the differentially expressed genes 
identified for IMR5/75, the list of upregulated genes of JQ1-treated LS cells included several 
genes for histone subunits. Those were excluded from the list of upregulated genes and are 
discussed separately. 
On the Reactome platform, a pathway analysis of all differentially expressed genes upon JQ1 
treatment in LS cells was performed (data not shown). For each time point, the 25 pathways 
with the lowest FDR were appraised. The pathway “RNA-Polymerase I promoter opening” was 
the only pathway upregulated at both the 24h and 48h time point. Additionally, for both time 
points upregulated pathways were identified related to the field of cellular senescence, 
telomeres and stress response. Besides this, upregulated genes at the 24h time point 
belonged to pathways of cellular transport and translation/protein synthesis. Upon 48h of JQ1 
treatment, pathways related to cell cycle, especially G1/S transition, to DNA repair, to TP53 
and to DNA methylation were upregulated.  
Downregulated differentially expressed genes in JQ1-treated LS cells were identified at the 6h, 
24h and 48h time point, whereas the number of differentially expressed genes at the 6h time 
point accounted for less than 5% of all downregulated genes identified by RNA-sequencing in 
LS cells (Figure 34B). The late time points 24h and 48h shared 997 genes identified as 
differentially expressed in both data sets, which equates to 43% of all downregulated genes. 
In contrast, the overlay between the downregulated genes at the 6h time point and the later 
time points was very low. The highest number of downregulated genes in LS cells was 
identified upon 24h of JQ1 treatment. A list of top hits among the downregulated genes was 
compiled as described for the JQ1 upregulated genes, complemented by the three differentially 
expressed genes downregulated at all three time points. Those shared genes were ANK1, 
DBH and SGIP1. Further interesting genes were RARG, coding for a retinoic acid receptor, 
TNFRSF10C belonging to the TNF receptor superfamily and SORBS3 involved in EGF 
signaling.  
Like the procedure for the JQ1 upregulated genes, a reactome pathway analysis was 
performed for the genes downregulated upon JQ1 treatment in LS cells. For each time point, 
the 25 pathways with the lowest FDR were viewed. The pathway analysis for the 6h time point 
came up with “neuronal system” as the sole pathway affected. At both late time points 24h and 
48h of JQ1 treatment, the downregulated genes were associated with pathways related to 
elastic fibres and extracellular matrix, to VEGF signaling and to TP53 related cell death. At the 
24h time point only, pathways associated with cell cycle and mitosis were downregulated, 
whereas Notch signaling and TRKA activation were downregulated at the 48h time point only.  
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Figure 34: RNA-sequencing of JQ1-treated LS cells. Analysis of the gene expression profiles of LS cells treated 
with 0.5 µM JQ1. Venn plots illustrate the overlap of DEG at different time points. The top target genes were 
identified by comparison of the 50 strongest DEG at 24h and 48h and all 6h down genes. The cutoff for DEG was 
set to a FDR of 0.01. A) Genes upregulated upon JQ1 treatment. For the time points 6h and 12h no upregulated 
DEG were identified. B) Genes downregulated upon JQ1 treatment. For time point 12h no downregulated DEG 
were identified. 
 
With an EC50 of 0.29 µM, the neuroblastoma cell line NBL-S was intermediate responding to 
JQ1 treatment in the viability screening. NBL-S cells are MYCN translocated and therefore 
express elevated levels of MYCN. 
In JQ1-treated NBL-S cells, the effects on the transcriptional level were broadly distributed. 
Differentially expressed genes, both up- and downregulated, were identified for all time points 
(Figure 35). At each of the early time points (6h and 12h) more than 2.000 genes were 
upregulated and downregulated, which is about 10-fold higher than the total number of 
upregulated genes after 24h of JQ1 treatment and 20-fold higher than the upregulated genes 
at the 48h time point. 
By comparison of the upregulated genes, 54 genes were identified that were upregulated at 
all time points, which are 1.9% of all genes upregulated in NBL-S upon JQ1 treatment (Figure 
35A). As visualized by the Venn diagram, a large proportion of genes was shared between the 
A
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ADI1 KIAA1683
ARC NAB2
B4GALT6 PAG1
DHRS2 PCDH17
EFR3B SERTAD1
EGR1 SH3GL2
FOS TMEM2
IER3
JQ1 up
  Dissertation Maike Christine Nortmeyer 
93 
 
early time points. The top hits among the 54 genes upregulated at all time points were selected 
by comparing the 200 differentially expressed genes with the lowest FDR. Those included 
HEXIM1, which is known to interact with Cyclin T1, TP53INP1 being involved in oxidative 
stress response and having proapoptotic functions or the transcription factors ZCCHC24 and 
CSRNP2. A pathway analysis using Reactome revealed 14 pathways upregulated at all time 
points (Table 12). The main fields the upregulated pathways belonged to were chromatin 
methylation and acetylation, transcription of rRNAs, and cellular senescence and telomeres. 
 
Figure 35: RNA-sequencing of JQ1-treated NBL-S cells. Analysis of the gene expression profiles of NBL-S cells 
treated with 0.5 µM JQ1. Venn plots illustrate the overlap of DEG at different time points. The top target genes were 
identified by comparison of the 200 strongest DEG of all time points. The cutoff for DEG was set to a FDR of 0.01. 
A) Genes upregulated upon JQ1 treatment. B) Genes downregulated upon JQ1 treatment.  
 
  
A
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Table 12: Pathway analysis of NBL-S RNA-sequencing data. Preselected pathways up-/downregulated at least 
at two time points are presented. 
Category JQ1 downregulated JQ1 upregulated 
Histone 
methylation+ 
acetylation 
 - DNA methylation (6-48h) 
- PRC2 methylates histones and DNA (6-48h) 
- HATs acetylate histones (6-48h) 
- HDACs deacetylate histones (6-48h) 
Extracellular 
matrix 
- Elastic fibre formation (12-48h) 
- molecules associated with elastic 
fibres (24+48h) 
- extracellular matrix organization 
(24+48h) 
- Collagen formation (24+48h) 
- Collagen chain trimerization 
(24+48h) 
- Collagen biosynthesis and modifying 
enzymes (24+48h) 
 
Senescence
+ Telomeres 
 - Packaging of telomere ends (6-48h) 
- Senescence-Associated Secretory Phenotype 
(SASP) (6-24h) 
- DNA Damage/Telomere stress induced senescence 
(6+12h) 
rRNA 
expression 
 - RNA Polymerase I promoter opening (6-48h) 
- RNA polymerase I chain elongation (6, 24, 48h) 
- RNA Polymerase I promoter clearance (24+48h) 
- B-WICH complex positively regulates rRNA 
expression (6-48h) 
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate 
rRNA expression (6-48h) 
- positive epigenetic regulation of rRNA expression 
(12-48h) 
- SIRT1 negatively regulates rRNA expression (6-
48h) 
- NoRC negatively regulates rRNA expression 
(24+48h) 
TCF/WNT, 
RUNX1/ 
RUNX3 
-RUNX3 regulates immune response 
and cell migration (6-24h) 
- RUNX1 regulates transcription of 
genes involved in BCR signaling 
(12+24h) 
- RUNX1 regulates genes involved in megakaryocyte 
differentiation and platelet function (12-48h) 
- Formation of the beta-catenin:TCF transactivating 
complex (6-48h) 
TRKA 
- Activation of TRKA receptors 
(6+24h) 
- NGF-independent TRKA activation 
(6+24h) 
 
others 
- NCAM1 interactions (6, 12, 48h) - Amyloid fibre formation (6-48h) 
- Meiotic recombination (6-48h) 
- Condensation of Prophase Chromosomes (6-48h) 
- Activated PKN1 stimulates transcription of androgen 
receptor regulated genes KLK2 and KLK3 (6-48h) 
 
 
In NBL-S in total more genes were down- than upregulated at all time points. Main effects were 
detectable at the early time points, with a large overlap of genes downregulated both at the 6h 
and at the 12h time point (Figure 35B). A comparison of the differentially expressed genes 
revealed that 121 genes were downregulated at all time points, which equates to 3.6% of all 
downregulated genes. Among the top hits of downregulated genes were several genes 
associated with the extracellular matrix (COL6A6, EMILIN1, GPR56, TNC). TNC is also 
functionally related to retinoic acid response and FGF signaling. Further growth factor related 
genes among the top hits were IGFBP5 involved in IGF signaling and TNS3 associated to 
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EGF. The gene DKK1 codes for the Dickkopf protein and has an antagonizing function in WNT-
signaling and anti-apoptotic properties. The results of the pathway analysis of the 
downregulated genes in NBL-S were less consistent than for the upregulated genes comparing 
the different time points (Table 12). No pathway was downregulated at all time points 
comparing the 25 pathways with the lowest FDR for each time point. A large number of 
downregulated pathways was related to the extracellular matrix, especially at the late time 
points 24h and 48h, which is consistent with the analysis of the top downregulated genes. 
Further pathways downregulated at more than one time point were related to TRKA, RUNX1 
and RUNX3 or cell adhesion. On the other hand, several pathways were specifically 
downregulated at one time point: For example, two pathways related to SERBP were lower 
expressed after 12h JQ1 treatment, whereas two pathways involving NOTCH3 were 
downregulated at the 6h time point only. 
 
The cell line NGP was categorized as JQ1 resistant in the viability screening. This finding was 
confirmed by the RNA-sequencing data. After 6h of JQ1 treatment, 853 upregulated and 1046 
downregulated genes were listed. The upregulated genes included histone genes and several 
genes belonging to the top hits found in RNA-sequencing profiles of the JQ1 sensitive cell 
lines, for example HEXIM1, CDKN2D or EGR1. Among the downregulated genes, amongst 
others E2F2 and CDK6 were detected. In contrast, at the time points 12h, 24h and 48h no 
differentially expressed genes were identified. This shows that JQ1 treatment leads to short-
term effects only in the resistant NGP cell line, whereas no changes in gene expression were 
assessed from 12h treatment onwards. 
 
d) Comparison of cell lines 
In the previous sections, the RNA sequencing results of IMR5/75, LS, NBL-S and NGP were 
described independently from each other. In the following part, the RNA expression profiles of 
the different cell lines will be compared regarding to general similarity, total numbers of 
differentially expressed genes and gene expression at single time points. Due to methodic 
differences in the analysis of IMR5/75 compared to the other cell lines, IMR5/75 RNA-
sequencing data cannot be included in all analyses of the present section. 
For assessment of the similarity of the gene expression profiles from all samples, a heatmap 
was generated, showing a hierarchical clustering of the top 100 differentially expressed genes 
of LS, NBL-S and NGP (Figure 36). DMSO and JQ1-treated samples, as well as both biological 
replicates of each sample were analyzed independently.  
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Figure 36: Heatmap of RNA-sequencing data upon JQ1 treatment. Hierarchical clustering of all samples based 
on the 100 top DEG. Neuroblastoma cell lines LS, NBL-S and NGP were treated with 0.5 µM JQ1 or DMSO only 
control in two biological replicates. JQ1-treated samples are displayed in green, DMSO control samples are 
indicated in pink. 
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The hierarchical clustering effectively sorted the cells by cell lines, for all three cell lines all 
samples from the same cell line, JQ1 and DMSO-treated, clustered closely together, with the 
exeption of two LS samples already identified as sample swap as shown in Figure 33. For 
NBL-S, the group of JQ1-treated samples and the DMSO control samples clustered apart from 
each other within the block of NBL-S cells. Thereby the JQ1-treated samples were strictly 
sorted by time points, with 48h upon JQ1 treatment closest to the DMSO control samples.  
In NGP, the samples treated with JQ1 formed two blocks, separated by the total number of 
control samples. One block comprised of the JQ1-treated samples of the early time points 6h 
and 12h, the other block comprised of the late JQ1-treated time points 24h and 48h. In contrast 
to the other cell lines analyzed, the 12h, 24h and 48h time points were represented by a single 
row instead of two biological replicates. This was due to the absence of differentially expressed 
genes at those time points.  
As described, the samples of the cell line LS clustered together. In contrast to NBL-S and NGP, 
no clear pattern was observed in LS samples differing between JQ1-treated and DMSO-
treated cells. 
An analysis of the total numbers of differentially expressed genes revealed large differences 
between the cell lines and time points. Figure 37A visualizes the total numbers of 
downregulated genes, Figure 37B the upregulated genes.  
In general, the total numbers of downregulated genes were higher than the number of 
upregulated genes. In LS cells, high numbers of differentially expressed genes were identified 
at the later time points 24h and 48h of JQ1 treatment. At the early time points 6h and 12h of 
JQ1 treatment, minimal effects were detected regarding the gene expression level. At the 12h 
time point no genes were differentially expressed, at the 6h time point no genes were 
upregulated and a small number of 109 genes had lower expression levels.  
For NBL-S cells, the distribution of the differential expressed genes to the time points was 
invers. The highest numbers of differentially expressed genes were detected at the early time 
points 6h and 12h with more than 2.000 genes up- and downregulated at each time point. On 
the late time points 24 and 48h the number of differentially expressed genes was constantly 
decreasing to 126 up- and 426 downregulated genes after 48h treatment with JQ1.  
The analysis of the JQ1 resistant NGP cells revealed no more than short time effects at time 
point 6h. At all other time points no differentially expressed genes have been identified. 
Based on the lists of the differentially expressed genes, certain potential key genes and genes 
of the pathways affected by JQ1 treatment in general were analyzed. A comparison of the 
upregulated and downregulated genes in this context revealed more similarities between the 
cell lines among the upregulated genes. A few genes have been upregulated in nearly all 
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samples harboring differentially expressed genes, for example HEXIM1, EGR1, GSK3-β or 
HAUS3. Additionally, many different histone genes were upregulated upon JQ1 treatment in 
all four cell lines, ranging from 14 different histone genes upregulated in LS to 42 genes in 
NBL-S cells.  
In contrast, the downregulation of genes was more individual with less similarities across cell 
lines and time points. This variance was true both for different time points in the same cell line, 
and for the same time point in different cell lines. By the absence of differentially expressed 
genes in several samples the analysis of genes globally downregulated upon JQ1 treatment 
became more complicated.  
Similar findings were true for the analysis of pathways across all 3 JQ1 sensitive and 
intermediate responding cell lines. Based on the lists of upregulated genes, pathways related 
to methylation, rRNA expression, Rho, cellular senescence and telomeres, and DNA repair 
were identified as upregulated in several cell lines and time points. Using the lists of 
downregulated genes, the variance of pathways affected was higher. Nevertheless, pathways 
related to extracellular matrix, TP53, Cell cycle and mitosis and Notch have been correlating 
with the downregulated genes of samples from more than one cell line. 
 
Figure 37: Differentially expressed genes upon JQ1 treatment. Total numbers of DEG comparing JQ1 and 
DMSO-treated cells. The FDR was set to 0.01 to define DEG. A) Numbers of downregulated DEG upon JQ1 
treatment. B) Numbers of upregulated DEG upon JQ1 treatment. 
 
To get insight in patterns of differential gene expression at early and late time points, the gene 
expression profiles of the three neuroblastoma cell lines LS, NBL-S and NGP were analyzed 
in a time-resolved manner. The Venn diagrams presented in Figure 38 show the overlap 
among the most differential expressed genes for each time point separately. IMR5/75 gene 
A B
0
500
1000
1500
2000
2500
6h 12h 24h 48h
n
u
m
b
e
r o
f 
D
EG
DEG upregulated
LS
NBL-S
NGP
0
500
1000
1500
2000
2500
6h 12h 24h 48h
n
u
m
b
e
r o
f 
D
EG
DEG downregulated
LS
NBL-S
NGP
  Dissertation Maike Christine Nortmeyer 
99 
 
expression data could not be included in this analysis, as the gene expression of this cell line 
has not been analyzed separated by time points. At the 12h time point, differentially expressed 
genes have been identified for NBL-S only, therefore no data are presented for this time point. 
With 6h upon JQ1 treatment, a high similarity was detected between the gene expression 
profiles of NBL-S and NGP, sharing 25.1% of the downregulated and 30.1% of the upregulated 
genes (Figure 38A). In LS cells, few genes were downregulated and no genes were 
upregulated at the 6h time point. Therefore, no more than 18 genes (0.7%) have been 
downregulated in all three cell lines.  
At the 24h and 48h time points no genes were differentially expressed in JQ1-treated NGP 
cells, so NBL-S and LS were the only cell lines compared at these time points (Figure 38B+C). 
For both time points an overlap of 10.1 respective 15.4% of all downregulated genes and of 
6.6% or 9.9% of all upregulated genes has been detected. These relatively small proportions 
must be put in relation to the discrepancy regarding the total number of differentially expressed 
genes for both cell lines. As shown in Figure 37, the total number of differentially expressed 
genes was in average 4 times higher for LS at the late time points compared to NBL-S. 
Normalization of the shared genes on the total number of differentially expressed genes in 
NBL-S resulted in about 40% analogy for the downregulated genes. For the upregulated 
genes, 63% analogy were detected after 24h and 34% after 48h of JQ1 treatment when 
normalizing as described. 
Taken together, JQ1 treatment induced broad changes in the gene expression profiles of the 
sensitive and intermediate responding cell lines included in this analysis. Affected genes can 
be assigned to central signaling pathways of G1/S transition, DNA damage response or 
senescence. Nevertheless, differences between the cell lines have been observed regarding 
effects occurring at early or late time points. 
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Figure 38: Time-resolved gene expression profiles upon JQ1 treatment. Venn diagrams of genes upregulated 
and downregulated comparing LS, NBL-S and NGP neuroblastoma cells treated with 0.5 µM JQ1 or DMSO only 
control and analyzed by RNA-sequencing. The data were sorted by treatment duration. A) DEG at the 6h time point. 
B) DEG at the 24h time point. C) DEG at the 48h time point. 
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5.2.10 Combined treatment of neuroblastoma cells with JQ1 and doxorubicin is more 
effective than single treatment 
In the majority of cases, chemotherapeutics are applied in combinatory therapies of two or 
more substances to avoid resistance development of cancer cells and thereby to increase the 
success of the therapy. As the RNA-seq results especially of the IMR5/75 neuroblastoma cell 
line revealed differential expression of DNA damage response genes, it is likely that JQ1 
influences those signaling pathways, but this is not resulting in massive cell death or 
permanent growth arrest. Combining JQ1 with a DNA intercalating drug could possibly 
increase the DNA damage to a level that cannot be compensated and consequently may then 
lead to cell death. Additionally, a successful combination of JQ1 and the intercalating 
chemotherapeutic drug doxorubicin is already described for leukemia cells [154].  
 
 
Figure 39: Timeline for combination treatment of JQ1 and doxorubicin. IMR5/75 cells were seeded 24h-48h 
before treatment depending on the different treatment protocols. The cells were treated with 0.5 µM JQ1 or 0.05 
µM doxorubicin or both. Treatment with both drugs was done in parallel or time-shifted. The cells were harvested 
and analyzed by flow cytometry.  
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IMR5/75 cells were treated with JQ1 or doxorubicin alone as well as with a combination of both 
drugs (Figure 39). The two drugs were either applied simultaneously or time-shifted. In the 
time-shifted experiments, the IMR5/75 cells were pretreated with the first drug, adding the 
second substance 24h later (= time point 0h).  
The analysis of IMR5/75 cells upon treatment with JQ1 and doxorubicin revealed clear 
differences between the treatments (Figure 40). After 12h of treatment the fraction of dead 
cells was similar for all treatment protocols. Differences were observed after 48h of treatment, 
which was the same time point when an increase of cell death was observed not only for JQ1-
treated IMR5/75 cells but also for other MYCN amplified neuroblastoma cell lines (section 
5.2.3). At the 48h time point, simultaneous application of both drugs was most effective, 
increasing the fraction of dead cells to 23%, compared to less than 10% in the untreated control 
and 14% with JQ1 single treatment. The time-shifted variants of the combination therapy both 
showed 17% cell death. 
At the 72h time point a statistically significant increase of cell death was measured for all 
samples compared to control (p<0.01). The highest rates of cell death were observed in the 
samples simultaneously treated with JQ1 and doxorubicin and in the samples pretreated with 
doxycycline before adding JQ1. In both cases the fraction of dead cells amounted 35%. 
Treatment with JQ1 alone resulted in 22% cell death and was thereby less effective than the 
single doxorubicin treatment. 
Summarizing, JQ1 was more effective when it was applied in combination therapy, either given 
simultaneously or with a doxorubicin pretreatment. It would have been expected that the JQ1 
pretreatment is more effective than doxorubicin pretreatment, with JQ1 downregulating DNA 
damage repair pathways prior to massive DNA damage induced by doxorubicin. On the other 
hand, it can be supposed that the DNA damage induced by doxorubicin treatment cannot be 
repaired effectively by the cells upon JQ1 treatment due to downregulation of DNA damage 
response pathways. 
The differential expression of DNA damage repair genes in JQ1-treated IMR/75 cells might be 
related to the function of BRD4 as histone chaperone. The combination of DNA intercalation 
by doxorubicin and inhibited histone chaperone function by JQ1 might result in high grade DNA 
damage leading to cell death.   
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Figure 40: Cell death of IMR5/75 treated with JQ1 drug combinations. IMR5/75 cells were treated with 0.5 µM 
JQ1 and 0.05 µM doxorubicin in different combinations (Fig. 39). Samples were harvested after 12h, 24h, 48h and 
72h. The cells were stained with propidium-iodide and analyzed by flow cytometry. Biological and technical 
triplicates were analyzed. Significance was tested with student t-test. 
 
In summary, treatment with the BET-Inhibitor JQ1 was highly effective in reducing the viability 
of 55% of the MYCN amplified and 30% of the MYCN non-amplified neuroblastoma cell lines. 
Among the 23 cell lines treated with the inhibitor, no further genetic factors besides MYCN 
were found priming the cells unambiguous as JQ1 sensitive or resistant. FACS analyses 
revealed an accumulation of JQ1 sensitive and intermediate responding cells in the G1-phase 
as well as an increase of cell death for MYCN amplified cell lines. Nevertheless, IMR5/75 cells 
showed a fast regrowth when removing the inhibitor. MYCN protein levels were reduced upon 
JQ1 treatment in most of the MYCN amplified neuroblastoma cell lines, though treatment of 
IMR5/75 cells with siRNA against different BET-proteins revealed that the MYCN knockdown 
was not directly induced by BET inhibition. Differential gene and protein expression were 
detected for a number of cell cycle related genes. Especially among the gene expression data, 
differences regarding time points and pathways affected in JQ1-treated cells were described. 
A combination therapy of JQ1 and doxorubicin was shown to be more effective than single 
treatment with the drugs. 
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5.3 Therapy with BET inhibitor BAY1238097 using a subcutaneous 
neuroblastoma mouse model 
 
In cell culture experiments, the two bromodomain inhibitors JQ1 and BAY1238097 showed 
high affectivity on 43% of the neuroblastoma cell lines in the panel used for viability screening, 
whereas 33% of the neuroblastoma cell lines were not affected by BRD4 inhibition. Especially 
anchorage independent growth was potently inhibited in all tested cell lines. Due to these 
promising results, therapeutic studies with the bromodomain inhibitor BAY1238097 were 
performed in mice. For these studies a subcutaneous neuroblastoma mouse model was 
chosen, because in this model, the xenograft tumor is palpable and measureable through the 
skin, which facilitates constant follow up of tumor growth.  
The experiments with the subcutaneous neuroblastoma mouse model were supported by Dr. 
Sina Gogolin and the Core Facility Tumor Models at the DKFZ and financed by Bayer AG. 
 
5.3.1 Method establishment of subcutaneous neuroblastoma xenograft models 
First, subcutaneous neuroblastoma mouse models were established for different 
neuroblastoma cell lines, including the MYCN amplified cell lines IMR5/75, LS and KELLY, the 
MYCN non-amplified cell line SH-SY5Y and the MYCN non-amplified, but translocated cell line 
NBL-S. Despite of the MYCN status, the cell lines were chosen to represent further mutations 
characteristic for certain subgroups of neuroblastoma tumors (Table 9, chapter 5.2.1). 
Two CD-1 nude mice per cell line were subcutaneously injected with neuroblastoma cells 
mixed with matrigel 1:1 in the right flank or with tumor cells only. The tumor growth was 
controlled and measured twice a week. 
A first control of tumor growth was performed seven days after implantation. At this time point 
one tumor deriving from IMR5/75 cells was detectable, whereas all other mice did not show 
tumors until day 12 or 18 of the experiment (Figure 41). Implantations of tumor cells without 
matrigel did not result in tumor growth (data not shown). 
The tumors arising from the cell lines LS, NBL-S and SH-SY5Y showed moderate tumor 
growth, reaching the maximum tolerable tumor size between day 30 and 49 after implantation. 
The growth behaviour of the two IMR5/75 tumors noticeably differed from each other. One of 
the mice harbored a very fast growing tumor that reached the maximum tumor size at day 18 
after implantation. In contrast, the tumor of the second IMR5/75 mouse was not palpable until 
day 18 after implantation and presented a moderate tumor growth reaching the maximum 
tumor size at day 38 after implantation. The neuroblastoma cell line KELLY formed very small 
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tumors that were detectable at day 18 and did not show a relevant further tumor growth over 
the following 30 days until the end of the experiment.   
Due to the fact that the tumors of KELLY neuroblastoma cells were not growing at all, it was 
decided to renounce this cell line for further experiments. It also became obvious from these 
experiments, that the usage of matrigel is essential for the growth of subcutaneous 
neuroblastoma xenograft tumors. 
 
Figure 41: Growth of subcutaneous neuroblastoma xenograft tumors. Tumor growth after implantation of cells 
together with matrigel from five different neuroblastoma cell lines. Two CD-1 nude mice per cell line were implanted 
with the tumor cells.  
 
5.3.2 Treatment of CD-1 nude mice harboring IMR5/75 xenograft tumors with 
BAY1238097 
As tumor growth was successfully estimated in 4 out of 5 neuroblastoma cell lines in the 
preliminary experiment, a preclinical study with a BAY1238097-treated and a control group 
was approached. 
7-8 weeks old CD-1 nude mice were subcutaneously injected with IMR5/75 neuroblastoma 
cells and matrigel in the right flank. The mice were examined daily, which comprehended 
measurement of tumor size, weighting and registration of general health condition. Mice with 
tumors were randomized into a control and a BAY1238097 treatment group. Treatment of the 
mice started, when the tumor reached an area of 25 mm² and was continued for up to 30 days. 
The dosage was 10 mg/kg BAY1238097 in NaCl 0.9% with pH=4, administered once daily per 
oral gavage. Because the control group was also used for comparison with two other inhibitors 
tested in parallel to BAY1238097, 80% PEG was given once per day as control vehicle. 
The control group comprised 22 mice, from these seven animals were excluded from the 
analysis due to intraperitoneal tumor localization or a shortened treatment frame of less than 
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five days (Table 13). From the remaining 15 animals nine mice were treated for 30 days until 
the endpoint of the experiment, whereas the other six mice had to be euthanized at an earlier 
timepoint when reaching the maximum tolerable tumor size, which was 14 mm diameter in any 
direction. The group treated with BAY1238097 (BETi) counted 16 animals. From those, four 
mice were excluded before randomization, resulting in 12 mice that were finally used for BETi 
treatment. In the end, two mice were treated for 30 days and seven animals had to be 
euthanized earlier because of the tumor burden. From the remaining three mice, one mouse 
was excluded from the study because of weight loss and 2 mice were injured- one during oral 
gavage and one by biting.   
Five mice of the control group were reinjected with IMR5/75 neuroblastoma cells in the left 
flank four weeks after the first implantation, because no tumor growth was detected in these 
animals up to this time point. The data from these mice are indicated in the following analyses. 
 
Table 13: Overview of the CD-1 nude IMR5/75 xenografts. Reasons for excluding animals from the analysis were 
treatment less than five days or intraperitoneal tumor localization. Mice euthanized due to weight loss or injuries 
are categorized as “others”. 
 
 
a) Tumor growth of BAY1238097-treated and control CD-1 nude mice 
Tumor growth of the IMR5/75 subcutaneous tumors was heterogeneous among both groups. 
In the control as well as in the BAY1238097-treated group were some tumors that were not or 
nearly not growing over the whole experimental period, whereas other tumors showed fast 
growth and reached the maximum tumor size in a short time frame. The growth curves of all 
tumors in this experiment are shown in Figure 42, starting from the first day of treatment until 
death of the mouse.  
Among the control group eight tumors nearly showed no tumor growth over the 30 days 
treatment period (Figure 42A). In contrast, a faster tumor growth was observed for seven of 
the 15 animals. The growth curves of these mice separated from the mice with no further tumor 
growth after about 15-20 days treatment. The growth behavior of the mice reinjected with tumor 
cells, because no tumor was growing in the first attempt (indicated in light blue in the Figure), 
did not differ from the other mice and included fast growing as well as not growing tumors. 
Control BETi
total animals: 22 
(excluded: 7)
total animals: 16 
(excluded: 4)
remaining animals: 15
→ endpoint: 9 (60%)
→ tumor size: 6 (40%)
→ others: 0
remaining animals: 12
→ endpoint: 2 (17%)
→ tumor size: 7 (58%)
→ others: 3 (25%)
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In the group treated with BAY1238097 most mice showed a fast and continuous tumor growth 
(Figure 42B). The growth curves of these fast growing tumors separated from those with no 
growth after 10-15 days of treatment, and thereby five days earlier than the control tumors. 
Among the BAY1238097 group was one tumor growing very fast (BETi_3), one tumor showed 
no growth at all (BETi_10) and one started fast tumor growth late during the treatment period 
(BETi_5). The mice for whose the experiment ended earlier for irregular reasons, such as 
injuries or weight loss, are indicated in light green in the Figure.  
Altogether the BAY1238097-treated group of tumors behaved more uniform than the control 
group. Health problems occurred for one mouse from the BAY1238097-treated group that lost 
15 % of its body weight. Beside this, the inhibitor and the control substance were well tolerated 
by the mice. 
Additional to the growth curves of the single tumors, the average tumor size on each treatment 
day was calculated for the control and BAY1238097-treated animals. These mean values are 
presented in Figure 43. Until treatment day 13 the mean tumor growth of the control and 
BAY1238097-treated animals proceeded quite parallel. From day 14 on, the BAY1238097-
treated tumors grew faster than the control tumors. This effect was detectable until treatment 
day 23. Then the mean tumor size of the BAY1238097-treated animals remained static, 
because four of the animals with large tumors were euthanized within two days. The control 
group showed slow but continuous tumor growth throughout the experiment. 
In total, the BAY1238097-treated group presented a faster and more homogeneous tumor 
growth than the control group. This is contrary to the expected results, based on the finding 
that BAY1238097 acted as a potent inhibitor in cell culture and effectively reduced viability in 
IMR5/75 cells. The high variability and the significant number of not growing tumors among 
the control group hindered a detection of potential inhibitory effects of the tested agent. 
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Figure 42: Tumor growth of each animal during treatment. Tumor growth curves of all animals starting from first 
day of treatment. Tumor size was measured through the skin with a caliper. A) Tumor growth of control animals. 
Dark blue graphs show animals with regular tumor growth. Light blue graphs show animals that were injected with 
tumor cells a second time on the opposite side. B) Tumor growth of BAY1238097-treated animals. Dark green 
graphs show animals with regular tumor growth. Light green graphs show animals that dropped out of the 
experiment due to irregular reasons (injury, weight loss). 
 
 
A
B
0
50
100
150
200
250
0 5 10 15 20 25 30
tu
m
o
r s
iz
e
 [m
m
²]
treatment days
BETi_1
BETi_2
BETi_3
BETi_4
BETi_5
BETi_6
BETi_7
BETi_8
BETi_9
BETi_10
BETi_11
BETi_12
0
50
100
150
200
250
300
350
0 5 10 15 20 25 30
tu
m
o
r s
iz
e
 [m
m
²]
treatment days
control_1
control_2
control_3
control_4
control_5
control_6
control_7
control_8
control_9
control_10
control_11
control_12
control_13
control_14
control_15
  Dissertation Maike Christine Nortmeyer 
109 
 
 
Figure 43: Comparison of tumor growth of BAY1238097-treated and control mice. The diagram shows the 
mean values of the tumor size from all animals for each treatment day. The LOCF method was used, calculating 
with the last value observed for animals excluded before end of the observation time. Animals that dropped out of 
the study for irregular reasons were not considered in the analysis. Tumor size was measured through the skin 
using a caliper. Significance was tested with student t-test (p>0.05). 
 
b) Effect of BAY1238097 treatment stated on treatment duration and tumor size 
Tumor growth curves are not the only way to assess the effectivity of the tested inhibitor 
BAY1238097 in vivo. Total treatment time and maximum tumor size provide additional 
information to state the effect of BAY1238097 treatment on IMR5/75 based xenograft tumors. 
Figure 44A demonstrates how many days the mice were treated during the experiment. The 
mice were treated with BAY1238097 or control vehicle for maximum 30 days and were 
euthanized the next day after measurement of tumor size in situ, which resulted in a total 
experimental duration of up to 31 days. Shorter periods occurred because of tumor burden or 
health reasons. For a successful therapy it would have been expected that treatment with 
BAY1238097 slows down tumor growth and thereby increases the time the mice remain in the 
study.  
Among the control group, several animals were in the experiment for the maximum duration of 
31 days, consequently the mean treatment duration was high with 27.9 days (median 30 days). 
In the BAY1238097-treated group (BETi), the mean and median treatment duration was clearly 
lower with 23.1 and 23.0 days, respectively. Altogether, the mice in the BAY1238097 group 
stayed in average one week shorter in the experiment, which was unexpected. 
The tumor size in situ of control and BAY1238097-treated mice is shown in Figure 44B. In the 
control group the tumors were smaller than in the BAY1238097-treated group: The mean size 
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of the control tumors was 138 mm², compared to 183 mm² in the BAY1238097 animals, 
measured in situ in living mice. After dissection of the euthanized animals the tumor size was 
measured again. The difference in size of the tumors ex situ was even higher with a mean size 
of 76 mm² for the control group and 144 mm² for the BAY1238097-treated animals. The 
variability of the control tumors was larger than for the BAY1238097-treated group, spanning 
from 34 to 328 mm². This variability was to be expected according to the inconsistent growth 
curves of the control animals. 
The finding that the tumors in the control group were smaller than the tumors of the 
BAY1238097-treated animals is contrary to the expected results. Together with the results 
from the treatment duration and the tumor growth, no inhibitory effect of BAY1238097 could 
be seen on IMR5/75 xenografts in CD-1 nude mice. In contrast, the tumors treated with 
BAY1238097 grew even better than those from the control mice.   
 
 
Figure 44: Effect of BAY1238097 treatment on treatment duration and tumor size. Animals that dropped out 
of the study for irregular reasons were not considered in the analysis. Significance was tested with student t-test 
(p>0.05). A) Treatment duration with BAY1238097 compared to the control group. The numbers of days the mice 
were followed up after treatment start in the BETi and the control group is presented. B) Tumor size at the end of 
the experiment. The tumor was measured in situ the day after the last treatment of the mice, using a caliper. 
 
c) Heterogeneity of tumor growth onset 
IMR5/75 xenograft tumors in CD-1 nude mice show high variability in tumor growth and tumor 
size. This is especially true for the control animals. Some differences are also seen in terms of 
the start of tumor growth, concretely the time from implantation of the tumor cells until the 
tumors reached a size of 25 mm², which was the cutoff size for the treatment start. The tumor 
onset of the control and BAY1238097-treated animals is shown in Figure 45A.  
A B
0
5
10
15
20
25
30
35
control BETi
d
ay
s 
w
it
h
 t
re
at
m
e
n
t
0
50
100
150
200
250
300
350
control BETi
tu
m
o
r 
si
ze
 [m
m
²]
  Dissertation Maike Christine Nortmeyer 
111 
 
The tumor onset of the control group is divided into three subgroups. The largest group with 
11 out of 15 animals has an early tumor onset with a period of 5-10 days between implantation 
and treatment start. One mouse took an intermediate time for tumor onset with 16 days, 
whereas tumor growth started late in three animals with more than 20 days incubation. The 
tumors from the mice reinjected with tumor cells all belonged to the early onset group, indicated 
in light blue in the Figure. The mice in the BAY1238097-treated group had either early or late 
tumor onset. Both groups consisted of six animals. The incubation time till tumor onset was 
equal to the time for the control group, with 6-9 days for early onset and 19-28 days for late 
tumors.  
To find out if an early or late tumor onset correlates with the tumor growth behavior, the 
treatment start and the treatment duration for each animal were plotted in a separate diagram 
(Figure 45B). No correlation was observed between tumor onset and treatment time. Both, the 
tumors with early and late tumor onset included slowly growing tumors from mice that were in 
the experiment until the 30 day treatment was finished as well as faster growing tumors that 
reached the maximum tumor size before the experiment ended. 
In summary, the differences in tumor onset are not the reason for the high variability of the 
tumor growth, as the control and BAY1238097-treated mice are similar distributed into early 
and late onset animals and as no correlation was found between tumor onset and growth 
behavior. 
 
 
Figure 45: Growth characteristics of IMR5/75 xenografts in CD-1 nude mice. A) The period of time between 
neuroblastoma cell implantation and tumor onset is demonstrated. Reinjected control mice are indicated in light 
blue. Significance was tested with student t-test (p>0.05). B) Correlation of treatment start and duration of treatment. 
Animals that dropped out of the study for irregular reasons were not considered in the analysis. 
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d) Macroscopic and histological differences 
At the end of the experiment the mice were euthanized. Photos were taken from the tumors in 
situ and after they were dissected, tumor size and weight were documented. Differences 
between the tumors were visible on the first glance regarding color and structure of the tumors. 
Some tumors were dark red, some light red with a marbled surface and some not colored at 
all, looking pale (Figure 46). Concerning the structure there were few tumors with a nodose 
structure, whereas most of the tumors had a smooth surface. A number of animals harbored 
two or three tumors close by but separated from each other. Those multiple tumors either 
belonged to the same or to different categories regarding tumor color. 
For histological appraisal, cryoslices were prepared and stained with hematoxylin/eosin. The 
appraisal was done by Dr. Tanja Poth from the pathology department. All tumors were 
identified as neuroblastoma. Further analysis regarding differentiation status of the tumor 
samples was not possible because the quality of the tumor material was not satisfactory. 
  
 
Figure 46: Macroscopic and histological appearance of IMR5/75 xenografts. Exemplary pictures from a dark 
red (Control_4), a light red (Control_7) and a pale (Control_13) subcutaneous xenograft tumor with the 
corresponding histological presentation are shown. 
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The results for each mouse concerning tumor growth, onset and size as well as macroscopy 
and histology are summarized in table 14 for control and table 15 for BAY1238097-treated 
animals.  
 
Table 14: Overview of IMR5/75 xenograft control mice.  
 
 
Table 15: Overview of IMR5/75 xenograft BAY1238097-treated mice. For BETi_1 and BETi_8 the growth 
behavior could not be categorized because the mice dropped out due to irregular reasons after 13 and 6 days.   
 
The majority of pale tumors were not or slowly growing, whereas the tumors colored light or 
dark red grew constantly in most cases. In the control group 4 out of 7 pale tumors had a low 
tumor content of 50% or less in the histological analysis. In contrast, all colored tumors had a 
tumor cell content >80%. From the five reinjected animals, in four mice the tumor was not 
mouse 
tumor in situ tumor ex situ histology 
growth onset 
size 
[mm²] 
size 
[mm²] 
weight 
[mg] 
macroscopy diagnosis 
tumor 
content 
necrosis 
control_1 ++ early 228 143 450 light red NB 80% No 
control_2 - early 56 39 40 pale NB 90% No 
control_3 - early 95 69 60 pale NB 80% No 
control_4 ++ early 215 162 510 dark red NB 90% No 
control_5 - late 34 28 20 pale NB 10% No 
control_6 + early 158 122 170 light red NB 90% No 
control_7 + late 194 130 320 light red NB 100% No 
control_8 ++ intermediate 168 115 190 dark red/pale NB 90% No 
control_9 ++ late 149 150 300 light red NB 90% Yes 
control_10 + early 328 132 280 dark red/light red NB 90% No 
control_11 - early 93 56 80 dark red NB 90% No 
control_12 - early 93 38 50 pale NB 100% No 
control_13 - early 91 30 30 pale NB 10% No 
control_14 - early 79 25 30 pale NB 50% No 
control_15 - early 84 22 20 pale NB 20% No 
 
mouse 
tumor in situ tumor ex situ histology 
growth onset 
size 
[mm²] 
size 
[mm²] 
weight 
[mg] 
macroscopy diagnosis 
tumor 
content 
necrosis 
BETi_1 ? late 63 67 77 light red NB 80% Yes 
BETi_2 ++ late 196 156 426 dark red NB 90% Yes 
BETi_3 +++ late 190 126 233 dark red/pale NB 100% Yes 
BETi_4 ++ late 202 123 251 dark red NB 100% No 
BETi_5 + late 129 94 118 light red NB 60% No 
BETi_6 ++ early 212 188 464 pale NB 80% No 
BETi_7 ++ early 242 160 490 dark red/pale NB 95% No 
BETi_8 ? late 107 74 133 light red NB 90% No 
BETi_9 ++ early 173 155 359 light red NB 70% No 
BETi_10 - early 52 54 15 pale NB 70% No 
BETi_11 ++ early 221 181 447 pale NB 80% No 
BETi_12 ++ early 208 210 421 dark red/pale NB 80% No 
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growing. These mice have in common that the tumors were pale and small and 3 out of 4 had 
a low tumor content of 50% and below in the histological analysis. 
When comparing the size of the tumors that was measured in situ through the skin with the 
real size measured after taking out the tumors, it was seen that in nearly all cases the real 
tumor size was smaller than measured in situ throughout the experiment. Especially in the 
control group were big differences between the size measured in situ and ex situ.  
 
Summarizing the results from the IMR5/75 xenograft tumors treated with BAY1238097 in CD-
1 nude mice, the expected effects were not seen. Treatment with the bromodomain inhibitor 
BAY1238097 did not result in growth inhibition, neither in smaller tumor size nor prolonged 
survival. In contrast, the tumors were more likely growing better when treated with the inhibitor 
compared to the control group. The high variability in the control group with many tumors that 
were not or slowly growing has distorted the results and caused the observed putative growth 
promoting effect of BAY1238097.  
Among the control group 8 out of 15 mice harbored not or slowly growing tumors, which 
equates more than half of the control animals. Among those were four mice reinjected with 
tumor cells because on the first attempt no tumor growth was detected at all. The heterogeneity 
of the tumors was also seen when comparing the appearance of the tumors and the tumor 
onset. In contrast to the appearance, the tumor onset was not correlating with tumor growth.  
Compared with the control group, tumor growth of the mice treated with BAY1238097 was less 
variable. It is not known why these animals with better tumor growth were pooled in the 
BAY1238097-treated group and were not equally distributed over both the BAY1238097 and 
the control group. In the BAY1238097-treated group only one tumor was not growing, whereas 
most of the mice harbored fast growing tumors. Comparing the growth curves, the exponential 
growth phase of the tumors started a few days earlier in the BAY1238097-treated mice. 
Due to these results, it was questioned if the variable tumor growth might be linked with an 
inappropriate mouse strain chosen for the experiment. The CD-1 nude mice used for tumor 
growth have no thymus and therefore lack a T-cell response including cytotoxic T-cells. B-cells 
and innate immune system are present in this mouse strain [155]. Though the CD-1 nude mice 
are especially recommended for xenograft tumor models, it was questioned if the remaining 
immunological competence may be enough to prevent tumor growth in the animals to different 
extent. 
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5.3.3 Comparison of different mouse strains for their use in a subcutaneous 
neuroblastoma mouse model 
Tumor growth of the IMR5/75 xenograft tumors in CD-1 nude mice was highly heterogeneous 
and slower as expected especially among the control mice. Due to these observations it was 
assumed, that the CD-1 nude mouse strain might not be suitable for a subcutaneous 
neuroblastoma mouse model. Therefore, two additional mouse strains of 
immunocompromized mice were tested for subcutaneous tumor growth of neuroblastoma 
tumor cells.  
For the study, tumor growth of the neuroblastoma cell lines IMR5/75, LS, NBL-S and SH-SY5Y 
was tested in the mouse strains NSG and NMRI compared to CD-1 nude. 5x106 tumor cells 
were subcutaneously injected in the flank and tumor size was measured twice per week. From 
each mouse strain, six animals were tested for each cell line. The experiment ended 50-56 
days after tumor cell implantation, dependent on the growth behavior of the cell line used. 
 
a) IMR5/75 xenografts 
In CD-1 nude mice harboring IMR5/75 deriving tumors, again a high variability in tumor onset 
and growth was observed (Figure 47A). One tumor was fast growing; it was detectable at day 
19 after implantation and reached the maximum tolerated tumor size at day 26. From the other 
five CD-1 nude mice, two harbored very small tumors with an average tumor weight of 260 mg 
(Figure 47B) and had a late tumor onset. In one mouse no tumor growth was detected at all, 
and in the remaining two animals a bulge was measured without a detectable tumor at 
dissection at the end of the experiment. 
Using the mouse strain NMRI, tumors were growing in all six mice. Until day 19 after 
implantation, the tumors were growing in parallel with similar sizes. Later on, they divided into 
two groups: four tumors were growing continuously, and two tumors showed a growth arrest 
for approximately 2.5 weeks before growing again. The average tumor weight was 490 mg.  
The most homogeneous growth of IMR5/75 tumors was observed in NSG mice. All mice 
harbored a tumor with similar growth curves and all six tumors reached the maximum tolerable 
tumor size before the endpoint of the experiment. The weight of the tumors showed a low 
deviation and the average tumor weight of 1.070 mg was the highest of all three mouse strains 
(p<0.005). 
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Altogether these results show that choosing a suitable mouse strain has high influence on 
tumor growth and tumor onset and thereby on the homogeneity of the group in total. A group 
of mice with a low deviation regarding the basic tumor growth increases the power of the 
complete data set of a mouse treatment study and facilitates finding of differences between 
control and drug-treated animals. 
 
Figure 47: IMR5/75 tumor growth in three different mouse strains. NSG (purple), NMRI (red) and CD-1 nude 
mice (green) were subcutaneously injected with IMR5/75 cells. A) Tumor growth of six animals from each mouse 
strain. B) Tumor weight at the endpoint. The tumor weight of CD-1 nude#3 is unknown. P-value was <0.005 for 
NSG mice compared to both other mouse strains (student t-test). 
 
 
b) other neuroblastoma cell lines: SH-SY5Y, LS, NBL-S 
The comparison of different mouse strains with IMR5/75 deriving xenograft tumors revealed 
clear differences regarding tumor growth behavior. Comparable results have been observed 
for the other three neuroblastoma cell lines LS, NBL-S and SH-SY5Y, which were also planned 
to be included in the BAY1238097 treatment study. 
With the cell line LS, tumor growth in the CD-1 nude mice showed the highest variability of all 
three mouse strains and the lowest growth rate (Figure 48A and B). In two CD-1 nude mice, 
no tumor was detected at all, two mice harbored a small and slowly growing tumor and two 
mice showed an intermediate tumor growth. In NMRI mice, five LS-derived tumors were 
growing in total. In NSG mice, tumors were growing in all six animals. The tumors were 
detected at day 18-21 after implantation and were growing quite homogeneously: four tumors 
showed a fast growth and two tumors were a bit delayed and growing in parallel with the tumors 
of the NMRI mice. Comparing size and weight of the LS-deriving tumors, the NSG mice had 
the largest tumors and the lowest variability in tumor size (p<0.05). 
Fig: mouse strains comparison, tumor growth
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Figure 48: Neuroblastoma tumor growth in different mouse strains. NSG (purple), NMRI (red) and CD-1 Nude 
mice (green) were injected with different neuroblastoma cell lines subcutaneously. Significance was tested with 
student t-test. A) Tumor growth of mice injected with LS cells. B) Tumor weight of LS neuroblastoma tumors. C) 
Tumor growth of mice injected with NBL-S cells. D) Tumor weight of NBL-S neuroblastoma tumors. E) Tumor growth 
of mice injected with SH-SY5Y cells. F) Tumor weight of SH-SY5Y neuroblastoma tumors.  
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Among the tumors deriving from NBL-S cells, NSG mice showed the fastest tumor growth and 
the highest tumor weight (Figure 48C and D, p<0.05). Each NSG mouse harbored a tumor, 
whereas among the NMRI as well as the CD-1 nude mice 3 out of 6 animals were negative for 
a tumor or showed ambiguous results. Tumor growth in the NMRI mice started between day 
36 and day 40 after implantation, in contrast to tumor onset in the NSG mice that took place 
between day 15 and day 22. In CD-1 nude mice the period until tumor growth was detectable 
was 28-36 days. In total, the variability within the NSG group was higher with NBL-S cells than 
for the cell lines LS and IMR5/75 discussed before. This is probably due to the clustering 
growth behavior of NBL-S cells, which is impeding equal implantation of the tumor cells. Still, 
tumor growth data in NSG mice showed better results regarding tumor growth, tumor onset 
and tumor size than in the other two mouse strains tested. 
The SH-SY5Y cell line showed the worst tumor growth rate from all four cell lines included in 
the experiment (Figure 48E and F). In the NSG mice injected with SH-SY5Y, 5 out of 6 mice 
developed a tumor. Among the NMRI mice four animals harbored a tumor and three tumors 
were observed in CD-1 nude mice. The growth curves with each mouse strain were more 
variable with SH-SY5Y than with tumors deriving from other neuroblastoma cell lines. At first, 
SH-SY5Y tumors were detectable in the NSG mice 20-28 days after tumor cell implantation. 
From the time point on, when the tumors were measureable, the SH-SY5Y deriving tumors 
showed a fast growth and the maximum tolerable tumor size was reached after a short period 
in all three mouse strains. The mean tumor weight at the endpoint of the experiment was 
comparable in all three mouse strains with the highest variance in the CD-1 nude mice and the 
lowest variance in NSG mice (p>0.05). 
 
The experiment with the other neuroblastoma cell lines LS, NBL-S and SH-SY5Y underlines 
that the NSG mice are the most suitable mouse strain for a subcutaneous neuroblastoma 
mouse model. NSG mice are a severely immunodeficient mouse strain with a non-functional 
T-, B- and NK-cell response [156]. In contrast, the CD-1 nude mice previously used for the 
subcutaneous mouse model are lacking a T-cell response, whereas the innate immune system 
is functional [157]. The differences between the mouse strains were most obvious with 
IMR5/75 cells but also the other three cell lines tested showed the best results in NSG mice. 
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5.3.4 Toxicity study with BAY1238097 in NSG mice 
Before starting a complex treatment study with a large number of animals, it was tested if the 
aimed daily dose of BAY1238097 of 10 mg/kg body weight was tolerated by the NSG mice. 
For this experiment, NSG mice without tumors were treated with BAY1238097 in NaCl 
0.9%/pH4 or control vehicle NaCl 0.9%/pH4 once daily for 30 days administered by oral 
gavage. Both the control and the BAY1238097 group comprised six animals each. The 
tolerance of the inhibitor was monitored by daily weighting of the mice. A weight loss of 10% 
or more would be the main sign that the administered dosage is too high. Aside weight loss 
other criteria, such as diarrhea or a poor general condition, were also monitored.  
 
Figure 49: Weight variability of mice treated with BAY1238097. Six mice were treated daily with BAY1238097 
or control for 30 days. Body weight of the mice was controlled daily. A) Highest and lowest weight of each mouse 
during the 30 days treatment compared to the average weight of this animal. B) Average body weight of all control 
and BAY1238097-treated mice for each treatment day. A trendline shows the change of body weight over time.  
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Figure 49A shows the variation in body weight for each of the control and BAY1238097-treated 
mice. The average body weight of each mouse was set to 100% and compared with the 
maximum and minimum body weight measured during the 30 days of the experiment. For most 
of the mice in both groups the maximum fluctuation ranged about 5% around the average body 
weight. In the control group, 1 out of 6 mice showed more than 10% weight loss, which was 
only temporary due to diarrhea. In general, BAY1238097 was well tolerated by the mice, no 
diarrhea or weight loss was observed in 5 out of 6 mice. One animal treated with BAY1238097 
showed a weight loss >20% and was immediately euthanized. 
Additional to the minimum and maximum body weight of each mouse it was interesting how 
the weight of the mice develops over the whole treatment period. Therefore, the mean body 
weight of all control and BAY1238097-treated mice was calculated for each treatment day 
(Figure 49B). A linear trendline gives an idea on the weight development over the whole 30 
days of treatment. The BAY1238097-treated mouse euthanized due to weight loss was 
excluded from the analysis. The analysis shows that both the control and the BAY1238097-
treated animals lost weight during the experiment.  
As the weight loss occurs in both the BAY1238097-treated and control group and no signs of 
side effects such as diarrhea or apathy, it is likely that the substance itself is not the reason for 
the dropping weight. There are two other reasons that could be an explanation for the moderate 
weight loss in both groups. Supposably, the animals are stressed when they are taken out and 
gavaged daily. Second, a local irritation of the gullet due to the oral gavage might lead to a 
lower food uptake. 
 
5.3.5 Full study: Treatment of NSG mice harboring heterotopic neuroblastoma 
xenograft tumors with BAY1238097 
After the end of the preliminary experiments, the full study with BAY1238097 applied to NSG 
mice with neuroblastoma tumors deriving from four different cell lines was performed. For each 
cell line, 12 animals for control and 12 animals for the BAY1238097-treated group were 
subcutaneously injected with neuroblastoma tumor cells. The cell lines used for this 
experiment were IMR5/75, LS, NBL-S and SH-SY5Y. Tumor size was measured twice a week 
through the skin, using a caliper. When the tumors reached 3-4 mm in diameter, mice were 
randomized and the treatment was started. The mice were treated with BAY1238097 in NaCl 
0.9%/pH4 or with the control vehicle NaCl 0.9%/pH4 once daily, administered by oral gavage 
for maximum 30 days. Criteria for a premature euthanasia of the mice were reaching of the 
maximum tolerated tumor size of 14 mm diameter in one direction, weight loss of more than 
20%, injuries or poor health condition. 
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a) IMR5/75 
The neuroblastoma cell line IMR5/75 is a MYCN amplified and highly proliferating cell line. In 
previous experiments under cell culture conditions, both BAY1238097 as well as JQ1 showed 
a high affectivity on IMR5/75 cells.  
In vivo, the time from implantation of the tumor cells until tumor onset was varying among the 
tumors deriving from IMR5/75 cells. Resulting out of this, randomization and treatment start 
among the IMR5/75 control tumors were widely distributed between day 9 and day 21 after 
implantation. In the BAY1238097-treated group nearly all animals started treatment at day 18 
after implantation, except two animals that were delayed until day 21 and 28.  
The tumor growth curves from all IMR5/75 tumors are separately presented in Figure 50, giving 
an idea on the heterogeneity of the groups and the growth characteristics the tumors in the 
control or BAY1238097-treated group might have in common. In the control group, all tumors 
were growing continuously throughout the experiment (Figure 50A). They could be divided in 
a group of seven fast growing tumors and five tumors with a delayed growth compared to the 
others. Among the group treated with BAY1238097 10 out of 12 tumors were continuously 
growing, one tumor showed a growth arrest and one tumor was growing slowly (Figure 50B). 
Compared to the control group, the growth curves of the tumors in the BAY1238097-treated 
group were less precipitous, especially in the early treatment days. The entry of the tumors 
treated with BAY1238097 into the exponential growth phase was delayed. 
Analysis of the tumor growth of IMR5/75 derving tumors was influenced by the differences in 
tumor onset, going along with varying growth characteristics of the tumors. Late onset tumors 
tended to present with fast tumor growth, reaching the maximum tolerated tumor size in 
relatively short time. As the mean tumor onset was five days earlier in the control group than 
in the BAY1238097-treated group, fast growing tumors could be overrepresented in 
BAY1238097-treated mice and disguise a potentially larger effect of drug treatment. 
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Figure 50: Tumor growth of IMR5/75 xenograft tumors. Treatment with BAY1238097 or control started at day 
one. The tumor size was measured through the skin twice a week. A) Tumor growth of control animals. B) Tumor 
growth of BAY1238097-treated animals. 
 
The survival of the mice was visualized in a Kaplan-Meier plot (Figure 51A). The endpoint at 
day 31 was reached by one animal from the control group and by three of the BAY1238097-
treated mice. All other mice reached the maximum tumor size before the experiment ended 
and therefore were euthanized earlier. Although the survival curves resemble each other, the 
median treatment duration was increased from 17.5 in the control group to 22.5 days in the 
BAY1238097-treated group. The increase of survival is not significant (p>0.05). 
Figure 51B compares the tumor size at the last day of treatment of each mouse. For IMR5/75 
the median tumor size of the control and the BAY1238097 group did not show significant 
differences (p>0.05). Most tumors had a weight between 150 mg and 200 mg, the variability 
was low.  
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Figure 51: Effect of BAY1238097 treatment on IMR5/75 xenografts. The effectiveness of BAY1238097 on 
xenografts from IMR5/75 neuroblastoma cells in NSG mice is demonstrated. Significance was tested with student 
t-test. A) Kaplan Meier plot illustrates treatment duration for control and BAY1238097-treated mice. B) Tumor size 
at the end of the experiment. The tumor was measured through the skin with a caliper. 
1 
Altogether, no significant inhibitory effect was observed for IMR5/75 deriving tumors. This was 
unexpected regarding to the results with IMR5/75 under cell culture conditions, showing high 
sensitivity upon JQ1 treatment (section 5.2). The inhomogeneity of the tumor onset especially 
in the control treatment group, might have had an impact on the results. 
 
b) LS 
LS is a MYCN amplified cell line with additional proliferation promoting amplifications of 
CCND1, MDM2 and CDK4. In vitro viability assays predicted an intermediate response to 
BAY1238097, whereas LS cells treated with the BRD4 inhibitor JQ1 showed high sensitivity to 
the substance. 
Subcutaneous xenografts deriving from LS cells reached the size necessary for treatment start 
20-25 days after tumor implantation. The mice in the control group showed a steady tumor 
growth with uniform tumor growth curves (Figure 52A). The maximum tumor size was reached 
by all 12 mice during treatment; no mice were treated for the complete 30 days. Compared to 
the control animals, the tumors in the BAY1238097-treated group were growing more slowly 
(Figure 52B). All tumors were getting larger continuously, but the growth curves were more 
plane than the tumor growth curves of the control animals. The tumor growth was 
homogeneous with most of the growth curves resembling each other. After 30 days of 
treatment with BAY1238097 two mice were alive, all other animals had to be euthanized due 
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to tumor burden. Tumor size of the BAY1238097-treated mice was significantly lower than 
tumor size of the control group at treatment day 24 (p<0.001) (Figure 52C). 
 
Figure 52: Tumor growth of LS xenograft tumors. Treatment with BAY1238097 or control started at day one. 
The tumor size was measured through the skin twice a week. A) Tumor growth of control animals. B) Tumor growth 
of BAY1238097-treated animals. C) LOCF analysis of tumor growth. Significance was tested with student t-test for 
day 24.  
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The Kaplan-Meier plot demonstrates that treatment with the inhibitor BAY1238097 effectively 
slowed down tumor growth and thereby prolonged the survival of mice with LS-derived tumors 
(Figure 53A). Until treatment day 18 the survival curves run parallel, then the remaining 
animals in the control group were dying fast with the last mice euthanized at day 24, whereas 
in the BAY1238097-treated group no further deaths occurred until treatment day 28. The 
median treatment duration was increased by therapy from 19.5 to 28 days, nevertheless this 
difference was not significant.  
The tumor size at the last treatment day was about 50 mm² lower in the BAY1238097-treated 
animals compared to the control group, representing a significant decrease in tumor size 
(p<0.01) (Figure 53B). For both treatment groups, the variation of the tumor size within the 
group was low.  
 
 
Figure 53: Effect of BAY1238097 treatment on LS xenografts. The effectiveness of BAY1238097 on xenografts 
from LS neuroblastoma cells in NSG mice is demonstrated. Significance was tested with student t-test. A) Kaplan 
Meier plot illustrates treatment duration for control and BAY1238097-treated mice. B) Tumor size at the end of the 
experiment. The tumor was measured through the skin with a caliper.  
 
Taken together, the BRD4 inhibitor BAY1238097 is inhibiting tumor growth of subcutaneous 
neuroblastoma tumors deriving from LS cells. The treatment with the inhibitor leads to a 
prolonged survival of the mice and to a reduction in tumor size. 
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c) NBL-S 
The neuroblastoma cell line NBL-S harbors a MYCN activating translocation leading to higher 
MYCN expression compared to MYCN non-amplified cell lines [158]. In vitro, NBL-S is 
classified as resistant to BAY1238097 and intermediate responding to JQ1.  
Nearly all animals with tumors deriving from NBL-S cells reached the cutoff tumor size for the 
start of the therapy at day 20 or 23 after implantation. The tumors of control mice were in 
general all growing continuously (Figure 54A). In the BAY1238097-treated group four mice 
(BETi 1, 5, 9, 10) harbored tumors that were not growing larger than 100 mm² during the whole 
30 days treatment period (Figure 54B). The remaining eight tumors were entering the 
exponential growth phase with a faster increase of tumor size after varying treatment periods. 
 
Figure 54: Tumor growth of NBL-S xenograft tumors. Treatment with BAY1238097 or control vehicle started at 
day one. The tumor size was measured through the skin twice a week with a caliper. A) Tumor growth of control 
animals. B) Tumor growth of BAY1238097-treated animals. 
The Kaplan-Meier plot demonstrates that the mice from both the control and the BAY1238097-
treated group died in a similar course and steadily throughout the experiment (Figure 55A). At 
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the last treatment day, one mouse from the control group and three mice from the 
BAY1238097-treated group were still alive, all others had to be euthanized earlier. The median 
treatment duration of the BAY1238097-treated group was 19.5 days, compared to 16.5 days 
in the control group. This difference is lower than for the two MYCN amplified neuroblastoma 
cell lines, IMR5/75 and LS, and was not significant (p>0.05). 
No significant differences in tumor size were assessed comparing the control and 
BAY1238097-treated groups (p>0.05) (Figure 55B). Whereas the tumor size of the control 
group was uniform at the end of the experiment, the BAY1238097-treated group comprised 
eight larger and four smaller tumors. 
 
Figure 55: Effect of BAY1238097 treatment on NBL-S xenografts. The effectiveness of BAY1238097 on 
xenografts from NBL-S neuroblastoma cells in NSG mice is demonstrated. Significance was tested with student t-
test. A) Kaplan Meier plot illustrates treatment duration for control and BAY1238097-treated mice. B) Tumor size at 
the end of the experiment. The tumor was measured through the skin with a caliper. 
 
Altogether the effects of BRD4 inhibition with the substance BAY1238097 on NBL-S deriving 
subcutaneous xenografts were marginal. The main effect was a growth arrest for a fraction of 
tumors, whereas other tumors were growing continuously. The difference between fast and 
slow growing tumors impeded the analysis of the data from the NBL-S mouse collective. 
 
 
d) SH-SY5Y 
The neuroblastoma cell line SH-SY5Y does not have a MYCN amplification and is the only cell 
line used in the subcutaneous mouse model that is negative for MYCN expression. Instead, 
SH-SY5Y cells have high mRNA and protein levels of c-MYC due to an activating translocation, 
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and a mutation in the ALK gene. In vitro, SH-SY5Y was classified as an intermediate responder 
to JQ1 and BAY1238097.  
For the SH-SY5Y tumors the tumor onset was inconsistent with a mean treatment start at day 
15 for control and a mean tumor onset of 20 days for the BAY1238097 group. This difference 
regarding tumor onset could have influenced the results as described for IMR5/75. The tumor 
growth curves of the 12 control-treated mice injected with SH-SY5Y were uniform with all 
tumors growing continuously throughout the experiment (Figure 56A). Remarkable was the 
long period from onset of the tumor growth until the growth was entering the exponential growth 
phase for both control and BAY1238097-treated animals. Compared to the control group, the 
tumor growth of the BAY1238097-treated mice was more variable and included two mice (BETi 
5, BETi 6) with no tumor growth at all, which was independent from early or late tumor onset 
(Figure 56B). Tumor growth of BAY1238097-treated animals was retarded late in the 
experiment.  
 
Figure 56: Tumor growth of SH-SY5Y xenograft tumors. Treatment with BAY1238097 or control started at day 
one. The tumor size was measured through the skin twice a week. A) Tumor growth of control animals. B) Tumor 
growth of BAY1238097-treated animals. 
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The Kaplan-Meier plot visualizes that up to treatment day 24 the control mice were surviving 
longer than the BAY1238097-treated mice due to two early deaths in the treatment group 
(Figure 57A). From day 24 on the tumors of the control group successively reached the 
maximum tumor size and had to be euthanized. In total, a prolonged median survival of 29 
days was observed in the BAY1238097-treated group compared to 25 days in the control group 
(not significant). In contrast to the other cell lines used for the subcutaneous mouse model, a 
high number of animals injected with SH-SY5Y did not reach the maximum tumor size during 
the treatment period. At the last day of treatment, three mice from the control group and five 
BAY1238097-treated animals were still alive. 
Although tumor growth within the BAY1238097-treated group was heterogeneous, a significant 
decrease in tumor size was observed for the BAY1238097-treated animals (p<0.05) (Figure 
57B).  
 
Figure 57: Effect of BAY1238097 treatment on SH-SY5Y xenografts. The effectiveness of BAY1238097 on 
xenografts from SH-SY5Y neuroblastoma cells in NSG mice is demonstrated. Significance was tested with student 
t-test. A) Kaplan Meier plot illustrates treatment duration for control and BAY1238097-treated mice. B) Tumor size 
at the end of the experiment. The tumor was measured through the skin with a caliper.  
 
Taking together, BAY1238097 treatment significantly decreased tumor growth of SH-SY5Y 
deriving neuroblastoma xenograft tumors. As 25% of the control and 42% of the BAY1238097-
treated animals were still alive at the end of the experiment, a longer period of treatment of 
approximately 40-50 days in total would have been adviceable to gain information on the final 
tumor growth of the remaining mice. This should be considered for further in vivo studies with 
SH-SY5Y cells.  
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The establishment of the subcutaneous neuroblastoma mouse model for different 
neuroblastoma cell lines including preliminary growth tests, the comparison of different mouse 
strains and the exclusion of drug toxicity were necessary to set up a preclinical in vivo study 
on BAY1238097 with reliable results. Especially the decision to analyze tumor growth in 
different mouse strains was indispensable to reduce variability of the data set and to increase 
the validity of the study. By repeating the BAY1238097 treatment study on IMR5/75 cells in 
NSG mice, the observed results with a tumor growth promoting effect of BAY1238097 in the 
CD-1 nude mice, could be relativized and explained as a result of the heterogeneity among 
the control animals in the CD-1 nude collective.  
The experiment on NSG mice with the cell lines IMR5/75, LS, NBL-S and SH-SY5Y showed a 
significant inhibitory effect of BAY1238097 on LS-deriving tumors, but no or minimal effects for 
the tumors originating from the other three cell lines. However, the sensitivity of neuroblastoma 
cell lines to BAY1238097 does not in general predict for the responsiveness in vivo. In the 
case of LS, predicted as good to intermediate responding, the results from the cell culture 
experiments with BRD4 inhibitors were comparable. For IMR5/75, the expected high sensitivity 
to BAY1238097 failed to be observed in vivo, as well as an intermediate sensitivity of NBL-S 
and SH-SY5Y to treatment with BET inhibitors.  
Especially for the IMR5/75 deriving tumors, the comparability of control and BAY1238097-
treated animals is limited in NSG mice due to the high variability of tumor onset between the 
control and the BAY1238097 group. As observed for all cell lines, the tumor onset has an 
influence on the tumor growth speed, tumors with a late onset included late in the treatment 
reached the maximum tolerated tumor size in short time. Thereby a shift between tumor onset 
in control and treatment group could have a relevant influence and mask potential therapeutic 
effects. An increase of the total number of animals is adviceable to increase the number of 
animals with similar tumor onset and thereby to improve the power of the study. 
 
5.4 Establishment of an orthotopic neuroblastoma mouse model 
 
As described in the introduction, an orthotopic xenograft mouse model has many advantages 
compared to heterotopic tumors growing subcutaneously. One main part of this thesis was the 
establishment of an orthotopic neuroblastoma mouse model using the IMR5/75 MYCN 
high/low and IMR32 MYCN high/low cell systems described in the results part 5.1 in detail. 
Aim of this project was to establish a mouse model close to the situation in humans with low 
or high MYCN expression in the tumor cells, but besides this the same genetic background. 
For better visualization of even small tumors, in vivo bioluminescence imaging was planned to 
be used, detecting stable luciferase expression in the human tumor cells. 
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5.4.1 Luciferase is expressed by cells used for orthotopic implantation 
First of all luciferase expressing cells were generated. IMR5/75 MYCN high/low and IMR32 
MYCN high/low neuroblastoma cells were transfected with the commercially available pGL4.50 
plasmid coding for a stable expressed firefly luciferase gene. Monoclonal subclones were 
tested for luciferase expression to identify clones with high levels of luciferase expression. 
 
Figure 58: Luciferase expression of monoclonal cell lines. Monoclonal luciferase subclones were generated by 
a two-step selection process. Luminescence was measured over a period of 30 sec. Luciferase expression was 
normalized by using equal amounts of total protein. In the graphs the mean values are shown for each clone.  A) 
Clones from IMR5/75 cell line. Untransfected IMR5/75 cells were used as a negative control. Luciferase expressing 
HeLa cells were used as positive control. Clones #6 and #9 had the highest luciferase expression. Those were 
frozen in liquid nitrogen and used for further experiments. B) Clones from IMR32 cell line. Untransfected IMR32 
cells were used as a negative control. IMR5/75 clone #6 was used as a positive control. Clones #11 and #7 had 
the highest luciferase expression. Those were frozen in liquid nitrogen and used for further experiments. 
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From IMR5/75, 16 subclones could be generated by monoclonal selection (Figure 58A). 
Clone#12 stopped growing after a few weeks in culture and had to be excluded from luciferase 
measurement. Among the remaining 15 subclones, luciferase expression was detectable in 10 
clones. The degree of the luciferase signals was quite varying between the different subclones. 
The highest levels of luciferase expression were measured in the subclones IMR5/75 luci#6 
and IMR5/75 luci#9.  
From IMR32, 14 subclones deriving from single cells were tested for luciferase expression 
(Figure 58B). 12 out of 14 subclones showed luciferase expression, with the highest 
expression levels in IMR32 luci#11, IMR32 luci#7 and IMR32 luci#13. IMR32 luci#13 showed 
divergent growth behavior; therefore this subclone was excluded from further culturing. The 
subclones IMR32 luci#11 and IMR32 luci#7 were chosen for further experiments. 
Summarizing, from both the IMR5/75 MYCN high/low and IMR32 MYCN high/low cell line two 
stable subclones expressing high levels of luciferase in vitro were generated for use in mouse 
experiments. 
 
 
5.4.2 Establishment of an orthotopic mouse model 
During establishment of the orthotopic mouse model, many different aspects of the method 
had to be improved to achieve the aimed tumor growth rate of 80%. For method optimization, 
small mouse collectives, dead mice remaining from breeding in the animal core facility or 
isolated adrenal glands provided from other DKFZ groups were used. The main points to 
improve were needle size, injection volume and fixation of the adrenal gland as well as 
improvement of the implantation itself. 
 
a) Needle size 
The first challenge of surgery was to find the ideal needle size to inject the neuroblastoma cells 
into the adrenal gland. The needle had to completely fit with the cut into the adrenal gland to 
avoid leakage of the injected neuroblastoma cells. On the other hand, the inner diameter had 
to be large enough to make sure, that the cells were not mechanically harmed when passing 
the needle, which could have an influence on the tumor growth rate. Therefore, the aim was 
to find a needle size that accounts for both aspects.  
For optimization of the needle size, 24 G (OD=0.55 mm), 27 G (OD=0.4 mm) and 30 G 
(OD=0.3 mm) were tested with IMR5/75 cells. The cells were assessed regarding fraction of 
dead cells, using trypanblue, and regrowth studies. 
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It was noticed that the fraction of dead cells increased proportional to the smaller diameter of 
the needle from 11.3% with the 24 G needle up to 27.8% dead cells with the smallest (30 G) 
needle tested (Table 16). Reseeding experiments, however, showed acceptable regrowth 
rates for all three needle sizes after 48h after reseeding. 
For the following in vivo orthotopic studies the 30 G needle was used. The smaller diameter 
minimizes damage to the adrenal gland and the cut can be completely placed in the organ. 
 
Table 16: Experimental scheme and results of the needle test.  
 
 
b) Injection volume 
A second issue for optimization was to define the maximum injection volume that fits into the 
adrenal gland, so that no cells are leaking out into the abdominal cavity. The adrenal gland of 
a mouse is about the size of a pinhead and has a dense structure. Literature research revealed 
that neuroblastoma research groups working with similar mouse models inject between 2 µl 
and 100 µl into the adrenal gland or the surrounding fat pad [126, 159, 160].  
Different volumes of cell suspension, colored with bromophenol blue for optical control, were 
tested. The result was that maximum 10 µl can be injected without cells leaking out.  
To avoid leakage of the tumor cell solution into the abdominal cavity, fibrin was used to seal 
the injection site directly after implantation of the cells, comparable to the method published by 
Cardoso et al. [161]. This failed because it was not possible to apply the fibrin fast enough and 
on the exact position of the puncture without spreading the fibrin along a larger area. Another 
attempt was to mix the cells with matrigel to make the cell suspension more viscous and to 
have the injection site sealed with matrigel, which hardens at body temperature. In this case, 
the total volumes working with were too small to mix cells and matrigel reproducible in defined 
proportions. Additionally, the small volumes of matrigel hardened before application, although 
usage of pre-chilled equipment and storage on ice. 
In summary, it was decided to inject the cells resuspended in 10 µL cell culture medium. The 
usage of matrigel or fibrin was not further considered. 
 
  
Needle size 24 G 27 G 30 G
Outer diameter 0.55 mm 0.4 mm 0.3 mm
Viability cell counter 88,7% 85,4% 72,2%
Regrowth Acceptable Acceptable Acceptable
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c) Fixation of the adrenal gland and automatically assisted injection 
The fixation of the adrenal gland and optimization of the implantation procedure was the main 
part that had to be improved to generate comparable experimental conditions with the 
orthotopic neuroblastoma mouse model. The small size of the mouse adrenal gland requires 
precise work, which is hindered by the flexible position of the adrenal gland in the surrounding 
fat pad.  
The adrenal gland was positioned in the field of view as seen in Figure 59B by holding skin 
and fat pad with a pair of forceps and using a spatula to clamp the kidney on the other side. 
The spatula as surgical instrument was chosen to make sure that the kidney was not harmed. 
 
 
 
Figure 59: Implantation of tumor cells in the adrenal gland. A) Schematic representation of the injection 
assistant used for orthotopic implantation. B) Size and structure of the adrenal gland (black arrow). Skin and muscle 
are fixed with forceps, instrument on the right. The kidney is clamped with a spatula, instrument on the left. C) Size 
of the needle (bottom of the picture) used for implantation compared to the size of the adrenal gland during 
implantation. 
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During injection, the small size of the adrenal gland was challenging. The cut of the needle 
precisely fitted into the adrenal gland, as seen in Figure 59C showing the proportions of needle 
and adrenal gland. Small movements, however, as they usually happen when pressing the 
plunger of the syringe, generally resulted in perforating the adrenal gland completely or slipping 
out of the needle. Due to this problem, it was necessary to separate the implantation process 
from the insertion of the needle in the organ. An injection assistant was used, schematically 
shown in Figure 59A. Here, the plunger of the syringe was connected to a metal thread. A 
motor unit was turning the metal thread in small and defined steps, controlled by a computer. 
At the top end of the syringe, a flexible tube was installed with a 30 G needle on the end.  
To inject cells into the adrenal gland, the needle was placed in a tube with cells in the right 
concentration and 10 µl were taken up two times by moving the plunger backwards assisted 
by the motor unit. After uptake, the needle was fixed in a needle holder and carefully inserted 
into the adrenal gland. At the right position, 10 µl of cell suspension were injected, controlled 
by the computer. The needle was kept in the adrenal gland for a few seconds after implantation 
and then taken out slowly. Between two injections, the tube was cleaned by ejection of 2x       
10 µl. 
The usage of the injection assistant had the big advantage, that insertion and implantation are 
completely separated. The surgeon can fully concentrate on correctly positioning the needle 
into the adrenal gland. 
 
5.4.3 Pilot study: Orthotopic neuroblastoma mouse model 
At the end of the method establishment process, a pilot study was started, implementing all 
results from the optimization experiments. A timeline visualizes the course of action of the 
experiment in Figure 60. 
A group of ten CD-1 nude mice were orthotopically injected with 5x105 human neuroblastoma 
cells from cell line IMR5/75 Luci#9 into the left adrenal gland. Swelling of the adrenal gland or 
the surrounding fat pad, indicative for a successful tumor cell implantation, was noticed for all 
mice except mouse #4 and #6.   
All mice of this group survived surgery. Wound healing was fast and without swelling or other 
complications. Altogether, surgery and implantation of the neuroblastoma cells was 
satisfactory along the mice in the pilot study. 
To compare tumor onset, tumor growth and metastasis of MYCN high and MYCN low 
conditions in the mouse model, MYCN knockdown started two weeks after implantation of the 
human neuroblastoma cells for half of the mice. The downregulation was based on the vector 
system consisting of tetracycline repressor and a MYCN-shRNA controlled by TetR-elements, 
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as described in results part 5.1. Mice #1-5 got doxycycline, which was orally administered in 
the drinking water. Doxycycline inactivates the tetracycline repressor, which enables 
transcription of the MYCN-shRNA and should selectively downregulate MYCN in the 
neuroblastoma cells. The results of MYCN downregulation in the mouse tumors are described 
in detail in results part 5.4.6. In the following sections, mice #1-5 will be referred to as MYCN 
low and mice #6-10 will be referred to as MYCN high describing the results of this experiment. 
 
 
 
 
 
Figure 60: Timeline of orthotopic mouse experiment. Cells were implanted at day one. Doxycycline treatment 
started two weeks after surgery. Tumor growth was first monitored at day 60 by MRI, additional MRI scans were 
performed in two-week intervals. Bioluminescence was measured two times in total, scheduled a few days before 
the 3rd and 4th MRI scan. Depending on the size of the tumors, the mice were euthanatized at day 89 or at the end 
of the experiment at day 103.  
 
Tumor growth was monitored by MR imaging fortnightly and by in vivo bioluminescence 
imaging at two additional sessions. In Figure 61 tumor growth is shown for each mouse. Table 
17 contains the tumor size calculated by MR imaging.  
With the first MR imaging at day 60 after tumor cell implantation, tumors at the adrenal gland 
could be identified in 7 out of 10 mice. In the MYCN low group, mice #1, #2 and #3 had a 
tumor, for mice #4 and #5 no tumor could be detected. Among the MYCN high group, mouse 
#6 was negative for tumor growth, for all other mice in this group MR imaging revealed tumor 
growth. 
Both in the MYCN low and MYCN high group, tumor size was highly variable. At the first MR 
imaging, both in the MYCN low and in the MYCN high group, one large tumor was detected 
compared to the others. In the MYCN low group, mouse #2 had a tumor of 0.4 ml, the other 
tumors in this group had volumes of 0.09 ml and 0.11 ml. Among the MYCN high mice, mouse 
#10 had a large tumor of 0.34 ml, whereas the others were ranging between 0.05 ml and 0.07 
ml.  
The following MR imaging examinations at day 74 and 88 after implantation confirmed that 
there are slow and fast growing tumors, independent of MYCN low and MYCN high conditions. 
Mouse #6 from the MYCN high group still showed no detectable tumor until the third MR 
imaging at day 88, then the tumor was growing fast. At the fourth MR imaging the tumor of 
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mouse #6 was the largest among the remaining tumors with a volume of 1.31 ml, despite the 
late onset of tumor growth.  
The fast growing tumors of mice #2, #7 and #10 exceeded the maximum tumor size before the 
endpoint of the experiment at day 89. All other mice were euthanized at the end of the 
experiment at day 103.  
Altogether, a tumor gowth rate of 80% was achived in the pilot study. The MYCN low group 
had a tumor growth rate of 60%, including one fast growing tumor. No tumors were detected 
in mice #4 and #5. In the MYCN high group, tumors were growing in all five animals. From 
those, three tumors were fast growing, including one with late onset. 
 
Table 17: Imaging results for each of the mice. Signal detectable (+ or ++), no signal/tumor (neg), no 
measurement (-). 
 
In both groups, the tumor growth was heterogeneous. As expected, in the MYCN high group 
more tumors were growing and the proportion of fast growing tumors was higher compared to 
the MYCN low group. As the total number of animals in the pilot study was low and as the 
experiment was not repeated for this thesis, the validity of the findings presented here is 
limited. The mouse model established here has been applied with a larger number of animals 
by the DKFZ group “Molecular Imaging” headed by Dorde Komljenovic. The tumor growth rate 
of 80% for the orthotopic neuroblastoma mouse model was verified by these experiments (data 
not shown). 
 
MRT [ml] ivBL [+/neg] end of 
experimentday 60 74 88 102 83 98
mouse 1
M
Y
C
N
lo
w
0.11 0.27 0,44 0.73 + + day 103
mouse 2 0.40 1.61 6,70 - ++ - day 89
mouse 3 0.09 0.23 0,32 0.48 + ++ day 103
mouse 4 neg neg neg neg neg - day 103
mouse 5 neg neg neg neg - - day 103
mouse 6
M
Y
C
N
 h
ig
h neg neg
0.17 1.31 - + day 103
mouse 7 0.07 1.07 5.55 - ++ - day 89
mouse 8 0.05 0.10 0.19 0.49 neg ++ day 103
mouse 9 0.06 0.06 0.04 0.02 + + day 103
mouse 10 0.34 1.78 7.90 - ++ - day 89
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Figure 61: Tumor growth of orthotopic tumors. Tumor volume was calculated by MRI. MYCN low tumors are 
displayed in green, MYCN high tumors in purple. Both groups contain fast and slow growing tumors. 
 
 
5.4.4 Imaging of orthotopic tumors 
For imaging of the orthotopic tumors, two different imaging methods were used: magnet 
resonance imaging and in vivo bioluminescence.  
MR imaging is a method widely used for imaging of organs and objects in medical and scientific 
applications. The patient is brought into a strong magnetic field, where protons, especially 
hydrogen in water molecules, are excited. These signals can be processed into an image [162]. 
In the used T2 measuring mode, water appears bright and solid tissues dark [163]. 
MR imaging was used to follow up tumor growth and to calculate the tumor volume. 
Measurements took place every two weeks starting at day 60 after tumor cell implantation and 
repeating the MR imaging at days 74, 88 and 102. Figure 62 shows exemplary images from 
the first and the third measurement at day 60 and day 88. The results and volume calculations 
of all MR images performed during this experiment are given in table 17. 
MR imaging was suitable for the aimed application. Tumors and kidneys could be defined 
clearly. The calculation of tumor volume was accurate by tracing the tumor through the different 
slices (width 1.0 mm) generated during the measurement. The time points for measurement 
were well chosen, at the first time point 90% of the mice were correctly identified as positive or 
negative for tumor growth.  
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The fortnightly intervals between the measurements were sufficient for most of the tumors. 
Solely for the fast growing tumors of mice #2, #7 and #10, shorter intervals would have been 
necessary. In the two weeks between the second and the third measurement, the volume of 
these tumors became 4-5 times larger with the result, that the maximum tumor size was 
exceeded during these two weeks. For tumors that show fast growth in the previous 
measurements, an additional imaging after one week would be advisable. 
 
 
 
 
 
 
 
 
Figure 62: MRI images of orthotopic tumors. Exemplarily, coronal pictures are shown from two different time 
points. Arrows indicate the position of the tumors. A) Tumors from two mice of the MYCN low group. B) Tumors 
from two mice of the MYCN high group. 
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Additional to the MR imaging, in vivo bioluminescence imaging was performed twice during 
tumor follow-up. This imaging method specifically detects luciferase-expressing cells and is 
therefore very useful not only to visualize the primary tumor but also potential metastases. 
For detection of the bioluminescence, the mice were intraperitoneally injected with a luciferin 
solution. The luciferase stable expressed by the human neuroblastoma cells converts the 
luciferin whereupon light is emitted and detected by a light sensitive camera.  
The in vivo bioluminescence imaging was performed with two different imaging systems. An 
overview of all measurements and results is given in table 17. Pictures were taken from the 
back and from the side of the mice.  
At day 83, a bioluminescence detector was used that was built at the DKFZ by the group 
“Functional and Molecular Emission Computed Tomography”. In this imaging study, 8 out of 
10 mice were included. Exemplary images for mouse #1 from the MYCN low group and mouse 
#7 from the MYCN high group are shown in Figure 63A. The three fast growing tumors #2, #7 
and #10 showed high luciferase activity. From the other five mice included in the 
bioluminescence imaging, moderate luciferase activity was detected in three animals. For 
mouse #4 no luciferase activity was expected, because MR imaging was negative for a tumor. 
Surprisingly, mouse #8 also showed no luciferase signal although a tumor was identified for 
this animal by MR imaging. Metastases were detected in none of the animals. 
The second bioluminescence imaging session took place at day 98 of the experiment (Figure 
63B). This time, a commercially available IVIS bioluminescence imager was used. From the 
remaining seven animals in the experiment at this timepoint (mice #2, #7 and #10 with fast 
growing tumors had been euthanized before due to tumor burden), five animals were included 
in the measurement. No imaging was performed with mice #4 and #5, which had been negative 
for tumor growth at all measurements up to this time point. All five mice showed luciferase 
activity in the area around the adrenal gland, which matches with the results of the MR imaging. 
Mouse #8, which was negative at the first bioluminescence imaging showed a strong luciferase 
signal this time. For each animal, there was a single location of the luciferase signal in the area 
of the adrenal gland and no hint for metastases. 
In comparison, the results of the in vivo biolumenscence imaging showed similar results.  
However, the pictures look different in some aspects. The IVIS system uses a color code to 
display the intensity of the luciferase signal. These colors cover the incident light picture of the 
animal, which is recorded for localization of the luciferase signal. The DKFZ system in contrast 
displays the luciferase signal as dark spots. Integrating the luciferase image in the incident 
light image enables to see more details of the structure of the tumor due to more transparent 
images.  
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Figure 63: Bioluminescence images of orthotopic tumors. ivBL imaging was performed with two different 
systems. Luciferin solution was injected i.p. and after 5 min of incubation the luminescence was measured. Incident 
light pictures were taken to overlay the signal with the contures of the animal body. A) ivBL imaging at day 83. 
Exemplarily, one mouse of each group is shown. Exposure time was 3 min. Luminescence is shown in dark. B) 
ivBL imaging at day 98. Two mice from the MYCN low and one mouse from the MYCN high group are shown. 
Exposure time was 2 min. Luminescence signal is scaled using a color code. 
 
5.4.5 Histologic analysis of orthotopic tumors 
The tumor samples from the orthotopic xenograft mice described in section 5.4.3 were 
histologically viewed to confirm that the tumors grown in the mice were neuroblastomas. The 
preparation of cryoslices and staining with haematoxylin and eosin was done at the laboratory 
of the pathological institute Heidelberg. Appraisal of the tumor samples was done by Dr. med. 
vet. Tanja Poth. Exemplary images of the tumors are shown in Figure 64. Table 18 gives an 
overview of the results from the histological analysis. 
A Mouse 7
MYCN high
Mouse 1
MYCN low
B Mouse 1
MYCN low
Mouse 3
MYCN low
Mouse 8
MYCN high
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All tumors included in the analysis were identified as neuroblastomas. In all tumor samples 
except tumor #8 necrotic areas were identified. From tumor #9 no histological analysis was 
prepared because there was not enough tumor material for both histology and other analyses. 
Further analysis of the differentiation grade was not possible due to suboptimal quality of the 
tumor material. A preparation for paraffin embedding instead of cryo slides would allow further 
histological analysis.  
 
Table 18: Results of the histological analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 64: Histology pictures of orthotopic neuroblastomas. Cryoslides and HE staining were performed at 
the pathological institute. Tumors were identified as neuroblastoma with widespread necrosis (T. Poth, 
pathological institute).    
Macroscopically, most of the tumors were of a dark red color and had a smooth or slightly 
nodose surface. The fast growing tumors did not look homogeneously but had darker and 
brighter areas. Tumors #3 and #9 were not dark red; instead they had a pale rose color. 
 
4
x 
2
0
x
4
x
2
0
x
Mouse 2
MYCN low
Mouse 7
MYCN high
Mouse 10
MYCN high
4
x
2
0
x
  Dissertation Maike Christine Nortmeyer 
143 
 
5.4.6 MYCN expression and RNA-seq profiles of MYCN high/low tumors 
In the previous sections, it was referred to the mice #1-#5 as MYCN low group and to mice #6-
#10 as MYCN high group. The analysis of the MYCN expression in these two groups will be 
discussed in this section. 
 
a) MYCN mRNA expression 
To assess MYCN gene expression levels, the orthotopic tumor material was analyzed by 
quantitative real time PCR, relating the MYCN gene expression to the expression of the 
housekeeping genes HPRT1 and SDHA.  
Compared to the housekeeping genes, the relative MYCN expression of the tumors in the 
MYCN low group (mice #1-#3) ranged between 0.9 and 1.0 (Figure 65A). Among the MYCN 
high group (mice #6-#10) the relative MYCN expression was 0.97 to 1.12.  
For the tumor sample of mouse #9 (MYCN high) no gene expression of MYCN and the 
housekeeping genes was measured by quantitative PCR. Analysis of the RNA sample on the 
bioanalyzer revealed that the RNA was degraded. Due to limited tumor material, the RNA 
isolation could not be repeated for this sample.  
 
Figure 65: MYCN mRNA expression of orthotopic tumors. Quantitative PCR was performed with mRNA isolated 
from tumor material frozen in liquid nitrogen. MYCN expression was normalized to the housekeeping genes HPRT1 
and SDHA. A) MYCN mRNA expression of single orthotopic tumors. B) Comparison of MYCN mRNA expression 
of MYCN high and MYCN low orthotopic tumors. P-value was >0.05 (student t-test). 
 
Apart from the single MYCN expression values of the tumors, the MYCN gene expression of 
the complete MYCN low and MYCN high group was analyzed (Figure 65B). The average 
relative MYCN expression of the MYCN low group, consisting of three tumors, was 0.95. The 
relative MYCN expression from the four tumors from the MYCN high group was 1.02 in 
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average. Although this difference is not significant, a tendency is seen, that the overall MYCN 
expression is slightly lower in the MYCN low group than in the MYCN high group. 
 
b) MYCN protein expression 
To validate the results from the MYCN mRNA expression analysis on protein level, western 
blot was performed with protein lysates generated from the xenograft tumors. 
Unfortunately, there are no results available from this experiment due to methodic problems. 
The bands detected by western blot were weak or looked washy, therefore quantification of 
the MYCN protein levels was not possible. It is supposed that the measurement of the protein 
concentration was malfunctioning because of blood and other contaminations in the tumor 
samples. The varying concentrations of tumor material in the samples together with an 
overload of the polyacrylamide gel probably caused problems with detection of accurate MYCN 
and β-Actin bands in the western blot. 
 
c) RNA-sequencing/ Comparison of expression profiles 
The analysis of MYCN mRNA and protein expression by qPCR and western blot were an 
attempt to measure the effect on MYCN directly. As known from cell culture experiments, the 
impact of MYCN downregulation is not only seen in lower MYCN mRNA and protein levels, but 
results in widespread changes in the gene expression profiles of the cells [59]. Therefore, the 
RNA isolated from the tumor samples was prepared for RNA sequencing. Aim of this 
experiment was a comparison of the RNA sequencing data from the MYCN low and MYCN 
high tumors of the mice with RNA sequencing profiles from the IMR5/75 MYCN high/low cells 
generated by cell culture experiments [145]. 
2.313 genes upregulated by MYCN under cell culture conditions were compared with the 2.000 
most upregulated genes in MYCN high tumors. Both gene expression profiles had 134 genes 
in common, which equates 1.8% of all genes analyzed in the Venn diagram. Similar results 
have been observed comparing 1.909 MYCN downregulated genes with the 2.000 most 
downregulated genes from the tumors. In this case, 145 genes were shared, which equates 
2% of the genes in the analysis. Altogether, this leads to the conclusion that no similarity exists 
between the orthotopic tumors and MYCN dependent gene expression. Additionally, the genes 
shared by tumors and cell culture conditions were screened for known MYCN target genes. 
No genes typically up- or downregulated by MYCN expression have been identified among 
those genes. 
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Figure 66: RNA-sequencing profiles of orthotopic tumors. RNA sequencing was performed with three MYCN 
low and five MYCN high tumors. All tumors from one category were analyzed together. A Venn diagram visualizes 
the overlap between genes up- and downregulated in MYCN high and MYCN low IMR5/75 cells in cell culture 
(MYCN up, MYCN down) and tumor material from the MYCN high and MYCN low-treated mice (tumor up, tumor 
down). MYCN knockdown was achieved by tetracycline treatment in cell culture or doxycycline administration to 
the mice.  
 
Taking together the results from qRT-PCR, western blot and RNA-sequencing, no reduction 
of MYCN or MYCN dependent gene expression has been proven for the group of MYCN low 
mice, leading to the conclusion that no effective reduction of MYCN has been achieved in the 
orthotopic mouse model. One possible explanation is that the doxycycline applied by drinking 
water did not reach the human tumor cells at the adrenal gland in an appropriate concentration. 
Though it has been shown that the tumors were well connected to the blood vessels by 
distribution of the substrate for in vivo bioluminescence, the oral administration of the 
doxycycline might have been unsteady by inconsistent drinking behavior of the mice. Further, 
it must be considered that the human MYCN high/low cells have been treated with doxycycline 
for more than three months in the orthotopic mouse model. This is not comparable to the way 
the model was used for cell culture application with an induction of the MYCN knockdown for 
shorter time periods. 
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Altogether, the orthotopic neuroblastoma mouse model was successfully established in the 
DKFZ group “Neuroblastoma Genomics”. The methodic improvements installed increased the 
tumor growth rate to 80%. The tumor growth was monitored by MR imaging. In vivo 
bioluminescence revealed a constant expression of the luciferase cloned into the human tumor 
cells and thereby facilitated follow up of tumor growth and proved the absence of metastases.  
Though, the heterogeneity of the tumor growth in both the MYCN high and the MYCN low 
group was complicating the analysis of the results. Among the group of ten mice, three mice 
showed a fast tumor growth, whereas the orthotopic tumors of the other mice were moderately 
or slowly growing. The possible impact of the mouse strain on this topic is discussed in section 
6.3 in more detail.  
On mRNA level, the MYCN knockdown of the xenograft tumor material was not convincing. 
Therefore, an indirect proof of the MYCN knockdown effects was aimed by RNA-sequencing 
of the orthotopic tumors and their comparison with a MYCN knockdown signature. 
Unfortunately, no similarity between the gene expression profiles was detected, leading to the 
conclusion that the MYCN knockdown was not effective in the orthotopic tumors, at least at 
the end of the experiment. Further work is necessary to ensure a long time stable MYCN 
knockdown in this mouse model. 
 
6 Discussion 
6.1 Categorization of neuroblastomas as sensitive/resistant upon BET 
inhibition in vitro and in vivo 
 
For this thesis, several neuroblastoma cell lines were treated in vitro and in vivo with BET 
inhibitors. Thereby a large number of different experimental approaches were illuminating 
different biological aspects of BET inhibition in neuroblastomas. One central question of this 
work was to estimate how neuroblastoma cells with certain genetic features will respond to 
BET inhibitor treatment, aiming to be able to suggest a potential therapy with a BET inhibitor 
to the suitable patients based on the biology of their tumor. For comparison of in vitro and in 
vivo results the focus will be on the cell lines used in the animal experiments (IMR5/75, LS, 
NBL-S, SH-SY5Y) as well as NGP as example for a cell line not responding to BET inhibition.  
Viability analysis of the neuroblastoma cell lines upon treatment with the BET inhibitors JQ1 
and BAY1238097 revealed a higher effectivity of the inhibitor JQ1 for all cell lines. The cell 
lines LS and IMR5/75 were both classified as sensitive upon JQ1 treatment with similar EC50-
values for JQ1 and BAY1238097. NGP cells presented as highly resistant with both inhibitors. 
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NBL-S cells were classified as intermediate responders to JQ1 treatment and an intermediate-
resistant response upon BAY1238097 therapy. Despite the lower effectivity of BAY1238097, 
this inhibitor was chosen for the in vivo experiments due to its superior pharmacokinetic 
properties, whereas in vitro experiments were performed with JQ1. 
Further insight into the functions of BET inhibition was gained by FACS-analyses used to 
estimate cell cycle and cell death of JQ1-treated neuroblastoma cells. An arrest in the G1 
phase of the cell cycle was shown for IMR5/75, LS and NBL-S, which was strongest in IMR5/75 
cells. This effect can be explained with the high proliferation rate of the IMR5/75 cells. IMR5/75 
cells have a doubling time lower than 24h, in this case the cells are accumulating faster in G1 
after completing the previous cell cycle than cells with a longer doubling time. An increase in 
cell death was observed in few MYCN amplified JQ1-treated cell lines only, most prominent in 
IMR5/75 cells. Despite the high levels of cell death, IMR5/75 were regrowing fast after washout 
of JQ1, showing that the long-term negative effects on cell proliferation of a shRNA induced 
MYCN knockdown were stronger than JQ1 treatment. These observations indicate that the 
effects induced by JQ1 treatment are temporary, especially for fast dividing IMR5/75 cells. 
In two independent publications a direct regulation of MYCN by BRD4 in neuroblastoma was 
stated [121, 122], suggesting MYCN as a target gene of BET inhibition. To evaluate this, the 
MYCN protein expression was tested by two methods in a larger panel of MYCN amplified 
neuroblastoma cell lines, showing a reduction of MYCN in most of the cell lines. Especially for 
IMR5/75 and LS, the effects on the MYCN protein levels were minimal or ambiguous. For both 
cell lines, MYCN is also not listed among the differentially expressed genes identified by RNA-
sequencing. For IMR5/75 and SK-N-BE(2)c treated with BRD4 siRNA the MYCN expression 
was not affected, leading to the conclusion that BRD4 is not absolutely required for MYCN 
expression in neuroblastoma.  
Based on the data collected as part of this thesis it was not possible to finally clarify which 
factors are pivotal for sensitivity to BET inhibition. Though, some relations have been observed 
between the cell lines and their response to BET inhibitor treatment. One observation is that 
all three MYCN amplified cell lines with a doubling time of 24h and below (IMR5/75, SK-B-
BE(2)c, IMR32) are BET inhibitor sensitive and show a prominent G1-arrest and high levels of 
cell death (Figure 67, left side). It is supposed that the fast cell cycle turnover causes a fast 
and strong accumulation of the cells in G1, presumably by the reduction of the transcription of 
cell cycle promoting genes, and an increase of cell death earlier than for cell lines dividing 
more slowly. On the other hand, the high proliferation rate goes in hand with a fast regrowth 
after the end of the therapy. Hence, this group of sensitive cells is characterized by early growth 
inhibitory effects that can be evaded immediately after removing the inhibitor and are thereby 
no permanent effects. For long term effects it is supposed that additional genetic aberrations 
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besides MYCN amplification are priming cells for BET inhibitor sensitivity (Figure 67, right 
side). This is the case for LS cells with amplifications of the cell cycle regulating genes CDK4, 
MDM2 and CCND1. Amplifications of CDK4 and MDM2 are also detectable in BET inhibitor 
sensitive TR14 and in resistant NGP cells. In detail, a comparison of different cell lines for the 
definition of general rules is difficult as not enough neuroblastoma cell lines with comparable 
patterns of genetic aberrations could be analyzed.  
For clinical settings, it is not only necessary to identify the most sensitive tumors, but also to 
define the group of tumors that will be highly resistant to avoid needless therapies. Among the 
group of MYCN amplified and JQ1 resistant cell lines are NGP and KELLY, both have an 
activation of TERT (Figure 67, bottom part). Besides the TERT activation, which was present 
solely in those two of the MYCN amplified cell lines, the genetic background of KELLY and 
NGP is quite different. In NGP, as described above, the cell cycle promoting genes CDK4 and 
MDM2 are amplified. KELLY harbor an inactivating mutation in the TP53 gene and an 
activating mutation in the ALK gene. A TERT activation and an ALT phenotype are two ways 
how neuroblastoma cells enable a stabilization of telomere length and avoid cellular 
senescence [164]. Among the MYCN non-amplified neuroblastoma cell lines, two further cell 
lines with telomere stabilization and resistant to JQ1 treatment were identified: GIMEN cells 
have a TERT activation and SK-N-FI cells have an ALT phenotype. Those results hint that the 
presence of long telomeres might be involved in BET inhibitor resistance, independent from 
the MYCN-amplification status. However, a TERT activation or ALT phenotype are not 
consistent in predicting the resistance upon BET inhibitor therapy, as there are cell lines 
harboring those genetic aberrations that are JQ1 sensitive or intermediate responding, such 
as SK-N-AS with an activation of TERT or CHLA-90 with an ALT phenotype. It is supposed 
that the resistant cell lines harbor further genetic aberrations enabling those cells to grow upon 
BET inhibitor therapy. Also there are several MYCN amplified neuroblastoma cell lines 
resistant upon JQ1 treatment without TERT activation or an ALT phenotype 
Altogether, clear definitions based on the genetic background of the cell lines could be 
formulated neither for BET inhibitor resistance nor for the identification of highly responsive 
cell lines. The panel of 23 neuroblastoma cell lines with diverging genetics was heterogeneous 
and too small to analyze universally valid hypotheses regarding BET inhibitor sensitivity 
statistically.  
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Figure 67: Resistance and sensitivity of neuroblastoma cells to BET inhibition. Genetic factors and growth 
characteristics supposed to be relevant factors for sensitivity or resistance of neuroblastoma cells upon JQ1 
treatment. The categories sensitive, intermediate and resistant are based on the results of the viability screening 
(section 5.2.1). DT= doubling time; amp= amplification; NA= non-amplified. Crossed out cell lines show contrary 
behavior upon BET inhibition that other cells with similar genetic background. 
 
In vivo, mice with LS deriving xenograft tumors showed a seven days prolonged survival upon 
treatment with BAY1238097, which is highly effective related to a total experimental duration 
of up to 30 days. No tumor growth inhibiting effects were detectable for tumors deriving from 
IMR5/75 cells although those cells had been highly sensitive to BET inhibitor treatment in vitro. 
The difference between both cell lines can be explained as those fulfill different criteria for JQ1 
sensitivity (Figure 67), leading to a long-term effect of BET inhibition on LS cells and non-
permanent effects on IMR5/75. 
The experiments with IMR5/75 xenograft tumors were performed in two different mouse 
strains, however the validity of the results was limited due to variability of tumor onset and 
inhomogeneity of tumor growth especially among the control group. Besides the explanation 
for non-permanent growth inhibitiong effects in BET inhibitor-treated IMR5/75 cells and tumors, 
it cannot be excluded that a potential inhibitory effect for tumor growth was obscured by the 
inconsistent control group.  
Summarizing the results for BET inhibitor treatment in vitro and in vivo, at present it is not 
possible to draw conclusions from a BET inhibitor sensitive cell culture setting to a successful 
therapy in vivo. 
SK-N-AS CHLA-90
NGP
Kelly
(MYCN AMP)
GIMEN
SK-N-FI
(MYCN NA)
resistant
TERT activation or ALT phenotype
Type 2 sensitive
MYCN amp, CDK4/MDM2 amp
LS
TR14
NGP
IMR5/75
IMR32
SK-B-BE(2)c
Type 1 sensitive
MYCN amp, DT<24h
sensitive
MYCN NA, TERT
intermediate
MYCN NA, ALT
  Dissertation Maike Christine Nortmeyer 
150 
 
6.2 BRD4 target genes in the cellular context 
 
The high-throughput analysis of mRNA and protein expression in various BET inhibitor-treated 
cell lines revealed high numbers of differentially expressed genes and proteins affected upon 
BET inhibitor treatment. Several proteins and genes belonged to pathways related to cell 
division, wnt signaling or TP53 related pathways. In this section some chosen target genes will 
be integrated in the cellular context and discussed regarding their potential role in 
neuroblastoma. 
A large number of publications dealing with BET proteins have shown an impact of BRD4 
expression on cell cycle progression for several cancer entities. It has been revealed that 
BRD4 affects multiple steps of the cell cycle. On one hand, Dey et al. have shown that BRD4 
has regulatory functions at the G2/M transition [111]. On the other hand, BRD4 is involved in 
the G1/S transition by interacting with replication factor C required for DNA replication [114]. 
In neuroblastoma cells, a growth arrest is observed for cells treated with the BET inhibitors 
JQ1 and I-BET726 [121, 122]. In line with these findings, the present work showed a significant 
cell cycle arrest in the G1 phase of the cell cycle for the JQ1 sensitive and intermediate 
responding neuroblastoma cell lines. Additionally, several genes belonging to pathways 
related to different phases of the cell cycle were identified as affected by JQ1 treatment. 
Besides the cell cycle effects in cancer cells, a G1 arrest is also induced in fibroblasts after 
BRD4 knockdown based on shRNA [113]. Mochizuki et al. showed that this G1 arrest was 
accompanied by a missing upregulation of G1 genes, which is induced by an increased binding 
of p-TEFb and RNA polymerase 2 to the promoters of these genes in untreated fibroblasts. 
In neuroblastoma, high CCND1 gene expression was detectable in a large proportion of cell 
lines, indicating a dependency of this cancer entity on Cyclin D1. Figure 68A compares the 
CCND1 gene expression of 21 neuroblastoma cell lines, showing high CCND1 levels 
especially in the CCND1 amplified LS cells. In comparison to human normal tissue and other 
cancer entities, CCND1 gene expression was elevated in neuroblastoma (Figure 68B). The 
DRIVE project realized a large-scale RNA-interference screening to identify potential synthetic 
lethal vulnerabilities in nearly 400 cancer cell lines, including nine neuroblastoma cell lines 
[165]. Compared to other entities, those neuroblastoma cell lines were highly dependent on 
CCND1 gene expression, emphasizing the importance of Cyclin D1 function for cell cycle 
progression and survival in neuroblastoma.  
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Figure 68: CCND1 expression in neuroblastoma. A) CCND1 gene expression in neuroblastoma cell lines. B) 
CCND1 gene expression in normal tissue (green) and different cancer entities (red). Neuroblastoma tumors are 
indicated with a red arrow. 
 
In this thesis, a decrease of cyclin D1 protein expression upon JQ1 treatment was observed in 
nearly all MYCN amplified neuroblastoma cell lines, verified by RPPA and western blot. As 
Cyclin D1 is important for G1/S transition and as neuroblastoma cell lines are highly dependent 
on Cyclin D1, it is supposed that the missing increase of Cyclin D1 levels in JQ1-treated cells 
abrogates cell cycle progression. This results in a G1 arrest as observed for JQ1 sensitive and 
intermediate responding cell lines. 
Cyclin D1 has been identified as a target of BRD4 in various cancer entities. Henssen et al. 
treated high risk medulloblastoma cells with JQ1 and described a downregulation of Cyclin D1 
in medulloblastoma with a siRNA mediated knockdown of BRD4 [166]. An influence of JQ1 on 
the Cyclin D1-CDK4-RB-axis going along with a reduction of the Cyclin D1 expression has also 
been observed in cell culture models of Merkel cell carcinoma and thyroid tumors [167, 168]. 
In NUT midline carcinoma, it was proven that an induction of Cyclin D1 expression was able 
to rescue carcinoma cells from a cell cycle arrest induced by JQ1 treatment [169]. Liao et al. 
additionally observed reduced Cyclin D1 protein expression upon JQ1 treatment and a 
synergistic effect of JQ1 and an inhibitor of CDK4/6 in the therapy of NUT midline carcinoma. 
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CDK4 and CDK6 are the corresponding CDKs of Cyclin D1 and essential for cell cycle 
progression at the G1/S transition, which explains the complete cell cycle arrest shown with 
this drug combination in NUT midline carcinoma. 
It is known that BRD4 influences gene expression by inactivation of strong enhancers and 
superenhancers [95]. CCND1 is regulated by a large superenhancer [146], which explains the 
sensitivity towards BET inhibitor treatment. In neuroblastomas, as this tumor entity is 
dependent on Cyclin D1, it is supposed that downregulation of the CCND1 gene might be 
responsible for the growth inhibiting effects. This could also explain the sensitivity of the 
CCND1 amplified LS cells towards BET inhibitor treatment in vivo, representing a 
neuroblastoma cell line highly dependent on elevated CCND1 gene expression. Compared to 
CCND1, downregulation of MYCN observed in 70% of the MYCN amplified neuroblastoma cell 
lines analyzed by RPPA and western blot might not be the main pathway for the growth 
inhibiting effects of BET inhibition in neuroblastoma cell lines. As CCND1 is a c-MYC target 
gene, it is possible that reduced MYCN expression upon JQ1 treatment additionally contributes 
to decreased Cyclin D1 expression in an indirect way. 
Besides Cyclin D1, other proteins related to the G1/S transition are affected by BET inhibition. 
Those include CDK4 and CDK6 as the corresponding CDKs for D-type cyclins as well as 
members of the E2F-protein family, which are important effector proteins of CDK4/6 kinase 
activity. RNA-sequencing revealed that CDK6 and E2F2 belonged to the genes with the 
strongest downregulation upon JQ1 treatment in all four cell lines. E2F1 did not belong to the 
most differentially expressed genes in RNA-sequencing but was downregulated on protein 
level in 4 out of 6 MYCN amplified neuroblastoma cell lines, as shown by western blot in this 
thesis. Lower E2F2 and E2F7 gene expression upon BRD4 knockdown is detected by 
Mochizuki et al., whereas E2F1 is not affected in this study on fibroblasts [113]. Hong et al. 
identified E2F2 as a direct target of BRD4 in hepatocellular carcinoma [170], showing that the 
results on gene and protein expression for neuroblastoma are applicable to other tissues and 
cancer entities.  
Consistent with the downregulation of cell cycle promoting genes by JQ1 treatment, cell cycle 
inhibitors were identified among the genes upregulated upon BET inhibition. The genes 
CDKN2D, CDKN2B and CDKN1A encode for inhibitors of CDK4 and CDK6 and were 
overexpressed in IMR5/75, LS and NBL-S neuroblastoma cells treated with JQ1. Upregulation 
of these CDK4/6 inhibitors has also been shown for JQ1-treated primary pulmonary cells [171]. 
The CDK-inhibitors are enhancing the cell cycle arrest induced by JQ1 by abrogation of cell 
cycle promoting kinase activity at the G1-S transition. This prevents RB phosphorylation and 
S-phase entry of the cell cycle. Together the effects on Cyclin D1, CDKs, E2F proteins and 
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CDK inhibitors by BET inhibition resulted in a multifactorial impact on the G1-S transition and 
explain the G1 arrest observed for JQ1 sensitive and intermediate responding cell lines. 
Besides the CDK4/Cyclin D-RB-E2F pathway, the TP53 axis is another signaling pathway 
leading to cell cycle arrest or apoptosis. BRD4 directly binds to p53 and is involved in the 
transcription of p53 target genes [102]. JQ1 treatment of AML cells does not abrogate the 
association of BRD4 and p53 but has an impact on the interaction of the BRD4-p53 complex 
with p53 effector genes, resulting in cell cycle arrest and apoptosis [172]. In this thesis, lower 
p53 expression on mRNA and protein level was observed in neuroblastoma cell lines treated 
with JQ1. Related to this, a downregulation of pathways related to DNA damage and p53 was 
noted in IMR5/75 cells.  
The stabilization of p53, resulting in its participation in cell cycle arrest and apoptosis, is 
induced by DNA damage, including double strand breaks [173]. In the recognition of double 
strand breaks, ATM plays a central role, phosphorylating p53 and histone H2AX, which is 
named γ-H2AX in its phosphorylated form and is an early marker for DNA damage in form of 
double strand breaks [174]. H2AFX, encoding for histone H2AX was upregulated in RNA-
sequencing of all four neuroblastoma cell lines. Related to this, elevated protein levels of 
RAD17, a protein involved in the recognition of DNA damage, was detected by RPPA for all 
cell lines at the 48h time point.  
The role of BRD4 in DNA damage response has been investigated by Floyd et al. [175]: In 
different human cancer cells treated with JQ1 a significantly higher increase of γ-H2AX was 
observed upon irradiation compared to DMSO-treated control. Isoform B of BRD4 acted as an 
inhibitor for DNA damage response signaling by interaction with condensin. JQ1 treatment 
inducing DNA damage response has also been observed for AML cells [172]. In general, JQ1 
enhances the recognition and first-line response to DNA damage in several cancer types. 
In contrast to this, effector pathways for DNA damage repair or cell cycle arrest induced by 
DNA damage seem to be not effective in neuroblastoma cell lines. By RNA-sequencing, 
downregulation of RAD50 was detected for 3 out of 4 cell lines. RAD50 is part of the MRN 
complex important for the repair of double strand breaks by homologous recombination and 
non-homologous end joining [176]. As discussed above, p53 is also downregulated in 
neuroblastoma cells. Taken together it can be supposed that JQ1 treatment is interrupting 
DNA damage signaling pathways, leading to an ineffective DNA damage response which on 
one hand sensitizes cells to DNA intercalating chemotherapeutics as shown by combined 
treatment of neuroblastoma cells with JQ1 and doxorubicin. On the other hand, it leads to an 
ineffective induction of cell death in cells treated with JQ1 alone due to lower p53 expression.  
A variety of histone genes was strongly upregulated upon JQ1 treatment in all four 
neuroblastoma cell lines. This included genes for up to 42 different types of histones and was 
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observed for all time points. HEXIM1 was identified as one of the genes most strongly and 
constantly overexpressed in JQ1-treated neuroblastoma cells. Upregulation of both HEXIM1 
and of histone genes upon JQ1 treatment was also observed by Zhu et al. in murine thyroid 
tumors, suggesting that the upregulation of histones might lead to an increase in chromatin 
remodeling and thereby has an impact on the transcription of further genes [168].  
The broad upregulation of HEXIM1 emphasizes its central role in the response to BET-inhibitor 
treatment. HEXIM1 is known to interact with Cyclin T, functioning as a negative regulator of 
pTEFb [177]. Further, HEXIM1 was identified to be a positive regulator of p53, inhibiting p53 
ubiquitination and thereby enhancing its functions on cell cycle and cell death [178]. As 
HEXIM1 is a substrate of HDM2, the human homolog of MDM2 and responsible for p53 
turnover, it is supposed that the regulation of p53 by HEXIM1 might result from competition of 
both HDM2-substrates [179].  
In neuroblastoma cells, a broad downregulation of gene expression was observed upon JQ1 
treatment. As negative regulator of p-TEFb based transcriptional regulation, elevated levels of 
HEXIM1 might contribute to deviant gene expression patterns in JQ1-treated neuroblastoma 
cells. In its second function as regulator of p53, high HEXIM1 expression should enhance the 
stability of p53 and thereby cell cycle arrest, as observed in JQ1-treated neuroblastoma cells. 
Contrary to this, lower TP53 gene expression and protein levels were detected in 
neuroblastoma cells upon JQ1 treatment. Possibly, the turnover of p53 was lower due to 
increased stability of p53, resulting in reduced TP53 gene transcription. 
GSK3-β was strongly upregulated upon JQ1 treatment both on mRNA and on protein level. 
The protein quantification by RPPA revealed a strong upregulation of GSK3-β both in MYCN 
amplified and MYCN non-amplified cell lines from the sensitive, intermediate or resistant 
group, especially at the late 48h time point. The inactive form of GSK3-β, phosphorylated at 
the Serine 9 residue [152], was not affected by JQ1 treatment in MYCN amplified 
neuroblastoma cells. In the RNA-sequencing analysis GSK3-β gene expression was 
upregulated for all cell lines. GSK3-β is a part of several signaling pathways including Wnt, 
Sonic hedgehog, PI3K/AKT or MAPK signaling and is thereby involved in fundamental cellular 
functions, such as cell proliferation, differentiation or apoptosis [149, 150].   
The most prominent function of GSK3-β is its role in Wnt-signaling. In the absence of Wnt, 
GSK3-β initiates the degradation of β-Catenin by phosphorylation of two serine residues, 
whereas in the presence of Wnt β-Catenin is stabilized and functions as a cofactor for the TCF 
transcription factor in the nucleus [180]. β-Catenin is downregulated by treatment with JQ1 in 
colon cancer, equating a decrease in TCF/β-Catenin mediated gene transcription [181]. 
Pathway analysis of the differentially expressed genes identified by RNA-sequencing revealed 
an upregulation of genes assigned to the pathway “Formation of β-Catenin:TCF 
  Dissertation Maike Christine Nortmeyer 
155 
 
transactivating complex” in LS and NBL-S cells at several time points. The upregulated genes 
mapping with the pathway among others included CTNNB1, coding for β-Catenin, TLE4 and 
several histone genes. TLE4 is an inhibitor of the transcriptional activation by the β-
Catenin/TCF complex and thereby reducing the transcription of Wnt target genes. The 
observed upregulation of both GSK3-β and TLE4 may lead to a functional knockdown of the 
β-Catenin/TCF mediated gene transcription and potent downregulation of Wnt signaling in 
JQ1-treated neuroblastoma cells. 
Besides the role in signaling, GSK3-β is a central factor for MYC protein turnover. GSK3-β 
phosphorylates MYC at the threonine 58 residue, which leads to ubiquitination of MYC by 
Fbw7 and to MYC proteolysis [50, 151]. Thereby high GSK3-β expression results in instability 
and a shorter half-life of MYC. Upregulation of GSK3-β observed upon JQ1 treatment could 
possibly contribute to the reduction of MYCN protein levels detected for a number of MYCN 
amplified neuroblastoma cell lines, independently from a direct targeting of MYCN by BRD4 
inhibition. A study published by Duffy et al. showed reduced MYCN mRNA levels and an 
increase of apoptosis upon pharmacological GSK3-β inhibition in MYCN non-amplified but 
MYCN transgenic neuroblastoma cells [182]. Further research on the interaction of BET 
proteins and GSK3-β could illuminate the background of the observed upregulation of GSK3-
β and, by suitable drug combinations, improve the therapeutic potential of a BET inhibition for 
neuroblastoma. 
 
6.3 Impact of the mouse strain on the growth of neuroblastoma 
xenograft tumors 
 
The experiments with the orthotopic neuroblastoma mouse model as well as the initial 
experiments using the subcutaneous neuroblastoma model were performed with CD-1 Nude 
mice, an immunodeficient mouse model broadly used for xenograft mouse models of several 
tumor entities. CD-1 Nude mice harbor an autosomal recessive mutation of the nude gene. 
Homozygous animals have a rudimentary, non-functional thymus resulting in absent T-cells 
and immunodeficiency, whereas animals heterozygous for the mutant nude allele are 
immunocompetent [157]. 
CD-1 Nude mice are largely used for xenograft applications at the subcutaneous and at the 
orthotopic setting with different human neuroblastoma cell lines. This includes IMR5, a cell line 
closely related to the IMR5/75 cell line used for both subcutaneous and orthotopic xenografts 
in this thesis and SH-SY5Y, which was included in the cell line panel for the subcutaneous 
animal experiments [126, 183]. Nevertheless, the results established as part of this thesis with 
the subcutaneous neuroblastoma model in CD-1 Nude mice clearly showed that tumor growth 
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and tumor heterogeneity are highly dependent on the mouse strain. As a delivery of 
heterozygous and thereby immunocompetent CD-1 Nude mice by mistake was excluded, the 
grade of immunodeficiency of the CD-1 Nude mouse strain was considered as a possible 
reason for the heterogeneous tumor growth.  
Immunodeficient mouse strains can be categorized into three subgroups, according to their 
grade of immunodeficiency (Table 19). The mouse strains with the lowest grade of 
immunodeficiency (here defined as category 1) do not exhibit a T-cell response but possess 
mature B-cells as well as functional NK cells. The CD-1 Nude mice belong to this category. In 
contrast, mouse strains from category 3 neither have functional T-, B- or NK cells and thereby 
no remaining adaptive or innate immune response. Those highly immunodeficient animals 
include the NSG mouse strain successfully used as model for the subcutaneous xenografts in 
this thesis. 
Table 19: Categorization of immunodeficient mouse strains. Categories are based on the level of immune 
defects. Adapted from Charles River Brochure [155].  
 Category 1 Category 2 Category 3 
Mature T-cells No No No 
Mature B-cells Yes No No 
NK cells Yes Yes No 
Mouse strains CD-1 Nude 
NMRI 
Athymic Nude 
BALB/c 
SCID hairless 
Fox Chase SCID 
NSG 
NOD SCID 
CB17 SCID 
 
The NSG (NOD SCID γ) mice have both a scid mutation resulting in an absent T- and B-cell 
response and lack the gamma chain of the IL2-receptor, leading to severe defects in the innate 
immune system including natural killer cells [156]. Due to the complete absence of any immune 
response, they are ideal for the engraftment of foreign tumor cells. Compared to the CD-1 
Nude and the NMRI mouse strain, the subcutaneous neuroblastoma xenograft tumors of the 
NSG mice showed the lowest variability regarding tumor onset, growth behavior and final tumor 
size with the four cell lines used in the subcutaneous neuroblastoma model in this thesis.  
According to current publications in the neuroblastoma research field, a variety of cell lines and 
mouse strains are used for subcutaneous and orthotopic neuroblastoma xenografts. For 
subcutaneous xenografts, both mouse strains from category 1 as athymic nude and from 
category 3 as NOD-SCID, CB17 SCID or NSG are common, mainly engrafting IMR32 or SH-
SY5Y neuroblastoma cells. For orthotopic neuroblastoma mouse models, the neuroblastoma 
cell lines SH-SY5Y, IMR32, SK-N-AS and KELLY are most commonly used. The mouse strains 
used for orthotopic tumor establishment included BALB/c, CD-1 Nude or athymic Nude from 
category 1 as well as NOD SCID from the third category. Taken together, the mouse strains 
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and cell lines used for both kinds of xenograft neuroblastoma mouse models display a broad 
range of cellular genetics and different grades of immunodeficiency. Based on the results of 
this literature search it was not expected that CD-1 Nude mice might not be suitable for tumor 
hosting in a subcutaneous neuroblastoma mouse model. 
Comparing the results from the subcutaneous neuroblastoma mouse model of IMR5/75 in CD-
1 Nude mice with the corresponding orthotopic model, some analogies are noticeable 
regarding to the heterogeneity of tumor growth. Among the eight tumors from the orthotopic 
neuroblastoma model, three tumors grew fast, four tumors grew slow and one tumor was 
growth arrested. The growth characteristics were not dependent on MYCN high or MYCN low 
conditions. Similarly, fast growing, slow growing and growth arrested tumors occurred in the 
subcutaneous neuroblastoma mouse model in both the control and in the BAY1238097-treated 
group. Testing different mouse strains revealed that an implantation of the human tumor cells 
in highly immunodeficient NSG mice resulted in the lowest variability of subcutaneous tumor 
growth for all four cell lines. This emphasizes that the variable tumor growth in a CD-1 Nude 
host is not specific for IMR5/75, rather NSG mice should be preferred in general. Based on 
these findings, testing the orthotopic mouse model with the NSG mouse strain would be 
advisable, because CD-1 Nude mice might not be the best mouse strain for this application. 
Implanting the human neuroblastoma cells orthotopically in NSG mice might reduce the 
heterogeneity of tumor growth in this animal model. 
 
6.4 Prognosis of the clinical relevance of BET inhibitors for 
neuroblastoma 
 
Over the past years, BET inhibitors have been handled as important new strategy for the 
treatment of c-MYC and MYCN overexpressing malignancies. Nevertheless, the experimental 
work regarding BET inhibition in neuroblastoma cell lines and in a subcutaneous mouse model 
revealed mixed results. The BET inhibitor JQ1 was highly effectively reducing viability in 55% 
of the MYCN amplified and 30% of the MYCN non-amplified neuroblastoma cell lines, hinting 
that besides amplified MYCN further genetic factors may be required to prime neuroblastomas 
towards BET inhibitors. Although JQ1 treatment resulted in an arrest in the G1-phase of the 
cell cycle and in few cases in increased levels of cell death, these effects were not permanent, 
and the neuroblastoma cells started to regrow immediately after washout of the drug. An effect 
on the MYCN protein expression upon JQ1 treatment was noticeable for the majority of the 
MYCN amplified neuroblastoma cell lines, however it was shown that the decrease of the 
MYCN expression is not a direct effect of BRD4 inhibition. At this point, the findings of this 
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thesis differ from the results published by Puissant et al. and Wyce et al. showing by ChIP-
sequencing that MYCN is a direct target of BRD4 in neuroblastoma [121, 122]. 
In vivo, the BET inhibitor BAY1238097 was well tolerated by the mice. However, the potency 
of BAY1238097 in animals was weak and the results from in vitro experiments regarding BET 
inhibitor sensitivity could not be transferred to in vivo applications using the same 
neuroblastoma cell lines. The cell line IMR5/75 highly sensitive in vitro did not show promising 
results in vivo, whereas IMR5 cells closely related to this cell line have been shown to respond 
well to therapy with the BET inhibitor OTX015 [123]. In this work, solely xenograft tumors 
deriving from the cell line LS were treated successfully with BAY1238097.  
In preclinical research, BET inhibitors have been shown to be potent inhibitors for both BRD4 
translocated and MYC overexpressing cancer cell lines, influencing cell proliferation, apoptosis 
and cellular differentiation [184]. Especially the option to target MYC genes on the 
transcriptional level and thereby having a potent drug for the therapy of MYC dependent 
cancers is promising. However, it should be kept in mind that only BET translocated or mutated 
cancers are treated with BET inhibitors as targeted small molecule therapy in the narrower 
sense. One example is the NUT midline carcinoma, where BRD4-NUT translocations are 
causative for the disease [115]. But also neuroblastomas harbor sporadic aberrations in the 
BRD4 gene. In the INFORM-study (Individual therapy for relapsed malignancies in childhood), 
tissue samples from relapsed childhood tumors are screened for mutations and genetic 
aberrations. In three cases of relapsed high-risk neuroblastoma, BRD4 aberrations were 
detected including SNVs, insertions and outlier gene expression. Interestingly, none of the 
tumors with a BRD4 aberration belongs to the group of MYCN amplified tumors, instead two 
of them have an ALT phenotype and one belongs to the TERT group of high-risk 
neuroblastomas. In a collective of newly diagnosed neuroblastoma tumors, no mutations of 
the BRD4 gene have been identified. 
Several clinical studies with BET inhibitors are currently ongoing, using BET inhibitors for 
different cancer types mainly aiming to treat MYC deregulated malignancies. This is striking 
insofar, that the knowledge of the biology of BET proteins and the mechanisms of its inhibition 
are relatively poorly understood. As epigenetic drugs, BET inhibitors have an impact on 
transcriptional initiation and elongation of various genes and are not specifically inhibiting MYC 
target genes. Beyond, all BET inhibitors available are not specific for BRD4, but are binding to 
all BET family members [116]. Thereby BET inhibition affects a broad range of biological 
processes, including insulin production, inflammation or adipogenesis [124]. It is unknown how 
those off-target-effects contribute to the cytotoxic effects of the therapy and if long-term effects 
will occur. The importance of BET proteins for cell biology can be estimated by the fact that 
mouse embryos homozygous for a BRD4 null allele are dying short after implantation, whereas 
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heterozygous mice still show severe abnormalities, such as head malformation or abnormal 
liver cells [185]. 
In all preclinical studies, as well as in this thesis, neuroblastoma xenograft mice well tolerated 
the therapy with BET inhibitors [121, 122]. Nevertheless, BET inhibition has an impact on the 
healthy mouse tissues as it was shown by Bolden et al., who have generated an inducible 
BRD4 knockdown model in mice, based on shRNA knockdown [186]. Upon BRD4 knockdown 
the mice show skin abnormalities, such as hyperplasia and hyperkeratosis, a reduction of 
Paneth cells and crypt disruption in the intestine, as well as haematologic disorders. 
An important side effect that needs to be considered when using BET inhibitors for cancer 
therapy is that an inhibition of BET proteins can lead to reactivation of HIV in T-cells latent 
infected and should therefore not be given to HIV positive patients [100]. Similar observations 
can be made for HPV and Herpesvirus [101, 187]. A study from Korb et al. shows that BRD4 
activates transcription in neurons and that mice treated with JQ1 show deficits regarding their 
long-term memory [188]. It is unknown, if similar effects have to be expected in humans treated 
with the BET inhibitors used for clinical trials. At last, it is likely that BET inhibitors may lead to 
transient male sterility by coinhibition of the testis specific BET protein BRDT [189]. 
Due to the fast regrowth observed in neuroblastoma cells treated with JQ1 in this thesis, it is 
advisable to administer BET inhibitors in combination therapy in clinical settings. One 
possibility might be the combination of JQ1 and doxorubicin, a DNA intercalating drug 
commonly used for neuroblastoma chemotherapy, was tested for this thesis. The combination 
of both drugs was more effective than single therapy, especially when administered 
simultaneously or when doxorubicin was applied prior to JQ1 treatment. However, it was 
shown by Bolden et al. that a combination of those drugs in vivo results in a lower weight gain 
after therapy due to increased toxicity at the intestine [186]. A different approach to identify 
effective drug combinations for BET inhibitors was used by Liu et al., who screened JQ1-
treated neuroblastoma cells in combination with more than 2.500 drugs [190]. Among the 33 
most effective drugs identified by the screen are several quinone containing compounds partly 
including DNA intercalating functions and anti-microtubule substances. Vincristine has the 
highest potency in this setting both in vitro and in vivo, whereas doxorubicin has not been found 
to belong to the potent synergistic substances.   
Taken together the findings presented in this thesis and the state of knowledge regarding BET 
biology, it is debatable if clinical trials with BET inhibitors should be performed already. Relying 
on the JQ1 viability data in this thesis, no more than 55% of the MYCN amplified 
neuroblastoma cell lines show high sensitivity upon treatment with JQ1 and would therefore 
probably profit from a BET inhibitor therapy. Nevertheless, this means deciding for or against 
a treatment with a BET inhibitor based solely on the presence or absence of a MYCN 
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amplification would expose 45% of the neuroblastoma patients with a MYCN amplification to 
a highly unspecific, toxic and not approved therapy without clear benefit for the patients. 
Moreover, this thesis showed that the sensitivity of neuroblastoma cell lines in vitro does not 
necessarily predict the responsiveness of the same cell line in vivo. This indicates that the 
results from preclinical experiments with BET inhibitors cannot be transferred to patient therapy 
without questioning. Further research is indispensable to identify other genetic factors besides 
amplified or overexpressed MYCN, which may prime neuroblastoma tumors for a therapy with 
BET inhibitors. Including suitable patients in clinical trials for BET inhibitors based on the 
results of further research would enhance the significance and power of these studies. 
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7 Abbreviations 
 
For chemical elements the common symbols were used for abbreviations. They are not listed 
here. 
 
ALT alternative lenghtening of telomeres 
AML acute myeloic leukemia 
amp amplified 
APS Ammonium persulfate 
BAY BAY1238097 
BD bromodomain 
BET bromodomain and extraterminal domain 
BETi BET inhibitor, abbreviation used for BAY1238097 
BSA bovine serum albumin 
°C degree Celcius 
C (-terminus) carboxyl (-terminus) 
CDK Cyclin dependent kinase 
cDNA complementary DNA 
ChIP Chromosome Immunoprecipitation 
cm, cm² Centimeter, square centimeter 
CTD C-terminal domain 
Ctrl control 
DAPI 4',6-diamidino-2-phenylindole 
DEG Differentially expressed genes 
DEPC Diethyl pyrocarbonate 
DKFZ German cancer research center 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP nucleoside triphosphate 
doxy doxycycline 
DSM needle code parameters: 3/8 circle, cutting, micro point 
DT doubling time 
DTT Dithiotreitol 
EC50 Half maximal effective concentration 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
et al. and others (lat) 
FACS fluorescence activated cell scanning 
FCS Fetal calf serum 
FDR False discovery rate 
FGF fibroblast growth factor 
for forward 
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g gravitational constant 
G Gauge 
g, mg, µg, kg Grams, milligrams, micrograms, kilograms 
G1/ G2 (phase) Gap phase, cell cycle 
h hours 
H2O dest. destilled water 
hi high 
HIV human immunodeficience virus 
HPV human papilloma virus 
IC50 half maximal inhibitory concentration 
IL2 Interleukin 2 
INFORM INdividual therapy FOr Relapsed Malignancies in childhood 
INSS international neuroblastoma staging system 
IVC isolated ventilated cages 
kDa Kilodalton 
l, ml, µl Liter, milliliter, microliter 
LB lysogeny broth 
lo low 
LOCF last observation carried forward 
M (phase) mitosis phase, cell cycle 
M, mM, µM molar, millimolar, micromolar 
mA Milliampere 
(Opti-)MEM minimum essential medium 
min minutes 
mm, mm² millimeter, square millimeter 
mRNA messenger RNA 
MRI/MRT magnetic resonance imaging/ tomography 
N (-terminus) Amino (-terminus) 
NA non-amplified 
neg negative 
NK (cells) natural killer (cells) 
nm Nanometer (wave lenght) 
NSG NOD SCID gamma 
NV not valid, viability category 
OD outer diameter 
p, q (chromosomes) short/ long chromosome arms 
PAGE polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCA principal component analysis 
PCR polymerase chain reaction 
PDX patient derived xenograft 
Pen/Strep Penicillin/ streptomycin 
PGA polyglycolic acid (suture) 
PI propidium iodide 
pmol Picomol 
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POD Peroxidase 
pRB retinoblastoma protein 
qPCR quantitative PCR 
res resistant, viability category 
rev reverse 
RLU relative light units 
RNA ribonucleic acid 
rpm rounds per minute 
RPPA Reverse Phase Protein Array 
rRNA ribosomal RNA 
RT room temperature 
S (phase) synthesis phase, cell cycle 
SDS Sodium dodecyl sulfate 
sec seconds 
sens sensitive, viability category 
(RNA)-seq (RNA)-sequencing 
shRNA small hairpin RNA 
siRNA silencer RNA 
SNV single nucleotide variation 
TBS Tris buffered saline 
TEMED Tetramethylethylenediamine 
tet tetracycline 
TetO2 Tetracycline operator sequence 
TetR Tetracycline repressor 
TH tyrosine hydroxylase 
tRNA transfer RNA 
V Volt 
WB western blot 
x times 
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